{"meta":{"query_hash":"929586e20008","filters":{"venue":"Blood Cancer Journal"},"cohort_total":129,"direct_labels_cover":0,"predictions_cover":129,"exported":129,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/929586e20008","api":"https://metacan.xera.ac/api/v1/cohort?venue=Blood+Cancer+Journal"},"results":[{"id":"W1964507957","doi":"10.1038/bcj.2014.75","title":"Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Weill Cornell Medical College","keywords":"Lymphoma; Suppressor; Burkitt's lymphoma; Cancer research; Tumor suppressor gene; Gene; DNA methylation; Medicine; Biology; Immunology; Carcinogenesis; Genetics; Gene expression","score_opus":0.00527948037420535,"score_gpt":0.23228438118724476,"score_spread":0.22700490081303942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964507957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502397,0.002691089,0.0011370986,0.0000532768,0.0000074493955,0.000009807017,0.00012686025,0.0000376704,0.00091280916],"genre_scores_gemma":[0.9984164,0.0008492258,0.00030002245,0.000011524103,0.0000051886664,0.0000034335994,0.00015182068,0.0000027819053,0.00025960346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999285,0.000013215434,0.000007614939,0.000016259835,0.000018541195,0.000015794389],"domain_scores_gemma":[0.99987316,0.000034661552,0.000031303207,0.000016528178,0.000023050696,0.000021221043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016453478,0.00012490395,0.00015666998,0.0005220511,0.00018974092,0.00026078572,0.00013424915,0.00017711849,0.0013172727],"category_scores_gemma":[0.00033297105,0.000090358335,0.00009887627,0.0002794506,0.00019665496,0.00013799133,0.00014443522,0.00029957178,0.00023915978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021656272,0.000020924173,0.022296127,0.00008086973,0.000010018477,0.0006183057,0.00010619547,0.00005377461,0.96991694,0.00010404219,0.00006394394,0.006512257],"study_design_scores_gemma":[0.00001994937,0.0002758077,0.27858123,0.000023039544,0.00009407294,0.011519036,0.00033404975,0.0008875727,0.701261,0.000459502,0.006536277,0.000008453477],"about_ca_topic_score_codex":0.0007297439,"about_ca_topic_score_gemma":0.00096501864,"teacher_disagreement_score":0.0013172727,"about_ca_system_score_codex":0.00018608235,"about_ca_system_score_gemma":0.00011222938,"threshold_uncertainty_score":0.0044066906},"labels":[],"label_agreement":null},{"id":"W1974642141","doi":"10.1038/bcj.2012.27","title":"Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Cancer Society Research Institute; Killam Trusts; University of Alberta; Alberta Cancer Foundation","keywords":"SOX2; Anaplastic large-cell lymphoma; Biology; Cancer research; Anaplastic lymphoma kinase; Embryonic stem cell; Stem cell; Carcinogenesis; Cell culture; Cancer stem cell; Molecular biology; Cell biology; Lymphoma; Cancer; Immunology; Pathology; Genetics; Medicine; Gene","score_opus":0.02941579013763417,"score_gpt":0.2718289785923664,"score_spread":0.2424131884547322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974642141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99788254,0.0009546706,0.0006210999,0.00002233305,0.00000518511,0.0000040809127,0.00011390828,0.000015825271,0.00038025196],"genre_scores_gemma":[0.998857,0.00032491484,0.00028472318,0.00001176239,0.0000049880055,0.000004919373,0.00012469658,0.0000028666686,0.00038413279],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998944,0.0000149735515,0.000013129536,0.000023749795,0.00003198134,0.000021849435],"domain_scores_gemma":[0.9999167,0.000017174358,0.00002193155,0.000009936478,0.000010140084,0.000024104467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009198863,0.00018867203,0.00013885218,0.00039020306,0.0001581526,0.00030242105,0.000086704866,0.0002905049,0.0005096736],"category_scores_gemma":[0.00012818909,0.000110669636,0.0001142305,0.00025834807,0.00029855475,0.00018554286,0.0001318007,0.00018896224,0.0002065601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009162861,0.000010463393,0.0034195876,0.000014761378,0.0000040824675,0.00063002063,0.000028818533,0.000025090227,0.9950995,0.000042575273,0.000010331771,0.00062320614],"study_design_scores_gemma":[0.000034590776,0.0003756536,0.1786086,0.0000061154014,0.000065101,0.013269653,0.00031990936,0.0022258724,0.8020768,0.0002628474,0.0027436789,0.0000111476365],"about_ca_topic_score_codex":0.00048286005,"about_ca_topic_score_gemma":0.0006900451,"teacher_disagreement_score":0.0005096736,"about_ca_system_score_codex":0.00020692972,"about_ca_system_score_gemma":0.00009634576,"threshold_uncertainty_score":0.0017050505},"labels":[],"label_agreement":null},{"id":"W2006431669","doi":"10.1038/bcj.2011.50","title":"Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Calpain; Calpastatin; Proteases; Apoptosis; Leukemia; K562 cells; Cancer research; Chemistry; Biology; Immunology; Molecular biology; Biochemistry; Enzyme","score_opus":0.006550593439214601,"score_gpt":0.23700384503349856,"score_spread":0.23045325159428395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006431669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778974,0.000986466,0.00043209584,0.000035236444,0.0000038380394,0.00001200869,0.00034327502,0.000027970957,0.00036936617],"genre_scores_gemma":[0.99788624,0.0005837375,0.0005022802,0.00003754201,0.000009086015,0.000014394871,0.00061290705,0.0000041470116,0.00034959766],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99985206,0.0000131317975,0.000015897904,0.00003452678,0.0000457092,0.000038768852],"domain_scores_gemma":[0.9997701,0.00003416683,0.00009833204,0.000012377829,0.000024527908,0.000060512248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109958004,0.00016090568,0.00025772073,0.0005263996,0.00013493345,0.00032990324,0.0000927807,0.00020320635,0.0013573193],"category_scores_gemma":[0.0002490983,0.00010127431,0.0001144179,0.00054274726,0.0001764333,0.00013641953,0.00014741518,0.00046047114,0.00027698773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010128003,0.00008202454,0.075187825,0.00006866962,0.000036033824,0.0004923946,0.00008324102,0.000084867825,0.9165828,0.00004403309,0.0001611942,0.0061641117],"study_design_scores_gemma":[0.00003483312,0.0004807209,0.8921235,0.000007730427,0.000044758697,0.0032448662,0.000083241204,0.00040023052,0.10184085,0.000105277635,0.0016283202,0.000005614638],"about_ca_topic_score_codex":0.00034590438,"about_ca_topic_score_gemma":0.00041880345,"teacher_disagreement_score":0.0013573193,"about_ca_system_score_codex":0.00017769073,"about_ca_system_score_gemma":0.00010747985,"threshold_uncertainty_score":0.004540682},"labels":[],"label_agreement":null},{"id":"W2007454067","doi":"10.1038/bcj.2013.23","title":"Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity","year":2013,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; Cytolysis; Virology; Leukemia; Immunology; Acute leukemia; Virus; Virotherapy; Biology; Myeloid leukemia; Medicine; Cancer research; Cytotoxicity; In vitro","score_opus":0.013750943640296541,"score_gpt":0.28983553832291326,"score_spread":0.2760845946826167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007454067","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96098554,0.006313127,0.027272476,0.00019416808,0.00005998702,0.000115383584,0.00018036355,0.00025551504,0.004623359],"genre_scores_gemma":[0.981703,0.0022830216,0.012064757,0.00006334392,0.000020484407,0.000041146406,0.00020615253,0.00003415939,0.0035839505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987674,0.00002401865,0.000009616887,0.000023246881,0.00004721074,0.000019127581],"domain_scores_gemma":[0.99992836,0.000017087743,0.00002523435,0.000011329864,0.000007364986,0.000010573958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016522701,0.0003132695,0.00016633574,0.00016604987,0.00006998533,0.00025968408,0.00014991287,0.00024204422,0.00075181696],"category_scores_gemma":[0.00010218763,0.00007970736,0.00014562355,0.00008349779,0.0002813334,0.00019887931,0.00017324109,0.00045727735,0.0003138743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000250714,0.000014493714,0.000049953862,0.000021023548,0.0000015101067,0.000016798913,0.000007090162,0.000056046603,0.9970962,0.00023696537,0.000022297794,0.00245247],"study_design_scores_gemma":[0.000012913728,0.00029832072,0.00053588464,0.000004153188,0.000006705818,0.00015819432,0.0000050528174,0.00043907264,0.9954592,0.00007547789,0.003002811,0.0000021146602],"about_ca_topic_score_codex":0.00013428293,"about_ca_topic_score_gemma":0.00027575588,"teacher_disagreement_score":0.00075181696,"about_ca_system_score_codex":0.0001609339,"about_ca_system_score_gemma":0.00015084633,"threshold_uncertainty_score":0.0025150776},"labels":[],"label_agreement":null},{"id":"W2015577159","doi":"10.1038/bcj.2012.47","title":"Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Receptor tyrosine kinase; Cancer research; KRAS; Somatic cell; Signal transduction; ERBB3; Germline mutation; Mutation; Multiple myeloma; Genetics; Gene; Cell biology; Immunology","score_opus":0.014892732451273484,"score_gpt":0.27513573417818304,"score_spread":0.26024300172690956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015577159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971724,0.00046082443,0.0012072201,0.00003598142,0.000003891686,0.000010910038,0.0003477875,0.000044680673,0.00071634375],"genre_scores_gemma":[0.99888545,0.00016271797,0.00057978084,0.000022617765,0.000004440728,0.0000023112818,0.00017639923,0.0000050655444,0.00016132102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997658,0.000024883073,0.00002092579,0.00009548067,0.000057813566,0.000035027366],"domain_scores_gemma":[0.9998776,0.000026408547,0.000053077874,0.000013704768,0.0000105594345,0.000018633009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016720989,0.00041646906,0.0004166339,0.00061524316,0.00036059934,0.00032756277,0.00014634809,0.0002593048,0.0012452109],"category_scores_gemma":[0.00034194315,0.00016804085,0.0002518016,0.0010429159,0.00022806482,0.00012307847,0.0003476307,0.00020331529,0.00025315178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088160887,0.00010028754,0.5026211,0.00021993158,0.000383253,0.022491807,0.0002903212,0.0010620509,0.4231491,0.0005979558,0.00077726215,0.04742523],"study_design_scores_gemma":[0.000037515554,0.0002749875,0.8798373,0.000025415857,0.00031126133,0.059124872,0.0002156974,0.0020669824,0.052186638,0.00097263086,0.004930102,0.000016573638],"about_ca_topic_score_codex":0.0010406714,"about_ca_topic_score_gemma":0.0013539052,"teacher_disagreement_score":0.0012452109,"about_ca_system_score_codex":0.0002556859,"about_ca_system_score_gemma":0.00017044369,"threshold_uncertainty_score":0.00416559},"labels":[],"label_agreement":null},{"id":"W2017202925","doi":"10.1038/bcj.2015.14","title":"Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Ontario Ministry of Research and Innovation; University of California, San Diego; National Cancer Institute; Ontario Genomics; National Institutes of Health; National Center for Advancing Translational Sciences; Ontario Institute for Cancer Research; Government of Canada; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada","keywords":"Epigenetics; DNA methylation; Somatic evolution in cancer; Biology; Chronic lymphocytic leukemia; Tumor progression; Genetics; Somatic cell; Methylation; Leukemia; CpG site; Disease; Cancer research; Cancer; DNA; Medicine; Gene; Pathology; Gene expression","score_opus":0.03955269313648678,"score_gpt":0.32959255775537166,"score_spread":0.29003986461888487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017202925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99922454,0.00018645638,0.0002711944,0.000010709255,4.584994e-7,0.0000038744574,0.0000856343,0.00000681262,0.00021030016],"genre_scores_gemma":[0.9993636,0.00007037283,0.00028559848,0.000008013215,0.0000020184673,0.000004052504,0.00013301452,0.0000018484168,0.00013139001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99989974,0.000018070365,0.000009353653,0.00002355829,0.000025391697,0.000023913903],"domain_scores_gemma":[0.9997602,0.00006192361,0.000083442304,0.000023949498,0.000032443033,0.000038071485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019274856,0.000089372,0.00013400805,0.00068036723,0.00015316493,0.00021817174,0.000087516935,0.0001309114,0.0007366998],"category_scores_gemma":[0.0005443388,0.0000752028,0.00007842233,0.00037177687,0.00014626146,0.00015027524,0.0001508882,0.00016000422,0.00011007058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005069473,0.0000376717,0.6046735,0.00004702774,0.000036119232,0.00042201552,0.00029235674,0.00034203118,0.36212108,0.00012179052,0.00009967895,0.031299822],"study_design_scores_gemma":[0.000010147256,0.0003356415,0.9702219,0.0000050128137,0.000029439612,0.0021984468,0.00013260105,0.00063034176,0.025580704,0.00009833318,0.00075143104,0.0000060912657],"about_ca_topic_score_codex":0.0011535018,"about_ca_topic_score_gemma":0.0023696192,"teacher_disagreement_score":0.0011535018,"about_ca_system_score_codex":0.00016448286,"about_ca_system_score_gemma":0.0001191435,"threshold_uncertainty_score":0.0024645329},"labels":[],"label_agreement":null},{"id":"W2018993327","doi":"10.1038/bcj.2015.11","title":"The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Generalitat de Catalunya; National Cancer Institute; Instituto de Salud Carlos III; Celgene","keywords":"Single-nucleotide polymorphism; Allele; Biology; Myelodysplastic syndromes; Internal medicine; Genotype; Allele frequency; Genetics; Gastroenterology; Bone marrow; Immunology; Medicine; Gene","score_opus":0.05709215149485445,"score_gpt":0.3246878956104926,"score_spread":0.26759574411563813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018993327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996829,0.0001261865,0.00003339932,0.000012760573,0.0000020775492,0.0000011276227,0.00002731456,0.0000015232484,0.00011290615],"genre_scores_gemma":[0.99984217,0.000022869537,0.000014104624,0.0000045219517,0.000004526055,0.0000011237762,0.000035619705,6.330876e-7,0.00007432533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997311,0.00008897848,0.00003351273,0.00006253746,0.000040449373,0.000043407428],"domain_scores_gemma":[0.999116,0.0002674303,0.00031022634,0.000049260372,0.000053293796,0.00020381164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036304074,0.0001742844,0.00018340173,0.0005293223,0.00015679402,0.00023145592,0.00015870552,0.00035159494,0.0012135642],"category_scores_gemma":[0.0015599078,0.00010362412,0.00017926967,0.00031335224,0.00020513046,0.00013497603,0.00015900846,0.00030259235,0.00018462271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059463567,0.000037800168,0.9947212,0.0000048669194,0.0000497255,0.00024096377,0.000033586708,0.000045710163,0.0024177209,0.000012877011,0.00003644885,0.0018045632],"study_design_scores_gemma":[0.000012110046,0.0002861548,0.9981201,0.000002773121,0.000041580304,0.00080146483,0.0000353369,0.00021873479,0.00034190173,0.00003865891,0.00009864698,0.0000024151725],"about_ca_topic_score_codex":0.0005304029,"about_ca_topic_score_gemma":0.0005478943,"teacher_disagreement_score":0.0012135642,"about_ca_system_score_codex":0.00013088719,"about_ca_system_score_gemma":0.00009401796,"threshold_uncertainty_score":0.004059732},"labels":[],"label_agreement":null},{"id":"W2019849294","doi":"10.1038/bcj.2013.50","title":"Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Cathepsin B; Chronic lymphocytic leukemia; Cancer research; Vorinostat; Cathepsin; Apoptosis; Histone deacetylase; Medicine; Immunology; Chemistry; Leukemia; Histone; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.021099606938949234,"score_gpt":0.29001114830507463,"score_spread":0.2689115413661254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019849294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960367,0.002522496,0.0004737772,0.00005871008,0.00001958684,0.0000343036,0.00006718471,0.000024006995,0.0007631835],"genre_scores_gemma":[0.99824095,0.00061568286,0.0006470867,0.00003330042,0.0000135346345,0.000022588603,0.000101415506,0.0000031152258,0.00032222344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997863,0.00007157602,0.000017158827,0.000033829925,0.000035552897,0.000055564175],"domain_scores_gemma":[0.9999168,0.000020531,0.000014415196,0.000010495934,0.0000060660814,0.000031718104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001944483,0.00032478402,0.00048630498,0.00027678657,0.00023533856,0.00028725227,0.00012734528,0.00023639713,0.001099619],"category_scores_gemma":[0.0001558172,0.00014826043,0.00031291283,0.00015831662,0.00020721383,0.000112205096,0.00035464086,0.0003752899,0.0002268207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021127614,0.00021454452,0.0034758106,0.00012344884,0.00005577589,0.0003755633,0.00008165682,0.00031844084,0.97677326,0.00007876282,0.00019862042,0.01619121],"study_design_scores_gemma":[0.00078964763,0.01385913,0.04091257,0.000027004606,0.00020004823,0.005963529,0.00013850912,0.0009826339,0.9273125,0.00013017113,0.009667121,0.000017183811],"about_ca_topic_score_codex":0.00031738228,"about_ca_topic_score_gemma":0.0012220367,"teacher_disagreement_score":0.001099619,"about_ca_system_score_codex":0.00025110945,"about_ca_system_score_gemma":0.00023687002,"threshold_uncertainty_score":0.0036785603},"labels":[],"label_agreement":null},{"id":"W2024362879","doi":"10.1038/bcj.2012.43","title":"Extremely low-frequency magnetic fields and survival from childhood acute lymphoblastic leukemia: an international follow-up study","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Electromagnetic Fields and Biological Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Electric Power Research Institute; Kræftens Bekæmpelse","keywords":"Hazard ratio; Medicine; Confidence interval; Internal medicine; Lymphoblastic Leukemia; Survival analysis; Overall survival; Proportional hazards model; Prospective cohort study; Survival rate; Leukemia","score_opus":0.008271763767366908,"score_gpt":0.24760234984613883,"score_spread":0.23933058607877192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024362879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973393,0.0007671571,0.00012590655,0.000051161347,0.0000054895304,0.0000123833715,0.00085123803,0.0000035004368,0.00084385154],"genre_scores_gemma":[0.99825484,0.00044987097,0.000062366555,0.000034470835,0.000014597386,0.000013545281,0.0010226652,0.000002799303,0.00014477776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996203,0.000111867186,0.000046843656,0.000082113576,0.000058725753,0.00008006629],"domain_scores_gemma":[0.998596,0.00018947903,0.00071380625,0.00017294748,0.00012596376,0.00020180098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081573514,0.00031541797,0.00030247928,0.0008782311,0.000436072,0.00061695307,0.00029882614,0.00044548162,0.0011733326],"category_scores_gemma":[0.002079647,0.00021241594,0.0005116489,0.0019319115,0.000264587,0.00051031046,0.0005225634,0.0007465268,0.0002388387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050115626,0.000054224794,0.99637336,0.00001904123,0.00011555386,0.00009010018,0.00015917244,0.000077770164,0.00018404344,0.00002255314,0.00012215295,0.0022809112],"study_design_scores_gemma":[0.000016138882,0.00011887786,0.9989741,0.000008806548,0.000104658124,0.00022016077,0.00007848038,0.000036370362,0.0000645445,0.000018742901,0.00035471204,0.000004416545],"about_ca_topic_score_codex":0.005887785,"about_ca_topic_score_gemma":0.0051895306,"teacher_disagreement_score":0.005887785,"about_ca_system_score_codex":0.00041724773,"about_ca_system_score_gemma":0.0003127735,"threshold_uncertainty_score":0.011707008},"labels":[],"label_agreement":null},{"id":"W2031119437","doi":"10.1038/bcj.2013.43","title":"Pharmacological targeting of eIF4E in primary CLL lymphocytes","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"EIF4E; Chronic lymphocytic leukemia; Medicine; Cancer research; Myeloid leukemia; Leukemia; Immunology; PI3K/AKT/mTOR pathway; Oncology; Biology; Translation (biology); Signal transduction; Genetics; Messenger RNA","score_opus":0.018326670456457937,"score_gpt":0.31478625160718254,"score_spread":0.2964595811507246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031119437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858655,0.0037295355,0.0031041473,0.0001789685,0.00013493467,0.00039756636,0.002290893,0.00023809834,0.0040603],"genre_scores_gemma":[0.98832756,0.0019426364,0.0037229059,0.00026320104,0.000053043153,0.00053124083,0.0020121615,0.00003499041,0.0031123727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999554,0.00008169378,0.000040022453,0.00008941478,0.00009539228,0.00013940316],"domain_scores_gemma":[0.99988496,0.000033721582,0.000016842381,0.000015787527,0.000018240018,0.000030512128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031136596,0.00057832955,0.0006794918,0.00039019543,0.00035399044,0.0005388966,0.0002694504,0.00041088907,0.004130758],"category_scores_gemma":[0.00017413308,0.0001992232,0.00043221784,0.0003181257,0.00025209683,0.00018440456,0.00036949487,0.0010918643,0.0010539227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028700382,0.00021231754,0.00022979364,0.00012042341,0.000008799007,0.00007058085,0.000049071637,0.00012894915,0.99657506,0.00004682265,0.00022882245,0.0020423364],"study_design_scores_gemma":[0.00011261808,0.0039919782,0.004914463,0.000022932372,0.00003967195,0.00048649454,0.000104769264,0.0005887039,0.9853114,0.00003648444,0.004380053,0.0000104175],"about_ca_topic_score_codex":0.00086554216,"about_ca_topic_score_gemma":0.001829811,"teacher_disagreement_score":0.004130758,"about_ca_system_score_codex":0.0004882614,"about_ca_system_score_gemma":0.00031220124,"threshold_uncertainty_score":0.013818741},"labels":[],"label_agreement":null},{"id":"W2038656901","doi":"10.1038/bcj.2011.52","title":"Drug-mediated inhibition of Fli-1 for the treatment of leukemia","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Cancer research; Oncogene; Carcinogenesis; Leukemia; Transcription factor; Haematopoiesis; Drug; Biology; Cell growth; Apoptosis; Loss function; Oncogene Proteins; Gene; Medicine; Pharmacology; Regulation of gene expression; Immunology; Stem cell; Phenotype; Cell biology; Cell cycle; Genetics","score_opus":0.030514505918436734,"score_gpt":0.3259653408600217,"score_spread":0.29545083494158497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038656901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803396,0.009320675,0.003802191,0.00025725353,0.00008922329,0.00043994884,0.0009591242,0.00016264296,0.0046293824],"genre_scores_gemma":[0.9826109,0.0065147625,0.0053885416,0.0001254107,0.000016689723,0.00019085279,0.00131904,0.000017079006,0.0038168197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999186,0.000017068063,0.0000063592597,0.000014688326,0.000023894087,0.000019513876],"domain_scores_gemma":[0.999967,0.000006833982,0.000008237431,0.0000032854473,0.000004528049,0.000010144801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016398034,0.0003812434,0.0003130811,0.00047022314,0.00014654722,0.00019579582,0.0002430006,0.00022518991,0.0010371192],"category_scores_gemma":[0.00008216263,0.00009780378,0.00023646318,0.00024772435,0.00017578647,0.00015164254,0.00013706276,0.00047764095,0.00029278078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048052816,0.0006026139,0.00039089657,0.00018430798,0.00002788484,0.00014151492,0.00004801903,0.000728638,0.96657795,0.00060226774,0.00053811085,0.029677395],"study_design_scores_gemma":[0.0002445134,0.004511603,0.0031041394,0.0000136741055,0.000041383446,0.0004326833,0.000013647894,0.0009461683,0.9801066,0.00006591893,0.010508095,0.000011608705],"about_ca_topic_score_codex":0.00043593213,"about_ca_topic_score_gemma":0.0020371336,"teacher_disagreement_score":0.0010371192,"about_ca_system_score_codex":0.00029172475,"about_ca_system_score_gemma":0.00029220825,"threshold_uncertainty_score":0.0034695268},"labels":[],"label_agreement":null},{"id":"W2045832601","doi":"10.1038/bcj.2013.24","title":"BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leukaemia and Lymphoma Research; Cancer Research UK; Genome Canada; Wellcome Trust; GlaxoSmithKline; Ontario Ministry of Research and Innovation; Pfizer; Eli Lilly and Company","keywords":"Bromodomain; Downregulation and upregulation; BET inhibitor; Cancer research; Dexamethasone; BRD4; Cytotoxic T cell; Cell cycle checkpoint; Medicine; In vitro; Cell cycle; Biology; Immunology; Epigenetics; Gene; Internal medicine; Genetics; Cancer","score_opus":0.010328341450849276,"score_gpt":0.23233811758586947,"score_spread":0.2220097761350202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045832601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897982,0.006512193,0.000761138,0.00015039225,0.00006858249,0.00009019556,0.00028645946,0.000076289834,0.002256621],"genre_scores_gemma":[0.98956376,0.0065239514,0.0012390052,0.000079111414,0.00003592078,0.00006611715,0.0005403604,0.00002031823,0.0019313855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999894,0.00001777627,0.0000075574153,0.000015983385,0.000027688413,0.00003702989],"domain_scores_gemma":[0.9999418,0.000011900556,0.000012288159,0.000008015756,0.000005503687,0.00002054154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015071967,0.00028501262,0.0006696472,0.00034984027,0.00015724228,0.00040514796,0.00028990867,0.00022644733,0.0012869462],"category_scores_gemma":[0.0001140172,0.00012601964,0.00023264313,0.00033442842,0.0002145755,0.0001819756,0.0001855558,0.00073708675,0.00031352558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024679569,0.0009843468,0.0014423223,0.00038488218,0.00009814742,0.0003924205,0.00010042348,0.0012196561,0.9484315,0.00054153206,0.00086859235,0.043068253],"study_design_scores_gemma":[0.0010095566,0.018079318,0.028688872,0.00005209504,0.0003132275,0.003285916,0.00013923697,0.0022652028,0.9175075,0.0002927929,0.028337086,0.000029150773],"about_ca_topic_score_codex":0.00049584877,"about_ca_topic_score_gemma":0.0019384217,"teacher_disagreement_score":0.0012869462,"about_ca_system_score_codex":0.00032574811,"about_ca_system_score_gemma":0.00029254804,"threshold_uncertainty_score":0.004305303},"labels":[],"label_agreement":null},{"id":"W2048050781","doi":"10.1038/bcj.2012.44","title":"The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"National Cancer Institute","keywords":"Haematopoiesis; Progenitor cell; Suppressor; Cancer research; Hematopoietic cell; Progenitor; Immunology; Stem cell; Hematopoietic stem cell; Biology; Medicine; Cell biology; Internal medicine; Cancer","score_opus":0.009836884992128394,"score_gpt":0.26679489073152185,"score_spread":0.2569580057393935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048050781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98607767,0.00788008,0.004334965,0.000097683835,0.000018301062,0.000016404088,0.00021121492,0.00006941237,0.0012942253],"genre_scores_gemma":[0.99625754,0.0016455429,0.00088950974,0.000015556006,0.000004035993,0.000008986947,0.00016360238,0.000009217174,0.001006093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991906,0.000016585054,0.000008768287,0.000022365999,0.000018669214,0.000014504187],"domain_scores_gemma":[0.9999174,0.000009489348,0.000038119288,0.000009575254,0.000007790783,0.00001768686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014857204,0.00034995266,0.00012523023,0.00025682346,0.00014014564,0.00037010617,0.00017690532,0.00020525511,0.000608162],"category_scores_gemma":[0.00012788935,0.00012965173,0.0001429313,0.00011220125,0.00025574127,0.00023638607,0.00023370693,0.00022602023,0.00024206522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014342343,0.000012384341,0.001582073,0.000040199415,0.000007717993,0.00012018062,0.000018459514,0.00014265733,0.99441886,0.00028328432,0.000025064077,0.003205694],"study_design_scores_gemma":[0.000023638646,0.0001969246,0.020948315,0.000015055531,0.000024812742,0.0008260139,0.00005070984,0.0020795823,0.9709563,0.000324916,0.004548227,0.0000055614278],"about_ca_topic_score_codex":0.0002620886,"about_ca_topic_score_gemma":0.00020392919,"teacher_disagreement_score":0.000608162,"about_ca_system_score_codex":0.00020994635,"about_ca_system_score_gemma":0.00014027947,"threshold_uncertainty_score":0.002034545},"labels":[],"label_agreement":null},{"id":"W2070181143","doi":"10.1038/bcj.2013.25","title":"Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University","funders":"Canadian Institutes of Health Research; McGill University","keywords":"EIF4E; PI3K/AKT/mTOR pathway; Initiation factor; Cancer research; Biology; Translation (biology); Eukaryotic initiation factor; Signal transduction; eIF4A; Cell biology; EIF4A1; Eukaryotic translation; Messenger RNA; Genetics; Gene","score_opus":0.012552256503552732,"score_gpt":0.2616538805580792,"score_spread":0.24910162405452646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070181143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903804,0.0032951338,0.0029489766,0.0001856499,0.000057802754,0.00006972875,0.0002160505,0.00027106013,0.0025751363],"genre_scores_gemma":[0.99612635,0.0014162278,0.0011203187,0.000041968862,0.000014548297,0.000029831845,0.00017707913,0.000016225125,0.0010572723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992704,0.000010046041,0.000006373351,0.0000134461925,0.000017593022,0.00002544645],"domain_scores_gemma":[0.9999627,0.0000060912007,0.000014200443,0.0000040695622,0.000003744504,0.000009300691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010881771,0.00027380727,0.00025257727,0.0002998664,0.00012270242,0.00026788452,0.00016690738,0.00013979129,0.0008795593],"category_scores_gemma":[0.000084401676,0.0000857832,0.0001432906,0.00021876165,0.00017555465,0.0001378343,0.00014387399,0.00044013446,0.00021725464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038612948,0.000167658,0.0002639598,0.000040637166,0.000013499998,0.000042028973,0.000016025453,0.00039922175,0.9865172,0.00025431463,0.00017305807,0.011726346],"study_design_scores_gemma":[0.000090679925,0.0014444913,0.0020713634,0.0000053514755,0.00004280672,0.00017119489,0.000016093692,0.0011811157,0.9886868,0.00007779022,0.006205805,0.000006574209],"about_ca_topic_score_codex":0.00038784015,"about_ca_topic_score_gemma":0.00086248736,"teacher_disagreement_score":0.0008795593,"about_ca_system_score_codex":0.00029386076,"about_ca_system_score_gemma":0.0002408102,"threshold_uncertainty_score":0.0029423833},"labels":[],"label_agreement":null},{"id":"W2081446512","doi":"10.1038/bcj.2014.71","title":"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Takeda Pharmaceuticals International; Takeda Oncology; Weill Cornell Medical College","keywords":"Medicine; Ixazomib; Follicular lymphoma; Nausea; Internal medicine; Neutropenia; Tolerability; Adverse effect; Pharmacodynamics; Gastroenterology; Lymphoma; Proteasome inhibitor; Pharmacokinetics; Pharmacology; Multiple myeloma; Toxicity; Carfilzomib","score_opus":0.014046845654841822,"score_gpt":0.27365247284934247,"score_spread":0.25960562719450064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081446512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663204,0.001460963,0.0003422268,0.00015146671,0.000032374355,0.0004993797,0.00017476827,0.00005855031,0.0006482047],"genre_scores_gemma":[0.9951143,0.0011298122,0.0011332687,0.00031480403,0.000074526906,0.0005957566,0.00065315445,0.000015060198,0.0009692492],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997013,0.00014756754,0.000011781689,0.000045445875,0.000030188547,0.00006370177],"domain_scores_gemma":[0.99964046,0.00006622725,0.00010450445,0.000027073078,0.000016791086,0.00014490669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007718517,0.0011406341,0.0019565197,0.00034927757,0.0002170474,0.0005559267,0.0005810288,0.00059636944,0.0012302891],"category_scores_gemma":[0.0007136355,0.00039289313,0.0006040245,0.00031885837,0.0005300167,0.0004501647,0.00021677458,0.0021388014,0.00034867923],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42705905,0.07421465,0.021939436,0.0010682285,0.0011781696,0.001103115,0.0008919997,0.00737291,0.16783203,0.00037515786,0.0048432453,0.29212216],"study_design_scores_gemma":[0.22146305,0.7254421,0.034903936,0.000047154295,0.0003181927,0.0009291823,0.00007465039,0.0031900674,0.009992347,0.00021900913,0.003380943,0.000039404487],"about_ca_topic_score_codex":0.00044815324,"about_ca_topic_score_gemma":0.0011674333,"teacher_disagreement_score":0.0019565197,"about_ca_system_score_codex":0.00079154054,"about_ca_system_score_gemma":0.00059512706,"threshold_uncertainty_score":0.0057430267},"labels":[],"label_agreement":null},{"id":"W2095588623","doi":"10.1038/bcj.2013.14","title":"The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Internal medicine; Oncology; Myeloid leukemia; Medicine; Univariate analysis; Fms-Like Tyrosine Kinase 3; Cytogenetics; Leukemia; Karyotype; Multivariate analysis; Mutation; Biology; Chromosome; Genetics; Gene","score_opus":0.006879801731779407,"score_gpt":0.26989237800630467,"score_spread":0.26301257627452523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095588623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993857,0.00039013007,0.000038916467,0.000022389699,0.0000031098227,0.0000027797582,0.00004668488,0.0000019184422,0.00010825687],"genre_scores_gemma":[0.9996413,0.00006162288,0.00004427837,0.000020318317,0.0000115866815,0.000003951361,0.00017070859,0.0000010941218,0.000045194334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997687,0.00006135487,0.00002755829,0.000041609277,0.00004156759,0.000059286427],"domain_scores_gemma":[0.9988494,0.00031028764,0.00040138123,0.00005961694,0.000054728607,0.00032455375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004757266,0.000255423,0.000333349,0.00046995317,0.00019956865,0.00035296986,0.00029404994,0.00044756194,0.0004337911],"category_scores_gemma":[0.0017354996,0.00015136706,0.00035187224,0.00039553334,0.00030729774,0.00032412453,0.00033462135,0.00039056235,0.00015105921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014841959,0.000058007096,0.99240595,0.000010893028,0.000053023487,0.00031595395,0.000047164114,0.00022519416,0.0010833206,0.00001531735,0.00008112899,0.0042197704],"study_design_scores_gemma":[0.00005224911,0.00080195384,0.9964814,0.0000053567155,0.000066786546,0.001390483,0.000055048135,0.0005739143,0.00033119056,0.000038089587,0.00019581061,0.000007779243],"about_ca_topic_score_codex":0.001036734,"about_ca_topic_score_gemma":0.0015526289,"teacher_disagreement_score":0.001036734,"about_ca_system_score_codex":0.00033243626,"about_ca_system_score_gemma":0.00023646047,"threshold_uncertainty_score":0.0025158525},"labels":[],"label_agreement":null},{"id":"W2149573012","doi":"10.1038/bcj.2014.51","title":"High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations","year":2014,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"NPM1; DNMT3B; CEBPA; Methyltransferase; Oncology; Myeloid leukemia; Hazard ratio; Internal medicine; Medicine; Hematology; Transplantation; Biology; Immunology; Cancer research; Genetics; Confidence interval; Mutation; Methylation; Karyotype; Gene","score_opus":0.014389393370973946,"score_gpt":0.28279065290005134,"score_spread":0.2684012595290774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149573012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847454,0.00029678087,0.0002212864,0.000060567112,0.0000050282124,0.0000081945545,0.00060176325,0.000013283935,0.00031846558],"genre_scores_gemma":[0.99824893,0.00013249983,0.00026832076,0.00003231907,0.0000205277,0.000015573876,0.0010915038,0.0000053033355,0.00018506832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979514,0.00003444743,0.000025040967,0.0000603353,0.0000468096,0.000038221242],"domain_scores_gemma":[0.9994561,0.0001119865,0.00024195059,0.00003555475,0.000039593513,0.00011477126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000313464,0.00030824312,0.0003468316,0.0006944451,0.0004060109,0.0004676404,0.00022193,0.0004413215,0.0021452124],"category_scores_gemma":[0.0007605753,0.00016805624,0.00021794118,0.000879581,0.00025626042,0.00027483513,0.0004009666,0.00054827594,0.00058371644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035742074,0.000039418363,0.99016714,0.000015327765,0.000027504151,0.00009010115,0.000031686926,0.0000800639,0.006482703,0.000020045642,0.00020774305,0.0024809134],"study_design_scores_gemma":[0.000007729289,0.000074807074,0.9977984,0.0000033618378,0.000020599275,0.00040061394,0.000048629725,0.0004255137,0.0008475454,0.000088847206,0.00028037583,0.0000034963718],"about_ca_topic_score_codex":0.00095674366,"about_ca_topic_score_gemma":0.0013650904,"teacher_disagreement_score":0.0021452124,"about_ca_system_score_codex":0.00020682813,"about_ca_system_score_gemma":0.00019743804,"threshold_uncertainty_score":0.007176399},"labels":[],"label_agreement":null},{"id":"W2202712680","doi":"10.1038/bcj.2015.104","title":"Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses","year":2015,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Teva Pharmaceutical Industries","keywords":"Logistic regression; Myeloid leukemia; Medicine; Oncology; Internal medicine; Hematology; Immunology","score_opus":0.040615305099031156,"score_gpt":0.31720429007754664,"score_spread":0.2765889849785155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202712680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994402,0.000895517,0.0028808732,0.0002539468,0.000030366467,0.000049444065,0.0008647653,0.000054836273,0.00056823296],"genre_scores_gemma":[0.9974324,0.000118458396,0.001107912,0.000028300357,0.00004334683,0.000056422625,0.000946257,0.000018654071,0.00024814808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976622,0.0014518728,0.0001435598,0.0003430052,0.00024146287,0.00015798249],"domain_scores_gemma":[0.98962736,0.0074288007,0.0015522136,0.00058286806,0.00029179777,0.00051702815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077672987,0.00051456626,0.00090119813,0.0009974502,0.00025259244,0.0007453376,0.00080907793,0.00057614397,0.0015341195],"category_scores_gemma":[0.008598869,0.00025983813,0.0021689485,0.0010059424,0.0003879017,0.0006662771,0.000677081,0.0015125284,0.00021032743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014472902,0.0001368561,0.96568507,0.00006407328,0.002036883,0.000113196904,0.00006803844,0.005416583,0.00049389625,0.0002352284,0.0008769385,0.010400291],"study_design_scores_gemma":[0.0008637528,0.005442758,0.8677562,0.000032227294,0.0015477753,0.000571602,0.00029322764,0.11937207,0.0007452736,0.00104278,0.002245309,0.000087037915],"about_ca_topic_score_codex":0.002483733,"about_ca_topic_score_gemma":0.0015488561,"teacher_disagreement_score":0.0077672987,"about_ca_system_score_codex":0.0005497877,"about_ca_system_score_gemma":0.0006275639,"threshold_uncertainty_score":0.04107791},"labels":[],"label_agreement":null},{"id":"W2294823670","doi":"10.1038/bcj.2016.9","title":"Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Deutsche Forschungsgemeinschaft; National Cancer Institute; Celgene","keywords":"IGHV@; Lenalidomide; Internal medicine; Chronic lymphocytic leukemia; Oncology; Medicine; Refractory (planetary science); Hematology; Fludarabine; Gastroenterology; Leukemia; Multiple myeloma; Chemotherapy; Biology; Cyclophosphamide","score_opus":0.05766062988039832,"score_gpt":0.36183303720276405,"score_spread":0.3041724073223657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294823670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844403,0.008683773,0.00015926368,0.0004069389,0.000043591623,0.00021961019,0.0012316254,0.00002642791,0.00078481727],"genre_scores_gemma":[0.9924936,0.0022243077,0.0005017979,0.00044973387,0.00009684802,0.00032479235,0.0033797175,0.000011262733,0.0005178973],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99871874,0.00097588,0.000068525216,0.000091161324,0.00008924802,0.0000563212],"domain_scores_gemma":[0.9980742,0.0005915604,0.00074534636,0.00014300704,0.00007592613,0.00037001344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038082479,0.000799509,0.0011721238,0.00021906932,0.00023465476,0.00093502307,0.000727497,0.0007341746,0.0012452203],"category_scores_gemma":[0.002128981,0.00028201658,0.00094157836,0.00043074184,0.00047687034,0.0004623318,0.0003380039,0.0012668823,0.00027160405],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8386451,0.004057979,0.072929114,0.00073996,0.0030317102,0.00011231999,0.00012249737,0.0018639335,0.006022417,0.00016324472,0.0030721487,0.06923955],"study_design_scores_gemma":[0.6011909,0.12720455,0.24865085,0.00033392516,0.005054695,0.00066957664,0.00013896693,0.0039121932,0.0031053214,0.0005014988,0.0091454275,0.000092092654],"about_ca_topic_score_codex":0.0008240992,"about_ca_topic_score_gemma":0.0020959955,"teacher_disagreement_score":0.0038082479,"about_ca_system_score_codex":0.000669125,"about_ca_system_score_gemma":0.0006940508,"threshold_uncertainty_score":0.020140171},"labels":[],"label_agreement":null},{"id":"W2417787511","doi":"10.1038/bcj.2016.36","title":"Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Fonds de Recherche du Québec - Santé; Deutsche Krebshilfe; Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Genome Canada","keywords":"Chemokine receptor; CX3CR1; Myeloid leukemia; Receptor; G protein-coupled receptor; Biology; CXCR4; Leukemia; Immunology; Myeloid; Cancer research; Chemokine; Genetics","score_opus":0.010879400758837152,"score_gpt":0.2460129510290285,"score_spread":0.23513355027019137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417787511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957022,0.0008207287,0.00084841467,0.000043645683,0.0000053573685,0.000013335247,0.0020051652,0.000019641811,0.0005415009],"genre_scores_gemma":[0.99258596,0.0008208427,0.0013995547,0.00007441997,0.000010164397,0.000045053446,0.0043206927,0.00001648737,0.0007269074],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998646,0.000013959717,0.000010055287,0.000042695105,0.000031474374,0.0000372898],"domain_scores_gemma":[0.9999473,0.000010060962,0.000016982369,0.0000050997564,0.000010718882,0.000009916087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008660281,0.00009951096,0.00029423504,0.00045417692,0.00021927766,0.00032992303,0.00007035598,0.00017246809,0.00088635704],"category_scores_gemma":[0.00017878403,0.00008608837,0.00025303088,0.00053565286,0.00011274619,0.00012731845,0.00022018397,0.00019498615,0.0002772633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046412274,0.000028862689,0.05292646,0.00012716127,0.000048856917,0.00017010378,0.00019627377,0.00024165743,0.933795,0.00011202514,0.0003032211,0.011586306],"study_design_scores_gemma":[0.000015613268,0.00023419959,0.9465328,0.00001800988,0.00013829245,0.001027567,0.00057576975,0.0023153732,0.044315692,0.0002260101,0.004586982,0.000013717039],"about_ca_topic_score_codex":0.00070736994,"about_ca_topic_score_gemma":0.0009877943,"teacher_disagreement_score":0.00088635704,"about_ca_system_score_codex":0.0001504404,"about_ca_system_score_gemma":0.00019258856,"threshold_uncertainty_score":0.0029651523},"labels":[],"label_agreement":null},{"id":"W2522441445","doi":"10.1038/bcj.2016.74","title":"Amyloid cast tubulopathy: a unique form of immunoglobulin-induced renal disease","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; Canadian Society of Nephrology","funders":"","keywords":"Tubulopathy; Antibody; Disease; Kidney; Medicine; Kidney disease; Amyloid (mycology); Amyloidosis; Immunology; Immunoglobulin A; Immunoglobulin G; Internal medicine; Pathology","score_opus":0.011926368532715604,"score_gpt":0.2677002099911104,"score_spread":0.25577384145839477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522441445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83172697,0.055664007,0.007249063,0.0038414944,0.0008264257,0.00040003986,0.0067379354,0.0007683568,0.092785664],"genre_scores_gemma":[0.9783967,0.010907284,0.0017974301,0.0012006501,0.0010638357,0.000037262034,0.0017746597,0.00006396039,0.0047582895],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99981016,0.000021678568,0.000020786807,0.000035305235,0.00006657313,0.000045556404],"domain_scores_gemma":[0.9995685,0.000096204574,0.00012949508,0.000021379174,0.000039371283,0.00014499953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014939316,0.0004295566,0.0007619014,0.0008578811,0.0004948369,0.0005856089,0.00032463946,0.0005302651,0.0039411555],"category_scores_gemma":[0.0009028801,0.00011608947,0.00015799358,0.0015284751,0.00038015624,0.0004655003,0.00056092726,0.00064138643,0.001350495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067185186,0.00029823897,0.18734547,0.0007644294,0.00010416439,0.6327497,0.00044947572,0.00045650647,0.013390561,0.003751596,0.036068194,0.12394988],"study_design_scores_gemma":[0.000042584892,0.00013439842,0.088378444,0.00014741872,0.00004362737,0.8898101,0.00015807063,0.0002294035,0.00094997126,0.001887305,0.018198077,0.000020634305],"about_ca_topic_score_codex":0.0008742786,"about_ca_topic_score_gemma":0.0012719629,"teacher_disagreement_score":0.0039411555,"about_ca_system_score_codex":0.0002872164,"about_ca_system_score_gemma":0.00042669894,"threshold_uncertainty_score":0.013184428},"labels":[],"label_agreement":null},{"id":"W2559984635","doi":"10.1038/bcj.2016.110","title":"MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia","year":2016,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Krebshilfe; Medizinische Fakultät, Universität Ulm; Canadian Institutes of Health Research; Universität Ulm; European Hematology Association; Barncancerfonden; Cancerfonden; Deutsche Forschungsgemeinschaft; Västra Götalandsregionen","keywords":"Myeloid leukemia; Medicine; Leukemia; Cancer research; Hematology; Myeloid; Suppressor; Oncology; Immunology; Internal medicine; Cancer","score_opus":0.016155506416765553,"score_gpt":0.29283192201753755,"score_spread":0.276676415600772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559984635","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28072593,0.045255423,0.0037645665,0.5611452,0.029595336,0.00017538754,0.00059981557,0.00044725972,0.07829111],"genre_scores_gemma":[0.83031994,0.014417007,0.0027461757,0.09481587,0.028307108,0.00013001454,0.000395006,0.000074843934,0.028793985],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996661,0.000079724334,0.00004636525,0.00003275224,0.00012726554,0.000047784426],"domain_scores_gemma":[0.99958223,0.0002057627,0.000044237477,0.000026873384,0.00005695762,0.0000839664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049227546,0.00024134989,0.0004946971,0.00015948054,0.00047649638,0.0007224817,0.00028438913,0.0019809816,0.0014725591],"category_scores_gemma":[0.0018463052,0.00013530077,0.0002482566,0.00015513258,0.00044536547,0.00032039572,0.00030412723,0.002221326,0.00078564946],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032107339,0.0004909095,0.030391777,0.0006194343,0.00012941194,0.12712564,0.00048710665,0.00091770175,0.12156841,0.017961295,0.3980287,0.2990689],"study_design_scores_gemma":[0.00081820565,0.0016957284,0.01890305,0.00012552473,0.000168045,0.11031438,0.00034661035,0.0030477012,0.053616583,0.010316614,0.80059665,0.00005081636],"about_ca_topic_score_codex":0.00018966732,"about_ca_topic_score_gemma":0.0004282654,"teacher_disagreement_score":0.0019809816,"about_ca_system_score_codex":0.00066525704,"about_ca_system_score_gemma":0.00032982018,"threshold_uncertainty_score":0.0049262047},"labels":[],"label_agreement":null},{"id":"W2588102416","doi":"10.1038/bcj.2017.10","title":"A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Genome Canada","keywords":"Myeloid leukemia; Leukemia; Cancer research; Medicine; Identification (biology); Stem cell; Computational biology; Cancer; Oncology; Biology; Immunology; Internal medicine; Genetics","score_opus":0.01758236777554964,"score_gpt":0.28041359196875115,"score_spread":0.2628312241932015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588102416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7224367,0.0073515787,0.25393358,0.0003498024,0.00011772198,0.0020137995,0.003655179,0.0014649524,0.008676613],"genre_scores_gemma":[0.8285691,0.0038484167,0.15632524,0.00022312831,0.00004469837,0.0011622886,0.0032048735,0.0001198394,0.00650235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999741,0.000057798898,0.00002119278,0.000071542345,0.00008330188,0.00002506984],"domain_scores_gemma":[0.9998821,0.000026267502,0.000015474065,0.000033699205,0.000024137333,0.000018208073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030594133,0.0004879708,0.00040337673,0.0007760526,0.00023546806,0.00025242777,0.00024414272,0.00022073007,0.0024450994],"category_scores_gemma":[0.00021473986,0.00022158958,0.00022427861,0.00034400684,0.00019241234,0.00016612525,0.0003880008,0.00043794583,0.00097435014],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006171044,0.000034038327,0.0003095298,0.000037913625,0.000007683251,0.00003499789,0.000012039293,0.00008059089,0.9931369,0.00006687721,0.00011659145,0.0061011566],"study_design_scores_gemma":[0.000016049582,0.00045925635,0.0030160088,0.0000060021885,0.000049331076,0.00064950035,0.000017397002,0.0009943352,0.9891424,0.00007161568,0.0055718264,0.000006411998],"about_ca_topic_score_codex":0.00025686165,"about_ca_topic_score_gemma":0.0010766987,"teacher_disagreement_score":0.0024450994,"about_ca_system_score_codex":0.00018783825,"about_ca_system_score_gemma":0.00036142205,"threshold_uncertainty_score":0.008179665},"labels":[],"label_agreement":null},{"id":"W2605150999","doi":"10.1038/bcj.2017.29","title":"Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"STAT5; Chronic myelogenous leukemia; T-cell receptor; CD8; T cell; Immunology; Leukemia; Imatinib mesylate; Cancer research; Medicine; Signal transduction; Biology; Imatinib; Internal medicine; Receptor; Immune system; Cell biology","score_opus":0.012434273716650008,"score_gpt":0.280681376245871,"score_spread":0.26824710252922096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605150999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754685,0.0011989109,0.00014021267,0.000070771464,0.00001401511,0.000024354295,0.00016546129,0.000016868182,0.0008225963],"genre_scores_gemma":[0.99902785,0.00024658232,0.000115933006,0.000045809404,0.000005624975,0.000023577604,0.00023150996,0.000001604011,0.00030156574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999144,0.000018563385,0.000009321465,0.000011050191,0.000018801991,0.000027887523],"domain_scores_gemma":[0.9999522,0.000008179092,0.000015323109,0.0000030835104,0.0000035921744,0.000017606893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013258235,0.00016264504,0.00025897153,0.00018308949,0.00010861483,0.00017074314,0.0000902556,0.00015878286,0.0014588201],"category_scores_gemma":[0.00014752317,0.000086990585,0.00015490717,0.0001492714,0.00011382937,0.000098078446,0.00011624223,0.00035497994,0.00023967659],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009334102,0.000783598,0.024945883,0.00020905981,0.00009593315,0.0005331927,0.00009144634,0.0007340188,0.9209716,0.00030068605,0.0013909377,0.04060958],"study_design_scores_gemma":[0.0018942183,0.027480872,0.46272326,0.00006514244,0.00030889912,0.003507788,0.00021809948,0.005270368,0.48178282,0.0004092875,0.016309531,0.000029717316],"about_ca_topic_score_codex":0.00021697061,"about_ca_topic_score_gemma":0.000565245,"teacher_disagreement_score":0.0014588201,"about_ca_system_score_codex":0.00016134384,"about_ca_system_score_gemma":0.00012792191,"threshold_uncertainty_score":0.0048802495},"labels":[],"label_agreement":null},{"id":"W2620976364","doi":"10.1038/bcj.2017.52","title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Interleukin-3 receptor; Transplantation; Medicine; Immunology; Haematopoiesis; Cancer research; Leukemia; Stem cell; Monoclonal antibody; Antibody; Oncology; Internal medicine; Biology","score_opus":0.03181450928796736,"score_gpt":0.3424555418308567,"score_spread":0.31064103254288933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620976364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550605,0.0013366606,0.0015717068,0.00007805243,0.000040452498,0.00022013966,0.0002700976,0.00005558894,0.0009212726],"genre_scores_gemma":[0.99725974,0.00045916,0.0009761761,0.00003289708,0.000019468207,0.00010866431,0.0006187423,0.000008336639,0.00051673193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975556,0.00008687931,0.000022954913,0.00003206632,0.000054317406,0.00004808714],"domain_scores_gemma":[0.999866,0.000024493396,0.000015799096,0.000030202447,0.000028840766,0.000034567493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046788718,0.00035087284,0.00058362994,0.0002516,0.00019178152,0.00032721035,0.00030330924,0.00030495762,0.0015916403],"category_scores_gemma":[0.00033515674,0.00015108212,0.00026247822,0.0002821021,0.00024942795,0.00019986191,0.0002905459,0.0007383694,0.00044971824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033468753,0.0012057463,0.0012856806,0.0001755081,0.000041228675,0.00011392095,0.00010913531,0.0010708994,0.9784424,0.00014441996,0.0003549238,0.013709473],"study_design_scores_gemma":[0.0010097385,0.029936524,0.0070241746,0.000016168879,0.00015392687,0.00074597093,0.000066167275,0.0042451397,0.95112485,0.00008691554,0.0055763195,0.000014021492],"about_ca_topic_score_codex":0.00072235987,"about_ca_topic_score_gemma":0.00067859393,"teacher_disagreement_score":0.0015916403,"about_ca_system_score_codex":0.00023307052,"about_ca_system_score_gemma":0.00029824037,"threshold_uncertainty_score":0.005324602},"labels":[],"label_agreement":null},{"id":"W2738560661","doi":"10.1038/bcj.2017.64","title":"Malignant T cells activate endothelial cells via IL-17 F","year":2017,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Novo Nordisk Fonden; Kræftens Bekæmpelse","keywords":"Cancer research; Medicine; Immunology; Biology; Cell biology","score_opus":0.027124843449397654,"score_gpt":0.3122429270310163,"score_spread":0.28511808358161866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738560661","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0537816,0.013699493,0.0024010923,0.8095875,0.0339549,0.0001316212,0.00013503207,0.00022589453,0.08608289],"genre_scores_gemma":[0.5824206,0.0103058545,0.00207054,0.25188252,0.097940385,0.0001648888,0.00014091465,0.000046888414,0.055027418],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950564,0.00023115594,0.00003334964,0.000031513584,0.0000945876,0.00010376317],"domain_scores_gemma":[0.9991334,0.0005223001,0.000075091986,0.00006703489,0.00011564422,0.00008659214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049367675,0.00034071587,0.00034144818,0.00022967701,0.0005903429,0.001152504,0.00036676292,0.0053490144,0.0071216114],"category_scores_gemma":[0.0029751004,0.00017999933,0.00032832622,0.00011821079,0.00060974096,0.0006762726,0.0004924374,0.0062541375,0.0028498692],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008678306,0.0005831692,0.015045061,0.00045811647,0.00007694028,0.13482638,0.00069624203,0.00045929456,0.016167149,0.027440926,0.66575485,0.13762398],"study_design_scores_gemma":[0.00049712625,0.00043150218,0.0037220165,0.00028276228,0.000066618675,0.06591457,0.00070850214,0.0018551775,0.007315491,0.017638408,0.90154,0.000027974515],"about_ca_topic_score_codex":0.00026887938,"about_ca_topic_score_gemma":0.00035881205,"teacher_disagreement_score":0.0071216114,"about_ca_system_score_codex":0.0007259747,"about_ca_system_score_gemma":0.00034382046,"threshold_uncertainty_score":0.023824215},"labels":[],"label_agreement":null},{"id":"W2760214433","doi":"10.1038/bcj.2017.86","title":"Meis2 as a critical player in MN1-induced leukemia","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; Deutsche Krebshilfe; University of British Columbia; BC Cancer Foundation; Vetenskapsrådet; Provincial Health Services Authority; Deutsche Forschungsgemeinschaft; Terry Fox Foundation; Genome British Columbia","keywords":"Biology; Myeloid leukemia; Cancer research; Leukemia; Myeloid; Progenitor cell; Phenotype; Hox gene; Stem cell; Gene expression profiling; Immunology; Genetics; Gene; Gene expression","score_opus":0.02087468825402057,"score_gpt":0.342248153853548,"score_spread":0.32137346559952745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760214433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840104,0.0050388286,0.0052308603,0.00022290547,0.00004099462,0.0000527663,0.0013362356,0.00018878073,0.0038782805],"genre_scores_gemma":[0.9814518,0.0025207277,0.0045742663,0.000060268812,0.000009628858,0.0000475399,0.0024966,0.000035943634,0.008803173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999366,0.0000059496933,0.0000049902546,0.00001696286,0.000023269748,0.000012308856],"domain_scores_gemma":[0.99997437,0.0000038022392,0.000006639355,0.0000029822781,0.0000032009211,0.000008984143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009139389,0.00040861883,0.00018754796,0.0001738686,0.00019721773,0.00026408976,0.00016332993,0.00014162132,0.0013648805],"category_scores_gemma":[0.00005235866,0.00008659026,0.00016647347,0.00012696057,0.0001484371,0.0001090403,0.00017059504,0.00040174345,0.00035020165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073614894,0.000014290266,0.0001794153,0.000025963489,0.0000026659175,0.000027306829,0.0000046586924,0.00006011873,0.99830735,0.00010117717,0.000034950157,0.0011685025],"study_design_scores_gemma":[0.0000054111047,0.000056137444,0.0026489624,0.0000026488194,0.0000061883097,0.00015250864,0.000007216303,0.0003419252,0.9926087,0.000030327205,0.004138615,0.0000013326838],"about_ca_topic_score_codex":0.0005444968,"about_ca_topic_score_gemma":0.0013856046,"teacher_disagreement_score":0.0013648805,"about_ca_system_score_codex":0.00041264112,"about_ca_system_score_gemma":0.00023498162,"threshold_uncertainty_score":0.004566014},"labels":[],"label_agreement":null},{"id":"W2771270080","doi":"10.1038/s41408-017-0020-0","title":"Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma","year":2017,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Oncolytic virus; Immune system; Multiple myeloma; Medicine; Malignancy; Immunotherapy; Virotherapy; Immunology; Clinical trial; Hematologic malignancy; Cancer research; Oncology; Internal medicine","score_opus":0.14036907443041122,"score_gpt":0.4619003633948275,"score_spread":0.3215312889644163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771270080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023840167,0.9980804,0.00022373328,0.00021552839,0.0002073594,0.0000074445875,0.000013312697,0.000009463661,0.0010043429],"genre_scores_gemma":[0.0011513431,0.99765635,0.00024090506,0.00018313288,0.00009884801,0.0000106309935,0.00002757993,0.000001959385,0.00062930293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998572,0.000023306207,0.000016982878,0.000023421782,0.000061272935,0.000017863065],"domain_scores_gemma":[0.9998653,0.000057260808,0.000021055535,0.0000049955556,0.000034872886,0.0000163862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005006471,0.00073297124,0.0010214769,0.0019352731,0.00026950717,0.0008503927,0.0008580246,0.0011735203,0.0019649887],"category_scores_gemma":[0.0004290653,0.0003090821,0.00044973902,0.0015925211,0.0004477215,0.0010954965,0.00064617035,0.002187807,0.0014571069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000935021,0.00012845336,0.0001275593,0.009972587,0.000099354074,0.0002697249,0.000068915004,0.00067385484,0.0048459405,0.0061459574,0.022856507,0.9547176],"study_design_scores_gemma":[0.000026074185,0.00012390045,0.00046719337,0.0014794046,0.0000773736,0.0012812049,0.00003396796,0.00016486105,0.0013544576,0.0016739934,0.9932989,0.000018614965],"about_ca_topic_score_codex":0.00064109464,"about_ca_topic_score_gemma":0.001212909,"teacher_disagreement_score":0.0019649887,"about_ca_system_score_codex":0.00069672184,"about_ca_system_score_gemma":0.0006000601,"threshold_uncertainty_score":0.006573558},"labels":[],"label_agreement":null},{"id":"W2771668512","doi":"10.1038/s41408-017-0023-x","title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","year":2017,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Amgen","keywords":"Blinatumomab; Lymphoblastic Leukemia; Medicine; CD19; Oncology; Acute lymphocytic leukemia; Internal medicine; Leukemia; Peripheral blood","score_opus":0.020605197598194517,"score_gpt":0.30439271494368203,"score_spread":0.2837875173454875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771668512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67784315,0.010792378,0.00256372,0.2347224,0.0057942728,0.00025827877,0.000737873,0.00025224884,0.06703559],"genre_scores_gemma":[0.944875,0.0045041083,0.0010505118,0.037175696,0.00479001,0.000052587395,0.00044561934,0.000049767335,0.007056682],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99963665,0.00009161709,0.00002749855,0.00004112253,0.00007535828,0.00012774745],"domain_scores_gemma":[0.99920696,0.0003028133,0.00009788744,0.000050545856,0.000066123444,0.00027569756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035496065,0.00034434497,0.0005396118,0.00034589003,0.0011001214,0.000698252,0.0007456626,0.003582244,0.0019679815],"category_scores_gemma":[0.002885062,0.00019923535,0.00048155242,0.00043627035,0.00064089673,0.0008376529,0.0005076431,0.0035226804,0.0008593676],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003916481,0.000097142845,0.015947105,0.000064813736,0.000022562437,0.93579566,0.00024530813,0.00037350517,0.0019015665,0.001995689,0.025005503,0.018159578],"study_design_scores_gemma":[0.0001957078,0.0005187746,0.02128513,0.0001381492,0.00007534674,0.9285467,0.00064089056,0.0025160564,0.0020250196,0.0039809323,0.040049855,0.000027372735],"about_ca_topic_score_codex":0.0021750405,"about_ca_topic_score_gemma":0.004020956,"teacher_disagreement_score":0.003582244,"about_ca_system_score_codex":0.0017753264,"about_ca_system_score_gemma":0.0008859707,"threshold_uncertainty_score":0.012880921},"labels":[],"label_agreement":null},{"id":"W2772253366","doi":"10.1038/s41408-017-0033-8","title":"MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sigrid Juséliuksen Säätiö; National Cancer Institute; Academy of Finland; Helsingin Yliopisto","keywords":"microRNA; Cancer research; Biology; Diffuse large B-cell lymphoma; Signal transduction; MAPK/ERK pathway; Chemoimmunotherapy; Lymphoma; Cancer; Biological pathway; Immunology; Gene expression; Gene; Cell biology; Genetics","score_opus":0.013978233493338417,"score_gpt":0.2677070162185166,"score_spread":0.2537287827251782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772253366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937534,0.004130664,0.001059921,0.000041633964,0.000008232592,0.00001909699,0.00019427224,0.000045725177,0.0007471727],"genre_scores_gemma":[0.9977055,0.000977789,0.00066929264,0.000034965513,0.0000061910923,0.000020316642,0.00016582916,0.000005978535,0.00041416034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998596,0.000028469207,0.0000131919705,0.000030723455,0.00003672942,0.00003124981],"domain_scores_gemma":[0.9999299,0.0000125871675,0.00003358525,0.0000050296576,0.00000939929,0.000009468349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016734625,0.00021018588,0.00017307895,0.0002865015,0.00011696863,0.00028559117,0.00008863303,0.00012984633,0.00037795719],"category_scores_gemma":[0.000263653,0.00013578984,0.00013781039,0.0001896382,0.00011800041,0.00014910311,0.00016148713,0.00017739821,0.00012951654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088346656,0.000051679428,0.030667417,0.00011297517,0.000042262865,0.00033669506,0.0001234827,0.0004980117,0.9405374,0.00022261718,0.00020431502,0.026319576],"study_design_scores_gemma":[0.00007039878,0.0007596561,0.4925021,0.000028275266,0.00016238862,0.0019738378,0.0002154922,0.004264706,0.49226236,0.00046979837,0.007268494,0.000022509024],"about_ca_topic_score_codex":0.00035018113,"about_ca_topic_score_gemma":0.00050841813,"teacher_disagreement_score":0.00037795719,"about_ca_system_score_codex":0.00025268254,"about_ca_system_score_gemma":0.00016115255,"threshold_uncertainty_score":0.0018333197},"labels":[],"label_agreement":null},{"id":"W2778096288","doi":"10.1038/s41408-017-0035-6","title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary; Mayo Clinic","keywords":"Medicine; Venous thrombosis; Internal medicine; Thrombosis; Polycythemia vera; Cardiology","score_opus":0.0634775556548781,"score_gpt":0.34844780470417197,"score_spread":0.28497024904929386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778096288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99932575,0.00021373706,0.00012473321,0.000029260747,0.0000059778367,0.0000072398634,0.000062306644,0.0000030999597,0.00022788956],"genre_scores_gemma":[0.99960953,0.00012139186,0.000065276494,0.00001948994,0.000018317889,0.0000054025586,0.00009187113,0.0000018342388,0.00006683697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99959,0.00014209664,0.000035839916,0.00009413473,0.00006412749,0.000073796495],"domain_scores_gemma":[0.99878937,0.00045146586,0.00027664224,0.000084760315,0.000059287297,0.00033854786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047143697,0.00030438715,0.00046669925,0.0005141689,0.00057738717,0.0006832451,0.00024775814,0.0005048073,0.0015622526],"category_scores_gemma":[0.0023602983,0.0003665282,0.0002767288,0.0006498754,0.0003378926,0.00047060344,0.0003665534,0.0006101982,0.00028808083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009200974,0.00006333605,0.9953656,0.0000061349447,0.0000203583,0.0018627344,0.00017182666,0.00003833854,0.00014689448,0.000017720522,0.00011092218,0.0021040512],"study_design_scores_gemma":[0.00005208522,0.0008154464,0.9778917,0.000018610528,0.000050010436,0.018973114,0.00080285996,0.0007193881,0.00021062573,0.00008482855,0.00036382835,0.000017481738],"about_ca_topic_score_codex":0.001256253,"about_ca_topic_score_gemma":0.0009983553,"teacher_disagreement_score":0.0015622526,"about_ca_system_score_codex":0.00021320545,"about_ca_system_score_gemma":0.00023971155,"threshold_uncertainty_score":0.005226314},"labels":[],"label_agreement":null},{"id":"W2789913912","doi":"10.1038/s41408-018-0050-2","title":"Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Ottawa; University of Calgary; Ottawa Hospital","funders":"","keywords":"Plerixafor; Hematopoietic cell; Term (time); Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Transplantation; CXCR4; Oncology; Function (biology); Internal medicine; Immunology; Stem cell; Receptor; Biology","score_opus":0.011379354230978871,"score_gpt":0.2886850860899934,"score_spread":0.2773057318590145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789913912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965144,0.008955475,0.00024848504,0.000340679,0.000037993526,0.00001207931,0.00005214061,0.000008763874,0.00069303095],"genre_scores_gemma":[0.99758947,0.0017123999,0.00013061616,0.00012152284,0.000067331435,0.0000064989413,0.00012928084,0.0000028812158,0.00024011369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978715,0.00008406061,0.000014689981,0.000017461862,0.000048878705,0.000047840003],"domain_scores_gemma":[0.9989604,0.00041486064,0.0002333767,0.000041944975,0.0000467377,0.00030273167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010196024,0.00023805027,0.00056355825,0.0002826125,0.0002085589,0.000564158,0.0003457153,0.00035857112,0.000837208],"category_scores_gemma":[0.0023888575,0.00005222328,0.00029022587,0.000254969,0.00038959886,0.0005185745,0.0003264031,0.0008825042,0.00018701458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08351982,0.005019974,0.52820987,0.00048793847,0.0005438469,0.0070032403,0.0003819725,0.004091175,0.02269335,0.0008829936,0.0019438257,0.34522203],"study_design_scores_gemma":[0.0008492883,0.067618825,0.9021448,0.00026983014,0.000939436,0.009333285,0.0005598921,0.0052115894,0.0076315915,0.0015213771,0.003881845,0.00003830266],"about_ca_topic_score_codex":0.0004294,"about_ca_topic_score_gemma":0.000532125,"teacher_disagreement_score":0.0010196024,"about_ca_system_score_codex":0.0003189639,"about_ca_system_score_gemma":0.00032320316,"threshold_uncertainty_score":0.005392194},"labels":[],"label_agreement":null},{"id":"W2790446180","doi":"10.1038/s41408-018-0064-9","title":"Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; ECOG-ACRIN Cancer Research Group; Harvard T.H. Chan School of Public Health; National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Medicine; Lenalidomide; Diffuse large B-cell lymphoma; Internal medicine; Lymphoma; Oncology; Retrospective cohort study; Clinical trial; Population; Multiple myeloma","score_opus":0.1007839434411648,"score_gpt":0.4406180394919117,"score_spread":0.3398340960507469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790446180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42337564,0.054331377,0.40282357,0.042959064,0.0049387473,0.02857753,0.0039217873,0.0041461796,0.034926128],"genre_scores_gemma":[0.66212475,0.010882531,0.291623,0.01343746,0.002302502,0.01273557,0.002061348,0.00034250037,0.0044904337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98695105,0.010052053,0.00036796698,0.0010767614,0.0012714616,0.0002806038],"domain_scores_gemma":[0.9892039,0.0040170425,0.0028475078,0.0015428084,0.0013182592,0.0010705185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026822792,0.0006120437,0.00090780744,0.0007243189,0.00041177194,0.0024783704,0.0011153537,0.0017409115,0.0029685786],"category_scores_gemma":[0.01235815,0.00039528246,0.00071079534,0.0005428769,0.0012748592,0.0024647545,0.0016691954,0.0024860294,0.00082859304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04089952,0.0054475316,0.01027247,0.0014862048,0.00057092,0.00043879222,0.00045027552,0.003688833,0.052374583,0.0144632235,0.031781465,0.8381261],"study_design_scores_gemma":[0.09583588,0.22501647,0.072443604,0.0023399638,0.0019329325,0.0063284496,0.0010212933,0.03877289,0.09232522,0.03791757,0.42539024,0.00067545415],"about_ca_topic_score_codex":0.00021976052,"about_ca_topic_score_gemma":0.0005944627,"teacher_disagreement_score":0.026822792,"about_ca_system_score_codex":0.00091873616,"about_ca_system_score_gemma":0.002197781,"threshold_uncertainty_score":0.14185417},"labels":[],"label_agreement":null},{"id":"W2791331105","doi":"10.1038/s41408-017-0039-2","title":"Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition","year":2018,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Faculty of Medicine, McGill University; McGill University","keywords":"Metabolism; Glutamine; Carbohydrate metabolism; Biology; Biochemistry; Medicine; Amino acid","score_opus":0.01505442161798423,"score_gpt":0.28737974831660995,"score_spread":0.27232532669862575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791331105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766972,0.0030918343,0.0007335791,0.009471096,0.00036113316,0.000030353825,0.00024777986,0.00010900062,0.0092579685],"genre_scores_gemma":[0.99458694,0.0006022055,0.00043646197,0.0022218216,0.00015618213,0.000022100314,0.00015927652,0.000009685327,0.0018052509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998658,0.000038602182,0.000011241978,0.000019332767,0.000029986699,0.00003500101],"domain_scores_gemma":[0.99984586,0.00005969776,0.000025500645,0.000016103975,0.000021858836,0.000031011485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014177819,0.0002448892,0.00029354545,0.00016695306,0.00025098043,0.00043593135,0.00016994888,0.00073040585,0.0016364774],"category_scores_gemma":[0.0005022371,0.00009175095,0.00015674334,0.00022026105,0.0002304329,0.00019423242,0.0001717362,0.00075363676,0.00037939902],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0123751275,0.00055787485,0.16413723,0.0003182036,0.00013358005,0.15809439,0.0007853833,0.0010432171,0.4991794,0.0026363167,0.019434495,0.14130466],"study_design_scores_gemma":[0.0009462688,0.005569413,0.35276473,0.00013506833,0.00029284367,0.35768843,0.002035702,0.0033953683,0.16194242,0.006117579,0.10902325,0.00008887825],"about_ca_topic_score_codex":0.00039382986,"about_ca_topic_score_gemma":0.0006318414,"teacher_disagreement_score":0.0016364774,"about_ca_system_score_codex":0.00042524035,"about_ca_system_score_gemma":0.00013458931,"threshold_uncertainty_score":0.0054745674},"labels":[],"label_agreement":null},{"id":"W2807346792","doi":"10.1038/s41408-018-0087-2","title":"Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Stem cell; Leukemia; Myeloid; Haematopoiesis; Cancer research; Medicine; Pharmacology; Oncology; Biology; Immunology; Genetics","score_opus":0.027511754514813476,"score_gpt":0.325757277402375,"score_spread":0.2982455228875615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807346792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98010135,0.001245971,0.0136396885,0.00019357096,0.0000119513425,0.000110229994,0.0017625315,0.0005919064,0.0023429794],"genre_scores_gemma":[0.981604,0.0009781681,0.013410014,0.000083774736,0.0000082373945,0.00005449689,0.0032421655,0.000025467361,0.0005937936],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987376,0.000023210925,0.000009063907,0.000021153348,0.000056932025,0.000015886988],"domain_scores_gemma":[0.9998902,0.000046417947,0.000030462541,0.0000067771048,0.00001656913,0.000009519381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020939118,0.00046681782,0.0007601644,0.0007412166,0.00012494362,0.0005216651,0.00024285977,0.00023266266,0.0011828126],"category_scores_gemma":[0.00046855785,0.00013313127,0.00065752235,0.000478243,0.00015189333,0.0002453758,0.00019709028,0.00022112209,0.00021657297],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016563713,0.0006947297,0.06993391,0.00088898523,0.00040119965,0.00040567035,0.000042091884,0.397984,0.39098582,0.002750361,0.0013389458,0.13291796],"study_design_scores_gemma":[0.00016572057,0.002104497,0.02378058,0.000032090145,0.00050300034,0.00033915465,0.00005929135,0.8334132,0.13152803,0.0024703941,0.005573951,0.000030117653],"about_ca_topic_score_codex":0.0010535853,"about_ca_topic_score_gemma":0.0018999061,"teacher_disagreement_score":0.0011828126,"about_ca_system_score_codex":0.00045654757,"about_ca_system_score_gemma":0.000651137,"threshold_uncertainty_score":0.003956914},"labels":[],"label_agreement":null},{"id":"W2884841488","doi":"10.1038/s41408-018-0103-6","title":"High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Medical Research Council; Université de Montréal; King's College London; Cancer Research UK; Compute Canada; National Institute for Health and Care Research; Leukemia and Lymphoma Society; Genome Canada; Blood Cancer UK; McGill University; Génome Québec","keywords":"Internal medicine; Oncology; Medicine; Myeloid leukemia; Cytogenetics; Cohort; Clinical trial; HMGA2; Biology; Gene; Genetics","score_opus":0.030074068534258973,"score_gpt":0.3631047606822544,"score_spread":0.3330306921479954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884841488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991866,0.00034853318,0.00013215601,0.000057697638,0.0000044658063,0.0000040378154,0.00008906369,0.0000050362432,0.00017253349],"genre_scores_gemma":[0.9994848,0.00008540945,0.00014029506,0.000019109255,0.0000148507,0.0000030770382,0.00017389694,0.0000017013822,0.000076867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996923,0.00013476044,0.00002647741,0.00004186233,0.0000678546,0.000036763187],"domain_scores_gemma":[0.99909186,0.00032739434,0.00028543072,0.00006457218,0.000056472047,0.00017429003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065833033,0.00016027845,0.00020823104,0.00037246846,0.0001657972,0.0003706503,0.00016996216,0.00022333459,0.00085918466],"category_scores_gemma":[0.0018457237,0.000116646515,0.0001248006,0.00037359024,0.0003483124,0.00016780067,0.00027498556,0.00041982994,0.00017934506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007148857,0.000036926125,0.9879496,0.000018474131,0.00005944547,0.00006677861,0.000029535606,0.00011466076,0.0054769455,0.000022928522,0.00017418672,0.0053356597],"study_design_scores_gemma":[0.000020897834,0.00015407076,0.99748033,0.0000037882485,0.000043044354,0.00023026728,0.000033653607,0.00044630602,0.001241238,0.00008171126,0.00026143464,0.0000032577175],"about_ca_topic_score_codex":0.00059080665,"about_ca_topic_score_gemma":0.00092023384,"teacher_disagreement_score":0.00085918466,"about_ca_system_score_codex":0.0001416767,"about_ca_system_score_gemma":0.00019945508,"threshold_uncertainty_score":0.0034816265},"labels":[],"label_agreement":null},{"id":"W2910040477","doi":"10.1038/s41408-018-0168-2","title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxicity; Cancer research; Antibody; Monoclonal antibody; Cell culture; Chemistry; Biology; Immunology; In vitro","score_opus":0.015420752743249182,"score_gpt":0.30757546229849314,"score_spread":0.292154709555244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910040477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964096,0.0009126313,0.0015903547,0.000050425504,0.000016587323,0.000025587104,0.0001406377,0.00006773014,0.0007864418],"genre_scores_gemma":[0.9975114,0.00033127345,0.0009515682,0.000023748707,0.0000079053225,0.000020554635,0.00020336751,0.00000790242,0.00094235846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998735,0.000030007071,0.000011976147,0.000021995093,0.00002830306,0.00003424896],"domain_scores_gemma":[0.999964,0.000006819729,0.000007708495,0.0000058394353,0.0000046763666,0.000010981107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010851287,0.00029714286,0.00025763377,0.000115589304,0.00007313814,0.0002264974,0.00014277274,0.00016890863,0.0013763391],"category_scores_gemma":[0.000075713186,0.000082237806,0.00018845753,0.000087744476,0.00014227128,0.0001728624,0.00021360163,0.00038671962,0.00038545718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001704015,0.00003478301,0.00009188641,0.000034215285,0.0000036575707,0.000024196645,0.000008725367,0.00006114712,0.99844366,0.000050615057,0.000035066278,0.00104157],"study_design_scores_gemma":[0.000026012054,0.00037548615,0.0008281741,0.0000022850747,0.000008954001,0.00015692844,0.000006175954,0.00059652736,0.9966175,0.000014660569,0.0013655968,0.0000017461327],"about_ca_topic_score_codex":0.00022154456,"about_ca_topic_score_gemma":0.00021706684,"teacher_disagreement_score":0.0013763391,"about_ca_system_score_codex":0.00017626751,"about_ca_system_score_gemma":0.00012338987,"threshold_uncertainty_score":0.00460428},"labels":[],"label_agreement":null},{"id":"W2920738037","doi":"10.1038/s41408-019-0190-z","title":"Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2019,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research UK","keywords":"Myeloid leukemia; Medicine; Myeloid; Internal medicine; Expression (computer science); MEDLINE; Bioinformatics; Computer science; Biology; Political science; Law","score_opus":0.024372206675235007,"score_gpt":0.3449138785461871,"score_spread":0.3205416718709521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920738037","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046856765,0.0014222064,0.0008283569,0.08591867,0.90741146,0.00002634243,0.0015610054,0.00030493605,0.0020584383],"genre_scores_gemma":[0.039479658,0.013918352,0.007904879,0.15630147,0.59763813,0.00024801688,0.006375915,0.0018044584,0.17632921],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968809,0.0005793595,0.0006216219,0.0004541962,0.0011569738,0.00030689017],"domain_scores_gemma":[0.9783427,0.006653868,0.0011564498,0.0010512116,0.011776336,0.0010193522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035847928,0.0021420452,0.0015369356,0.0030095608,0.002206951,0.0027122148,0.0030491957,0.006066733,0.030976936],"category_scores_gemma":[0.06049117,0.00095032697,0.0014804947,0.0017650644,0.0016128009,0.0017038016,0.0014254989,0.008858363,0.017123517],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005149845,0.0000060048287,0.00019670936,0.00010482295,0.000017780794,0.0006851487,0.000037996666,0.0000486842,0.00007990534,0.0004717258,0.99160004,0.006699717],"study_design_scores_gemma":[0.00012234825,0.000046810193,0.0021907112,0.0007566485,0.00013071414,0.004685341,0.00014539459,0.00052337436,0.0008791124,0.0022144788,0.9882125,0.000092548165],"about_ca_topic_score_codex":0.014201828,"about_ca_topic_score_gemma":0.012453195,"teacher_disagreement_score":0.030976936,"about_ca_system_score_codex":0.0028694444,"about_ca_system_score_gemma":0.0038627984,"threshold_uncertainty_score":0.1036281},"labels":[],"label_agreement":null},{"id":"W2923666301","doi":"10.1038/s41408-019-0196-6","title":"Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; National Institute for Health and Care Research; National Institutes of Health; American Society of Hematology; Cancer Research UK; National Cancer Institute; University College London; Celgene; University College London Hospitals NHS Foundation Trust; Sanofi; GlaxoSmithKline; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Internal medicine; Refractory (planetary science); Multiple myeloma; Interim analysis; Lenalidomide; Transplantation; Phases of clinical research; Clinical trial; Oncology; Gastroenterology; Surgery; Adverse effect; Biology","score_opus":0.02122107329605373,"score_gpt":0.35036038003859094,"score_spread":0.3291393067425372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923666301","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.287611,0.6613553,0.0065812687,0.01173937,0.0009988426,0.00081183814,0.00196194,0.0006365825,0.028303951],"genre_scores_gemma":[0.48871776,0.47594738,0.009275444,0.012460809,0.0017667902,0.0007308173,0.0046953536,0.0003004665,0.006105174],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990872,0.00032167125,0.00014004172,0.000069507136,0.0003193245,0.00006229468],"domain_scores_gemma":[0.9973085,0.0013292676,0.00046466693,0.00012197167,0.00060930435,0.0001663664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057120407,0.00043511967,0.0016719254,0.0006088347,0.00017419651,0.0014064186,0.0010940577,0.0007990086,0.0012133255],"category_scores_gemma":[0.0033129107,0.00027492057,0.000849626,0.0009037572,0.00040673124,0.00094664044,0.00032381382,0.0023499997,0.0005706914],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054269405,0.00073567417,0.0039470084,0.0038053226,0.00052668556,0.00038306427,0.00024193051,0.001072524,0.021526556,0.00078308186,0.015022632,0.9465286],"study_design_scores_gemma":[0.0370296,0.08810278,0.09974389,0.0049903626,0.005539485,0.0077386727,0.00043620443,0.006423648,0.049717676,0.003589477,0.69641924,0.0002689649],"about_ca_topic_score_codex":0.0006027064,"about_ca_topic_score_gemma":0.0015935936,"teacher_disagreement_score":0.0057120407,"about_ca_system_score_codex":0.00061772414,"about_ca_system_score_gemma":0.00076609635,"threshold_uncertainty_score":0.030208528},"labels":[],"label_agreement":null},{"id":"W2925264218","doi":"10.1038/s41408-019-0200-1","title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Carfilzomib; Multiple myeloma; Intensive care medicine; Population; Clinical trial; Ixazomib; Internal medicine","score_opus":0.01894229791230373,"score_gpt":0.29470740091309067,"score_spread":0.27576510300078694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925264218","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032529482,0.9938945,0.00017336254,0.0007190202,0.00008600823,0.000048010053,0.00015466799,0.0000089283785,0.0016625482],"genre_scores_gemma":[0.045976054,0.9497111,0.0011262762,0.0016208979,0.00020305994,0.000075417825,0.0004942191,0.0000038337785,0.0007891629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99934906,0.00025598632,0.00017527798,0.000048063095,0.00013515039,0.00003656559],"domain_scores_gemma":[0.9995433,0.0002050722,0.00015203177,0.000010364507,0.00006919844,0.000020064701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010746154,0.0002597017,0.0009407686,0.0009120444,0.00018214592,0.000620391,0.00037936537,0.0003568,0.0017886143],"category_scores_gemma":[0.0019942722,0.00010284544,0.00091127475,0.0008191031,0.000119898206,0.00045138484,0.00030112438,0.0005680575,0.00033907624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001522023,0.00009362557,0.002627262,0.05210249,0.0017317816,0.0002625501,0.00009997833,0.0002897945,0.0013524096,0.0006397161,0.013439501,0.92583895],"study_design_scores_gemma":[0.0023010701,0.0030342685,0.03197634,0.09381192,0.010704175,0.0058689793,0.00044108028,0.0004745125,0.0043180534,0.0031080123,0.84390736,0.000054325064],"about_ca_topic_score_codex":0.0010552026,"about_ca_topic_score_gemma":0.0033966769,"teacher_disagreement_score":0.0017886143,"about_ca_system_score_codex":0.0004304297,"about_ca_system_score_gemma":0.00076183927,"threshold_uncertainty_score":0.0059835315},"labels":[],"label_agreement":null},{"id":"W3021689191","doi":"10.1038/s41408-020-0321-6","title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Chromosomal translocation; Venetoclax; Amyloidosis; AL amyloidosis; Medicine; Internal medicine; Oncology; Cancer research; Leukemia; Immunology; Biology; Genetics","score_opus":0.025811673003337074,"score_gpt":0.29806781107969577,"score_spread":0.2722561380763587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021689191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52001244,0.40754664,0.0068295235,0.008238473,0.0023373526,0.0004957629,0.00077395537,0.0007723458,0.052993502],"genre_scores_gemma":[0.93766886,0.046713036,0.0023912934,0.0022648613,0.0006735426,0.00011987384,0.00045788166,0.000037945552,0.009672638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999472,0.000014387616,0.000002449722,0.0000060194425,0.00001730533,0.000012629325],"domain_scores_gemma":[0.9999229,0.000020908728,0.000014643744,0.000004149417,0.000006308686,0.000031061056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017037072,0.00015528472,0.00034181782,0.00028888174,0.0003435796,0.0002312651,0.00015897615,0.0002766913,0.0036952994],"category_scores_gemma":[0.00032849624,0.000034611967,0.00018010888,0.00022018858,0.00013545928,0.00015965186,0.00010817937,0.0010501592,0.0006259272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056820316,0.0022202944,0.008319501,0.0013422172,0.00024853917,0.011297974,0.0001928912,0.00078755873,0.026646303,0.0030296943,0.03971613,0.9005169],"study_design_scores_gemma":[0.010661203,0.03156687,0.16027789,0.0023437443,0.00061518396,0.16627733,0.00034941905,0.0046060192,0.022954881,0.007541465,0.5926872,0.00011878326],"about_ca_topic_score_codex":0.0006800642,"about_ca_topic_score_gemma":0.0016903108,"teacher_disagreement_score":0.0036952994,"about_ca_system_score_codex":0.00025259028,"about_ca_system_score_gemma":0.00020138323,"threshold_uncertainty_score":0.012362063},"labels":[],"label_agreement":null},{"id":"W3023905358","doi":"10.1038/s41408-020-0319-0","title":"The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Multiple myeloma; Bone marrow; Internal medicine; Cohort; Gastroenterology; Retrospective cohort study; Biopsy; Renal function; Pathology; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.014517996752799115,"score_gpt":0.24561186572125138,"score_spread":0.23109386896845227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023905358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9170376,0.06984249,0.0012843764,0.006203143,0.00039141838,0.000067045454,0.0004116223,0.00007029695,0.0046920087],"genre_scores_gemma":[0.9872241,0.009590712,0.0011675803,0.0012116553,0.00042352497,0.000019345087,0.0001920706,0.0000150101805,0.00015602694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986463,0.00050574116,0.0003065115,0.0001270887,0.000304338,0.00011008757],"domain_scores_gemma":[0.9909978,0.0035500566,0.00235049,0.00031539972,0.0019704779,0.00081575685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002370097,0.00034249094,0.0005883984,0.0014058716,0.00045861944,0.00086636684,0.00076923246,0.0009207131,0.0008495479],"category_scores_gemma":[0.012122145,0.00033409634,0.00029983837,0.00094036444,0.0005196076,0.001102032,0.00029442526,0.0006830661,0.0003867353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002454655,0.000041241932,0.9587237,0.00016331533,0.000044492783,0.0030465398,0.00016358844,0.00012251367,0.0008244757,0.000056303343,0.0015619778,0.035006426],"study_design_scores_gemma":[0.000036148245,0.0003375213,0.96904874,0.00078882254,0.0001283771,0.022435373,0.0017589733,0.0009322889,0.00090224185,0.00021587482,0.0033923083,0.000023244835],"about_ca_topic_score_codex":0.0035504387,"about_ca_topic_score_gemma":0.006481962,"teacher_disagreement_score":0.0035504387,"about_ca_system_score_codex":0.00032155178,"about_ca_system_score_gemma":0.00077750825,"threshold_uncertainty_score":0.01253444},"labels":[],"label_agreement":null},{"id":"W3024544545","doi":"10.1038/s41408-020-0324-3","title":"Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"LEO Fondet; Kom op tegen Kanker; Kræftens Bekæmpelse; Novo Nordisk Fonden; H. Lundbeck A/S; Lundbeckfonden; Novo Nordisk","keywords":"FOXP3; Immunology; Staphylococcus aureus; Lymphoma; Biology; Immune system; Cancer research; Antigen; MHC class II; T cell","score_opus":0.027901647223077017,"score_gpt":0.3006441397954133,"score_spread":0.2727424925723363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024544545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994405,0.0001342221,0.00017942037,0.000014519591,0.000003640662,0.000005608937,0.00001860956,0.0000085305655,0.00019496265],"genre_scores_gemma":[0.99943405,0.0000880205,0.00016075368,0.00001744671,0.000002934601,0.0000075392854,0.00003823146,0.000003267932,0.00024773125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994063,0.000014657557,0.000007751499,0.000009575477,0.000013572944,0.000013753161],"domain_scores_gemma":[0.999931,0.000018665254,0.000018023273,0.0000060208436,0.000006065103,0.000020289617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007344264,0.00017246102,0.0001231765,0.00019935108,0.0000921892,0.00010681563,0.00004908119,0.00017152836,0.0011159313],"category_scores_gemma":[0.00016415447,0.000084193634,0.00012843184,0.00007248954,0.00014985182,0.00008820236,0.00014233723,0.00027679052,0.0001277174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014409075,0.000029023047,0.0024292462,0.00001700829,0.0000027394437,0.0009298085,0.000038028535,0.000031772935,0.9951138,0.00004295018,0.000026221462,0.0011952244],"study_design_scores_gemma":[0.00022634672,0.0021275303,0.21168485,0.000026608845,0.00006749765,0.017211724,0.00039017427,0.0028270104,0.7614441,0.0005072158,0.0034746237,0.000012192411],"about_ca_topic_score_codex":0.00016739285,"about_ca_topic_score_gemma":0.00035433922,"teacher_disagreement_score":0.0011159313,"about_ca_system_score_codex":0.000108475935,"about_ca_system_score_gemma":0.000061438965,"threshold_uncertainty_score":0.0037330985},"labels":[],"label_agreement":null},{"id":"W3083502363","doi":"10.1038/s41408-020-00357-4","title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Internal medicine; Multiple myeloma; Regimen; Hazard ratio; Clinical endpoint; Oncology; Adverse effect; Randomized controlled trial; Confidence interval","score_opus":0.10023944158936043,"score_gpt":0.37622240002227375,"score_spread":0.2759829584329133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083502363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985134,0.009807525,0.00045622553,0.0005764757,0.00014892747,0.0008837587,0.0015587683,0.00007375666,0.0013606565],"genre_scores_gemma":[0.9885467,0.0032426363,0.0012658664,0.0012774266,0.00026425224,0.0010996622,0.0030862105,0.000033045537,0.0011842444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985561,0.0009963628,0.000068869515,0.00011979562,0.00013537648,0.00012348052],"domain_scores_gemma":[0.99892384,0.0002743138,0.00034098167,0.00010480906,0.000065761014,0.0002903558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044568703,0.0008705715,0.0017247169,0.0003009398,0.0002253508,0.00090604543,0.0007463568,0.00087432645,0.0017846122],"category_scores_gemma":[0.0017834643,0.00032604265,0.00234575,0.0003718731,0.00045950164,0.0006220171,0.0005200516,0.0021297967,0.0003608347],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89289963,0.009372162,0.008754101,0.0006925625,0.0038208438,0.00009481435,0.00013384591,0.001631512,0.007278913,0.00018576146,0.0029959402,0.07213993],"study_design_scores_gemma":[0.7479631,0.1962538,0.04352309,0.00013691126,0.0032429846,0.000259718,0.00007318861,0.0011388948,0.0017120959,0.0003708164,0.00527051,0.000054875993],"about_ca_topic_score_codex":0.00060823705,"about_ca_topic_score_gemma":0.002448866,"teacher_disagreement_score":0.0044568703,"about_ca_system_score_codex":0.0007437432,"about_ca_system_score_gemma":0.0008578198,"threshold_uncertainty_score":0.023570418},"labels":[],"label_agreement":null},{"id":"W3095225774","doi":"10.1038/s41408-020-00375-2","title":"Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Lenalidomide; Internal medicine; Daratumumab; Medicine; Oncology; Hazard ratio; Population; Multiple myeloma; Confidence interval","score_opus":0.03944056650698583,"score_gpt":0.3211153016057787,"score_spread":0.28167473509879287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095225774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974687,0.0017095004,0.00013768137,0.000068831854,0.000020198488,0.00008071208,0.00029710887,0.0000058287537,0.0002113833],"genre_scores_gemma":[0.99845994,0.0002711857,0.00018519379,0.000089712856,0.000033596665,0.00008649606,0.00065853336,0.0000037279783,0.00021157197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990965,0.0004589514,0.00011971263,0.00013709384,0.000109908986,0.00007778328],"domain_scores_gemma":[0.99937683,0.00023418311,0.00014532486,0.00009209551,0.000044702345,0.0001069397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016699424,0.00052121334,0.001605956,0.0006103639,0.0002486541,0.0006548723,0.00043954406,0.00034241096,0.0012895684],"category_scores_gemma":[0.0017728336,0.00024914675,0.0028186536,0.000537481,0.00021179547,0.0003274488,0.0005318558,0.0003883894,0.0001325084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41190165,0.0010613903,0.45057026,0.0010864604,0.03464718,0.0009069322,0.00042491982,0.001423198,0.016787644,0.00022030638,0.0024927335,0.07847725],"study_design_scores_gemma":[0.036203854,0.034915075,0.8800684,0.00017020215,0.031819243,0.0021264765,0.000831478,0.0040902784,0.0037831739,0.00055436406,0.005322071,0.000115310715],"about_ca_topic_score_codex":0.0007241129,"about_ca_topic_score_gemma":0.0017544016,"teacher_disagreement_score":0.0016699424,"about_ca_system_score_codex":0.00035220533,"about_ca_system_score_gemma":0.00037953755,"threshold_uncertainty_score":0.00883162},"labels":[],"label_agreement":null},{"id":"W3112832052","doi":"10.1038/s41408-020-00391-2","title":"Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Proteinuria; Medicine; Receiver operating characteristic; Gold standard (test); Albuminuria; Urine; Urology; Creatinine; Internal medicine; Renal function; Cohort; Cutoff; Area under the curve; Gastroenterology; Kidney","score_opus":0.013394281776035879,"score_gpt":0.2685380778017706,"score_spread":0.2551437960257347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112832052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993042,0.0002680624,0.00009338311,0.000022099839,0.000005932297,0.000003943585,0.00011421447,0.0000053644003,0.0001827197],"genre_scores_gemma":[0.99967515,0.000055172186,0.00006202206,0.0000141977,0.000009827503,0.000004301474,0.00014274428,0.0000018258002,0.000034745495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989755,0.00033078727,0.0001311919,0.00030939392,0.0001666464,0.000086535445],"domain_scores_gemma":[0.9960855,0.0013296725,0.0014868169,0.00032240804,0.00035405206,0.00042155615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011686978,0.00033124926,0.00050721987,0.0010400936,0.00035895896,0.0008314533,0.0003812708,0.0005752902,0.0010295175],"category_scores_gemma":[0.004842844,0.00030060203,0.0003684045,0.0007123689,0.00042964425,0.00060788123,0.00038464487,0.00055764645,0.00027513978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062914405,0.000008425282,0.99916613,0.0000035689386,0.000028611517,0.00008696615,0.000020965557,0.000042920263,0.00011322616,0.0000046699315,0.00003661717,0.00042507277],"study_design_scores_gemma":[0.0000066029015,0.00006895964,0.9984849,0.0000028128807,0.000018750294,0.000724523,0.00006337683,0.00047391848,0.000053000356,0.000014935571,0.00008347061,0.00000489694],"about_ca_topic_score_codex":0.0013277169,"about_ca_topic_score_gemma":0.001002035,"teacher_disagreement_score":0.0013277169,"about_ca_system_score_codex":0.00021884906,"about_ca_system_score_gemma":0.0001770025,"threshold_uncertainty_score":0.0061807632},"labels":[],"label_agreement":null},{"id":"W3132537256","doi":"10.1038/s41408-021-00429-z","title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Minimal residual disease; Medicine; Cancer research; Leukemia; Hematology; Drug development; Immunology; Oncology; Pharmacology; Drug; Internal medicine; Tyrosine kinase; Receptor","score_opus":0.02705962028518334,"score_gpt":0.34454831379110384,"score_spread":0.3174886935059205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132537256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909213,0.00340434,0.0036292581,0.0001549094,0.000019817324,0.000022661252,0.000077741955,0.000065735985,0.0017041848],"genre_scores_gemma":[0.9972236,0.0005443269,0.0013556697,0.00003370664,0.000010718533,0.000018042363,0.00006350234,0.0000056841836,0.00074477337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987197,0.000031341493,0.000005722666,0.00002042776,0.000031270945,0.00003933924],"domain_scores_gemma":[0.99994636,0.000016535994,0.000013535291,0.000008234762,0.000004024709,0.000011175176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001726206,0.00027086033,0.0003413909,0.0001803505,0.00015141556,0.00047057137,0.00020324899,0.00025737277,0.0010009353],"category_scores_gemma":[0.00014620554,0.00012320575,0.00015422728,0.00012524074,0.0002589088,0.00038890622,0.00018262868,0.00049965933,0.00014825306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005903217,0.00011330237,0.0014346105,0.00006295243,0.000008292363,0.00004823421,0.000046049205,0.0009999806,0.9821378,0.0005317985,0.000114831186,0.013911792],"study_design_scores_gemma":[0.00020046317,0.0025848735,0.015311313,0.000013374278,0.000052409025,0.0007936847,0.000132788,0.014189763,0.9610124,0.0006815234,0.0050126626,0.000014736321],"about_ca_topic_score_codex":0.00058414193,"about_ca_topic_score_gemma":0.0010242654,"teacher_disagreement_score":0.0010009353,"about_ca_system_score_codex":0.00029114127,"about_ca_system_score_gemma":0.00021628241,"threshold_uncertainty_score":0.0033484697},"labels":[],"label_agreement":null},{"id":"W3135629194","doi":"10.1038/s41408-021-00440-4","title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Mayo Clinic","keywords":"Immune system; Immunology; Multiple myeloma; Immunosurveillance; Tumor microenvironment; Immunotherapy; Cancer research; Biology; Immunosuppression; Stem cell; Medicine; Cell biology","score_opus":0.012191571370281424,"score_gpt":0.2555898192621097,"score_spread":0.2433982478918283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135629194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993154,0.00025308665,0.0001608246,0.0000065077206,9.911564e-7,0.000004799376,0.00006199459,0.000007657336,0.00018876734],"genre_scores_gemma":[0.9995604,0.000059420327,0.0001537498,0.000010606601,0.00000303064,0.0000062023364,0.00010870754,0.0000026370112,0.00009519841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999824,0.000029414141,0.000013453323,0.00005305529,0.000039221904,0.000040895993],"domain_scores_gemma":[0.9998344,0.000021482381,0.000063471314,0.000027004471,0.00001939543,0.000034127053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014466196,0.0001403473,0.00023528966,0.0005707257,0.00021624798,0.0003006476,0.00011545822,0.00016757553,0.0007099119],"category_scores_gemma":[0.00023706318,0.000106733154,0.00012042596,0.00042615097,0.00021141313,0.00011289896,0.00026610974,0.0002171337,0.00016522259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011994276,0.00007657779,0.2636699,0.000053136842,0.000059682596,0.00093837065,0.00039857786,0.00017603983,0.72221816,0.00013425075,0.00011397181,0.010961885],"study_design_scores_gemma":[0.000015396125,0.00036889876,0.9735284,0.0000040565724,0.000025512665,0.0029825196,0.00017214377,0.0002868905,0.021973131,0.00009028152,0.0005473115,0.000005392845],"about_ca_topic_score_codex":0.0005869883,"about_ca_topic_score_gemma":0.0008206227,"teacher_disagreement_score":0.0007099119,"about_ca_system_score_codex":0.00019686979,"about_ca_system_score_gemma":0.00010623035,"threshold_uncertainty_score":0.002374947},"labels":[],"label_agreement":null},{"id":"W3154921500","doi":"10.1038/s41408-021-00463-x","title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); McGill University Health Centre; McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Polycythemia vera; Thrombosis; Hematology; Medicine; Internal medicine; Phenotype; Gastroenterology; Immunology; Biology; Genetics","score_opus":0.048162946961059695,"score_gpt":0.3147656740675299,"score_spread":0.2666027271064702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154921500","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949988,0.00040955818,0.00013933718,0.00071043835,0.00005374325,0.000009246963,0.00012284389,0.0000061433957,0.00354996],"genre_scores_gemma":[0.9992495,0.000105473744,0.000041479376,0.00016676255,0.0000840538,0.000002989886,0.00006592149,0.0000029379123,0.00028079588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961495,0.00014720061,0.000044008997,0.000047611768,0.00007028173,0.00007598332],"domain_scores_gemma":[0.99841905,0.0007257237,0.00026489055,0.0000909604,0.00019163708,0.00030771244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033839597,0.00012685976,0.00032805308,0.0006297286,0.00026014625,0.00045226846,0.00021034629,0.0006398094,0.0021796902],"category_scores_gemma":[0.0034406553,0.000082200095,0.00017315224,0.00058200373,0.00020509642,0.00027009725,0.00018965537,0.0004941139,0.00043046946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001737806,0.0001398636,0.95827466,0.00002923726,0.00003656174,0.023534756,0.00022284841,0.00006893121,0.0037911045,0.00040089674,0.0009781832,0.010785113],"study_design_scores_gemma":[0.00006397039,0.00062542025,0.9231024,0.000019442425,0.00003851102,0.07194631,0.00052113214,0.0007544149,0.0008993551,0.00048599858,0.0015318102,0.000011251618],"about_ca_topic_score_codex":0.0006496341,"about_ca_topic_score_gemma":0.0006293413,"teacher_disagreement_score":0.0021796902,"about_ca_system_score_codex":0.00028930508,"about_ca_system_score_gemma":0.00010319143,"threshold_uncertainty_score":0.007291734},"labels":[],"label_agreement":null},{"id":"W3168326299","doi":"10.1038/s41408-021-00507-2","title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; bluebird bio; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Surgery","score_opus":0.036563343465977595,"score_gpt":0.3583077447515886,"score_spread":0.321744401285611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168326299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977119,0.000820936,0.00049320573,0.000054848482,0.00001959611,0.000069092464,0.00045209582,0.000029628236,0.00034873094],"genre_scores_gemma":[0.99816245,0.00016886684,0.00041235122,0.00004385717,0.000029320374,0.00009069703,0.0009096838,0.000012391087,0.0001705619],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965959,0.0023133038,0.00016463365,0.00057635835,0.00019673425,0.00015297603],"domain_scores_gemma":[0.99506986,0.0021262353,0.0015895021,0.0006945265,0.00013220478,0.0003875942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008663065,0.00067106547,0.001146248,0.00045487448,0.00011888905,0.0008963797,0.0010645214,0.0006610993,0.0017122069],"category_scores_gemma":[0.006668426,0.00027974276,0.0024072118,0.0003975406,0.00039002506,0.0010779487,0.0009834864,0.0010556857,0.00029979693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7139891,0.0037477084,0.1841048,0.00082454813,0.014061685,0.000112045374,0.00026738492,0.013717809,0.0036446995,0.0005393687,0.00096675416,0.06402411],"study_design_scores_gemma":[0.040968485,0.22879978,0.6688214,0.00015387018,0.007477293,0.00052769843,0.00033183463,0.04584254,0.0021931762,0.0011550058,0.003576257,0.0001526432],"about_ca_topic_score_codex":0.0005942097,"about_ca_topic_score_gemma":0.0006631747,"teacher_disagreement_score":0.008663065,"about_ca_system_score_codex":0.00073773676,"about_ca_system_score_gemma":0.0005472959,"threshold_uncertainty_score":0.04581517},"labels":[],"label_agreement":null},{"id":"W3175478791","doi":"10.1038/s41408-021-00505-4","title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Internal medicine; Medicine; Gastroenterology; Biomarker; Cohort; Hematology; Oncology; Monoclonal; Immunology; Monoclonal antibody; Antibody; Biology","score_opus":0.029876526239525292,"score_gpt":0.31746582814420443,"score_spread":0.28758930190467913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175478791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993148,0.0003298589,0.00003244643,0.000025170404,0.0000028552463,0.000002623887,0.00010725069,0.0000033154492,0.00018162625],"genre_scores_gemma":[0.99961996,0.000064931155,0.000033170803,0.00001068264,0.000007836708,0.0000023424657,0.00019476996,8.39068e-7,0.00006540729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981636,0.00003972339,0.000022675273,0.000039702936,0.000042744297,0.00003878359],"domain_scores_gemma":[0.999033,0.00019543088,0.00041946245,0.000055372235,0.00006990168,0.00022687377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044492973,0.00025906437,0.00038619776,0.00080971734,0.00031737293,0.00048547154,0.000244058,0.00045012098,0.0008557661],"category_scores_gemma":[0.001889517,0.00017400576,0.0003254408,0.00081567717,0.00026754173,0.00036570974,0.00049412635,0.00049195887,0.00018110735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003345422,0.000011772269,0.997849,0.0000041563985,0.000025926065,0.000041673356,0.000017986431,0.000059248145,0.0002800947,0.000010972081,0.00003969066,0.0013249994],"study_design_scores_gemma":[0.000008690159,0.0001129688,0.9991184,0.0000027034987,0.000025609264,0.00019188476,0.000024840223,0.00028791858,0.00009487523,0.00004625657,0.00008395153,0.0000018376999],"about_ca_topic_score_codex":0.002140023,"about_ca_topic_score_gemma":0.0024053643,"teacher_disagreement_score":0.002140023,"about_ca_system_score_codex":0.00029798117,"about_ca_system_score_gemma":0.00019909749,"threshold_uncertainty_score":0.0042551756},"labels":[],"label_agreement":null},{"id":"W3177665412","doi":"10.1038/s41408-021-00522-3","title":"Drug importation: limitations of current proposals and opportunities for improvement","year":2021,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Panacea (medicine); Business; Drug prices; Authorization; Drug; International trade; Law; Public economics; Economic policy; Medicine; Economics; Pharmacology; Political science; Computer security; Alternative medicine","score_opus":0.18921442342185205,"score_gpt":0.34818537186670157,"score_spread":0.15897094844484952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177665412","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004677635,0.019251328,0.0004248443,0.34592745,0.6313385,0.000018977813,0.000056510075,0.00008225979,0.0028534438],"genre_scores_gemma":[0.00091185863,0.019884007,0.0008150197,0.094078474,0.878457,0.00003401565,0.000039824605,0.00005846017,0.005721295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9768935,0.0054918765,0.0035400782,0.0020876245,0.011124461,0.00086239935],"domain_scores_gemma":[0.7626965,0.14499536,0.0053738803,0.006079157,0.07331059,0.0075446195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047888484,0.0027302357,0.0034468065,0.0045363666,0.0043884595,0.0155279245,0.0053583407,0.025207894,0.0104194],"category_scores_gemma":[0.16725469,0.0011192871,0.002770428,0.0036462622,0.008190725,0.01575353,0.0023704085,0.03521914,0.007866537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016549368,0.000016440681,0.000027546355,0.00030504173,0.000012031036,0.00005676286,0.00003760045,0.000052675296,0.00002163609,0.0054794885,0.9809522,0.01302194],"study_design_scores_gemma":[0.000033938148,0.000016434973,0.00017121699,0.0010675362,0.000026656708,0.00011749943,0.00012494087,0.00027075675,0.00004851814,0.016386919,0.9817073,0.000028357357],"about_ca_topic_score_codex":0.0035437865,"about_ca_topic_score_gemma":0.0070744185,"teacher_disagreement_score":0.047888484,"about_ca_system_score_codex":0.007831742,"about_ca_system_score_gemma":0.011948239,"threshold_uncertainty_score":0.25326157},"labels":[],"label_agreement":null},{"id":"W3198880734","doi":"10.1038/s41408-021-00544-x","title":"A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Singapore General Hospital; National University of Singapore; Onyx Pharmaceuticals; Duke-NUS Medical School","keywords":"Carfilzomib; Dexamethasone; Medicine; Cyclophosphamide; Internal medicine; Phase (matter); Oncology; Intensive care medicine; Chemotherapy; Lenalidomide; Chemistry","score_opus":0.025987748150059484,"score_gpt":0.3327062772657641,"score_spread":0.30671852911570463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198880734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7568472,0.030563315,0.0020931712,0.15662618,0.011721583,0.0033729214,0.0052680466,0.0004287618,0.033078812],"genre_scores_gemma":[0.87043035,0.0093023805,0.004184124,0.08039477,0.004498162,0.0021394945,0.0041266056,0.000077041084,0.024847096],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971205,0.00012339026,0.000017246319,0.00004615764,0.000043165437,0.00005796249],"domain_scores_gemma":[0.9993026,0.00020511687,0.000057220182,0.000023630442,0.000049443774,0.00036202846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093251513,0.0005108969,0.001127319,0.00020253166,0.0004732413,0.0008618446,0.00066253013,0.0030141638,0.0044509526],"category_scores_gemma":[0.0011598157,0.0002417845,0.0006061303,0.00025414283,0.00036447798,0.00054128084,0.00023869892,0.0039838175,0.0012892496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22338083,0.019391222,0.011229095,0.0009343246,0.0008961449,0.0066532893,0.00048209185,0.0020672623,0.020110333,0.0019225244,0.2105362,0.5023968],"study_design_scores_gemma":[0.48623756,0.20046723,0.04293446,0.0003519593,0.00094796286,0.009100086,0.00030473107,0.005406641,0.0060291914,0.0042664967,0.24385177,0.00010194828],"about_ca_topic_score_codex":0.0012074934,"about_ca_topic_score_gemma":0.0045550303,"teacher_disagreement_score":0.0044509526,"about_ca_system_score_codex":0.0012895984,"about_ca_system_score_gemma":0.0008803718,"threshold_uncertainty_score":0.014889896},"labels":[],"label_agreement":null},{"id":"W3204092402","doi":"10.1038/s41408-021-00555-8","title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Genentech; Aptitude Health; AbbVie","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine","score_opus":0.011538544988294298,"score_gpt":0.27638876329451056,"score_spread":0.26485021830621625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204092402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843854,0.0010139705,0.00008769858,0.000037943963,0.000008023882,0.000019079458,0.00009869153,0.000008252086,0.00028774267],"genre_scores_gemma":[0.9991837,0.00021739132,0.00010107697,0.000051151117,0.000017400569,0.000012787987,0.00023504373,0.0000015984716,0.00017988235],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997044,0.0001196001,0.000022909298,0.00005509835,0.00003982313,0.0000581752],"domain_scores_gemma":[0.99900204,0.000290314,0.00038378205,0.00010142578,0.00005649229,0.00016590947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011120585,0.00017721833,0.00093596213,0.0001678903,0.00016970582,0.0003488779,0.00015456456,0.00042136176,0.0011535666],"category_scores_gemma":[0.0013320245,0.00010170672,0.0004977111,0.00022451524,0.00018267761,0.00024193831,0.00020971526,0.00081717403,0.00014560285],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38173023,0.005404921,0.26597014,0.00046750487,0.0012056397,0.0006348339,0.00047809308,0.0019106187,0.06430861,0.00022629353,0.0015576876,0.27610543],"study_design_scores_gemma":[0.0167583,0.13945244,0.8243582,0.00008051297,0.0011458823,0.0013184559,0.00011765174,0.0025704035,0.009478599,0.00017869774,0.004484142,0.000056784684],"about_ca_topic_score_codex":0.0003397849,"about_ca_topic_score_gemma":0.0006907235,"teacher_disagreement_score":0.0011535666,"about_ca_system_score_codex":0.00025226967,"about_ca_system_score_gemma":0.00017827113,"threshold_uncertainty_score":0.0058811903},"labels":[],"label_agreement":null},{"id":"W3206224016","doi":"10.1038/s41408-021-00561-w","title":"Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Acute promyelocytic leukemia; NPM1; Retinoic acid receptor alpha; Myeloid leukemia; Retinoic acid; Cancer research; Retinoic acid receptor; Leukemia; Myeloid; Hematology; Medicine; Arsenic trioxide; Internal medicine; Biology; Oncology; Immunology; Genetics; Karyotype","score_opus":0.010544463350792267,"score_gpt":0.2419341986136415,"score_spread":0.23138973526284923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206224016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818688,0.0017762939,0.00081529166,0.00095093163,0.00009736591,0.000043051088,0.00040094313,0.00004311786,0.014004209],"genre_scores_gemma":[0.99735653,0.0003786424,0.00015563316,0.00025597002,0.00021743687,0.000013856412,0.0003028059,0.00001106409,0.0013080528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996773,0.00004323571,0.00003233835,0.000066337656,0.0000638224,0.000116991636],"domain_scores_gemma":[0.9990847,0.00019216047,0.00022493019,0.00006830489,0.0001185543,0.00031135566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020846368,0.00036687677,0.0004336997,0.00065531087,0.0005414299,0.0004967452,0.00031701336,0.0010070115,0.0023497269],"category_scores_gemma":[0.0018774726,0.00011162829,0.00019639527,0.00070906506,0.00031514082,0.00048663703,0.00033764206,0.00063936505,0.00093810575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001080108,0.00017422371,0.5389695,0.00004858593,0.000027195016,0.4321411,0.00035482703,0.00048415,0.0064545088,0.0011068837,0.00199223,0.01716671],"study_design_scores_gemma":[0.000029545914,0.00038313642,0.29029918,0.00002280159,0.00003440768,0.7018953,0.00031666007,0.0007602244,0.000536341,0.0011136192,0.0045791278,0.000029738905],"about_ca_topic_score_codex":0.00066005386,"about_ca_topic_score_gemma":0.0005000636,"teacher_disagreement_score":0.0023497269,"about_ca_system_score_codex":0.00045323686,"about_ca_system_score_gemma":0.0002205275,"threshold_uncertainty_score":0.007860661},"labels":[],"label_agreement":null},{"id":"W3208012644","doi":"10.1038/s41408-021-00565-6","title":"Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine; Pediatrics","score_opus":0.01351894866652132,"score_gpt":0.28720051549605913,"score_spread":0.2736815668295378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208012644","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037160632,0.000934371,0.00032382034,0.07888905,0.91741544,0.000015677053,0.00063178164,0.00011996657,0.0012983002],"genre_scores_gemma":[0.036151405,0.009444815,0.004093437,0.20569415,0.61676604,0.00020554686,0.0018549223,0.0011140844,0.12467557],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970355,0.0005359861,0.00055898086,0.00040616957,0.0011294481,0.0003338712],"domain_scores_gemma":[0.9820739,0.00734457,0.0011849698,0.0010986611,0.0073380726,0.00095973804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038304378,0.0018622626,0.002314361,0.0023778046,0.0020825267,0.0025505763,0.0031448756,0.008711941,0.01357752],"category_scores_gemma":[0.04856237,0.0011085618,0.0015701692,0.0014181768,0.0017238714,0.0014001089,0.00090956065,0.012448206,0.010079513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007889901,0.000011563371,0.00019489459,0.00008771595,0.000021114176,0.0010450387,0.000023641163,0.00005217433,0.000038053826,0.00037646428,0.99397016,0.0041002086],"study_design_scores_gemma":[0.0002532594,0.0000942545,0.0030729026,0.00057738426,0.00017950065,0.00548269,0.0001367962,0.0008281568,0.00073882774,0.0014185993,0.9871272,0.00009038263],"about_ca_topic_score_codex":0.015920864,"about_ca_topic_score_gemma":0.017050168,"teacher_disagreement_score":0.015920864,"about_ca_system_score_codex":0.004252991,"about_ca_system_score_gemma":0.003831122,"threshold_uncertainty_score":0.045421362},"labels":[],"label_agreement":null},{"id":"W3208762835","doi":"10.1038/s41408-021-00568-3","title":"A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Menzies Centre for Australian Studies, King's College London, University of London; Gillings School of Public Health; Sidney Kimmel Comprehensive Cancer Center; King's College London; CHILDREN with CANCER UK; Johns Hopkins University","keywords":"Mitoxantrone; Cytarabine; Myeloid leukemia; Medicine; Biomarker; Internal medicine; Oncology; Refractory (planetary science); Hematology; Leukemia; Myeloid; Cancer research; Chemotherapy; Chemistry; Biology","score_opus":0.01458154797642146,"score_gpt":0.28983538762658784,"score_spread":0.27525383965016637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208762835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339818,0.0050110146,0.0009303994,0.051710427,0.0016955251,0.00012658506,0.0015220115,0.00008130328,0.0049410425],"genre_scores_gemma":[0.9682072,0.00078883115,0.0011464014,0.025257466,0.0022165375,0.000080032056,0.0008062634,0.000020598161,0.0014767245],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991652,0.00028871707,0.00010655396,0.00013046489,0.00020974869,0.00009935758],"domain_scores_gemma":[0.9974189,0.0013418056,0.00029592868,0.00012057147,0.00041539894,0.0004073978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010402764,0.00024749822,0.0007691086,0.00042287292,0.00047771083,0.0008709913,0.00045099776,0.0018566516,0.0006649579],"category_scores_gemma":[0.0038446763,0.00022200894,0.00045161057,0.00057253975,0.0002660296,0.00037797992,0.00017654,0.001267082,0.00033251234],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029997211,0.0015082754,0.7431608,0.0002666261,0.00069941,0.036605928,0.00034513985,0.00132798,0.026103884,0.0009250601,0.050550815,0.10850889],"study_design_scores_gemma":[0.0032692698,0.016793074,0.80631745,0.00023527206,0.0013817656,0.06035035,0.0006947265,0.012381414,0.017503835,0.0032987972,0.077605225,0.00016879028],"about_ca_topic_score_codex":0.00081429025,"about_ca_topic_score_gemma":0.0019262717,"teacher_disagreement_score":0.0018566516,"about_ca_system_score_codex":0.0009838463,"about_ca_system_score_gemma":0.00071657135,"threshold_uncertainty_score":0.0071383715},"labels":[],"label_agreement":null},{"id":"W3216448276","doi":"10.1038/s41408-021-00569-2","title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Risk stratification; Medicine; Stratification (seeds); Internal medicine; Oncology; Intensive care medicine; Biology","score_opus":0.043779452069503774,"score_gpt":0.3397416861487298,"score_spread":0.295962234079226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216448276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996815,0.000448899,0.0014678285,0.000096230775,0.000022973993,0.000021907685,0.00037948907,0.00003409064,0.0007135582],"genre_scores_gemma":[0.99839383,0.0000697742,0.00068745104,0.00001358308,0.000020236934,0.000011280891,0.00061718456,0.0000057361162,0.00018090747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998696,0.0005696479,0.000094169365,0.00023142115,0.00023843933,0.0001702631],"domain_scores_gemma":[0.99586606,0.0014757698,0.001304019,0.00048569607,0.0004900996,0.00037840015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028463993,0.00061334885,0.0006193075,0.0008500966,0.00027846842,0.00084497686,0.0005020287,0.0004247706,0.00072549476],"category_scores_gemma":[0.00940264,0.00016521629,0.00064114446,0.00081212434,0.00019308683,0.0006179888,0.000753177,0.00092751754,0.0002659109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012610569,0.000044031072,0.9849726,0.000011752132,0.0001622988,0.00005752223,0.00005396606,0.0016018304,0.000475255,0.000068698835,0.00023514446,0.011055744],"study_design_scores_gemma":[0.000048155456,0.0011393295,0.9807427,0.000012917516,0.00022398139,0.00027028393,0.00007988579,0.015574695,0.0008374068,0.0003406618,0.0007075849,0.000022502845],"about_ca_topic_score_codex":0.0036242155,"about_ca_topic_score_gemma":0.003981984,"teacher_disagreement_score":0.0036242155,"about_ca_system_score_codex":0.00047613835,"about_ca_system_score_gemma":0.00046220666,"threshold_uncertainty_score":0.015053391},"labels":[],"label_agreement":null},{"id":"W344822596","doi":"10.1038/bcj.2015.35","title":"NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates; Killam Trusts; University of Alberta; Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; MSH2; Cancer research; Phosphorylation; Tyrosine kinase; Tyrosine phosphorylation; Anaplastic large-cell lymphoma; Transfection; Tyrosine; Molecular biology; Chemistry; Biology; Cell biology; Signal transduction; DNA mismatch repair; Biochemistry; DNA repair; Lymphoma; Medicine; DNA; Gene; Internal medicine; Immunology","score_opus":0.024010159222079917,"score_gpt":0.26744182695403806,"score_spread":0.24343166773195815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W344822596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946966,0.00078148104,0.0035019626,0.00007274176,0.00001771469,0.000015363632,0.00025750216,0.000048614576,0.00060808024],"genre_scores_gemma":[0.99594444,0.00050534465,0.0018969321,0.000021652077,0.000010529881,0.000018486475,0.00045275694,0.000009964443,0.0011398598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987364,0.000018589628,0.0000130143635,0.000027532704,0.000051707295,0.000015459626],"domain_scores_gemma":[0.99993503,0.000011934912,0.000022949507,0.000008047275,0.0000053144768,0.000016602238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101056765,0.00028835452,0.00014585047,0.00015807225,0.00013298182,0.00018972755,0.00023183471,0.00024657656,0.00084600603],"category_scores_gemma":[0.00011877857,0.00010289038,0.00015911843,0.000105840256,0.00020818003,0.0001749067,0.0002534747,0.0002745596,0.00038718496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042276526,0.0000069381244,0.0002906453,0.00002201158,0.0000029701469,0.00012046034,0.000004646891,0.000037476075,0.99868864,0.00011542288,0.000017524479,0.00065090874],"study_design_scores_gemma":[0.0000070288215,0.000058675294,0.0025439113,0.0000021678775,0.000006199199,0.0010244701,0.000010796222,0.00068577833,0.99309593,0.00007773606,0.0024850182,0.0000023467253],"about_ca_topic_score_codex":0.00025130992,"about_ca_topic_score_gemma":0.00035414824,"teacher_disagreement_score":0.00084600603,"about_ca_system_score_codex":0.00026687374,"about_ca_system_score_gemma":0.00016797181,"threshold_uncertainty_score":0.0028301477},"labels":[],"label_agreement":null},{"id":"W4200418432","doi":"10.1038/s41408-021-00584-3","title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","year":2021,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Leukemia & Lymphoma Society of Canada; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; University of British Columbia; Genome British Columbia; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Genome Canada; Terry Fox Research Institute","keywords":"Myeloid leukemia; Myeloid; Azacitidine; Medicine; Differentiation therapy; Acute promyelocytic leukemia; Myelodysplastic syndromes; Immunology; Haematopoiesis; Cancer research; Stem cell; Biology; Retinoic acid; Bone marrow; DNA methylation","score_opus":0.06473534785784331,"score_gpt":0.3828485920994154,"score_spread":0.3181132442415721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200418432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028561458,0.9820354,0.002200901,0.0039721993,0.0011883697,0.00003337996,0.00006805506,0.000055230896,0.0075902846],"genre_scores_gemma":[0.022683514,0.9647545,0.0020721671,0.0025413625,0.0012425617,0.000047676025,0.00013469004,0.000020471574,0.0065029752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981385,0.000045887224,0.000018173401,0.000022531267,0.000075193806,0.00002444962],"domain_scores_gemma":[0.99987924,0.00003785559,0.000019388384,0.0000076055285,0.000036250327,0.000019594136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038701412,0.00031084928,0.0005418073,0.0005874881,0.00026680328,0.0007409059,0.00036603922,0.00057198125,0.0026196088],"category_scores_gemma":[0.00038094964,0.0001048001,0.00026216707,0.00044802294,0.0004352632,0.0009695464,0.00061327283,0.002014045,0.0012331571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024621523,0.0001408098,0.00044467274,0.007539189,0.00006629258,0.00058744435,0.00028128127,0.0007102528,0.037987337,0.039984617,0.056339443,0.85567236],"study_design_scores_gemma":[0.000030812258,0.00020345383,0.00040144127,0.00061258295,0.000029282643,0.0011409662,0.00004845965,0.00016066122,0.005762689,0.006004605,0.98559475,0.000010329104],"about_ca_topic_score_codex":0.00042284996,"about_ca_topic_score_gemma":0.0010061536,"teacher_disagreement_score":0.0026196088,"about_ca_system_score_codex":0.00060820545,"about_ca_system_score_gemma":0.00055260083,"threshold_uncertainty_score":0.0087634325},"labels":[],"label_agreement":null},{"id":"W4206490155","doi":"10.1038/s41408-021-00600-6","title":"Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal","keywords":"Multiple myeloma; Immunoglobulin light chain; Medicine; Antibody; Immunoglobulin A; Internal medicine; Myeloma protein; Immunology; Immunoglobulin G; Oncology","score_opus":0.03656930127434755,"score_gpt":0.31523575146382365,"score_spread":0.2786664501894761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206490155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6759794,0.0043873903,0.0008528622,0.27558574,0.0075153657,0.00007366313,0.00056174607,0.00013300523,0.034910824],"genre_scores_gemma":[0.94054216,0.00095602643,0.0005600452,0.04261227,0.010502496,0.000029319706,0.00021376861,0.000029166322,0.0045547094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994752,0.00014409111,0.000061515064,0.000057460737,0.00008958877,0.00017217446],"domain_scores_gemma":[0.99665654,0.0019634145,0.00029018451,0.00010176801,0.00031666632,0.0006715607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006001213,0.00034178622,0.00078803685,0.00072251895,0.001078283,0.0011179323,0.00054415467,0.0051246993,0.0023630015],"category_scores_gemma":[0.005780474,0.0002693415,0.00047435958,0.00063220615,0.0005150342,0.00062214007,0.00025532854,0.0038389752,0.00068983604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004543382,0.0013051638,0.6405162,0.00011339563,0.00011207805,0.19530037,0.0005222396,0.00059403555,0.0040167198,0.0013386148,0.10362937,0.048008367],"study_design_scores_gemma":[0.00077260705,0.0026295295,0.62277335,0.00030219796,0.00032986514,0.3081691,0.0015765136,0.008951153,0.0025000283,0.0071243374,0.044721037,0.00015030643],"about_ca_topic_score_codex":0.0041426774,"about_ca_topic_score_gemma":0.0054972144,"teacher_disagreement_score":0.0051246993,"about_ca_system_score_codex":0.0011157028,"about_ca_system_score_gemma":0.0010266589,"threshold_uncertainty_score":0.0082371235},"labels":[],"label_agreement":null},{"id":"W4210625548","doi":"10.1038/s41408-021-00602-4","title":"Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study","year":2022,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"Hamilton Health Sciences Foundation; Cancer Care Ontario; Hamilton Health Sciences","keywords":"Multiple myeloma; Medicine; Outcome (game theory); Population; Internal medicine; MEDLINE; Health care; Intensive care medicine; Environmental health; Biology","score_opus":0.03334740798546452,"score_gpt":0.329829562829504,"score_spread":0.29648215484403945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210625548","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022726195,0.12732661,0.0006026925,0.099506795,0.74030757,0.00012638773,0.0043434645,0.00014014523,0.0049200887],"genre_scores_gemma":[0.0687346,0.051843807,0.001070392,0.086174965,0.7796096,0.0002717111,0.0020125539,0.00011501341,0.010167297],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9962528,0.0014007104,0.0006359608,0.00044847766,0.0010821054,0.00017987493],"domain_scores_gemma":[0.96687263,0.023791017,0.0019201131,0.0007149113,0.0053572203,0.0013441904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0078030345,0.0012374246,0.0027836596,0.0017406597,0.0007500609,0.004044319,0.0013631644,0.00422296,0.0026816435],"category_scores_gemma":[0.023993349,0.0007523345,0.0019366458,0.00207247,0.0008101769,0.0011318912,0.0004894112,0.0045268177,0.0010436047],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020173183,0.00025290798,0.03595925,0.0033702934,0.0025110561,0.00065336394,0.00013424862,0.000090644266,0.00027807758,0.0003755077,0.92405474,0.030302513],"study_design_scores_gemma":[0.004825538,0.0015898221,0.46351463,0.0071077654,0.012026775,0.0027938273,0.0011984892,0.0018832869,0.00072202855,0.0024904057,0.50144416,0.00040337493],"about_ca_topic_score_codex":0.0022299064,"about_ca_topic_score_gemma":0.0048948545,"teacher_disagreement_score":0.0078030345,"about_ca_system_score_codex":0.0007637005,"about_ca_system_score_gemma":0.001479711,"threshold_uncertainty_score":0.04126692},"labels":[],"label_agreement":null},{"id":"W4220863985","doi":"10.1038/s41408-022-00639-z","title":"Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Karyotype; Leukocytosis; Essential thrombocythemia; Internal medicine; Gastroenterology; Medicine; Clinical significance; Biology; Pathology; Chromosome; Genetics; Polycythemia vera; Gene","score_opus":0.019627244049158665,"score_gpt":0.3221583252107662,"score_spread":0.30253108116160754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220863985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995572,0.00011442417,0.00004073823,0.000010716274,0.0000014607951,0.0000019335919,0.000105100706,0.0000019936049,0.00016648063],"genre_scores_gemma":[0.99978036,0.00003728161,0.000022635266,0.0000032817532,0.0000032235675,0.0000018041476,0.000112054884,5.4609046e-7,0.000038814014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998227,0.000036044,0.00002124964,0.0000367711,0.00004011217,0.00004309773],"domain_scores_gemma":[0.99927515,0.00023737543,0.00022557656,0.00004788149,0.00006334199,0.00015060912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003343592,0.00018549828,0.00017298921,0.0006969054,0.00023374616,0.0002965375,0.00019135904,0.00024157666,0.0013080562],"category_scores_gemma":[0.0017804286,0.00019278917,0.00012395509,0.0006335576,0.00027505637,0.00021801828,0.00027157064,0.00021369675,0.00014527835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011299727,0.0000079885995,0.997895,0.000002925542,0.000008121058,0.00062025286,0.000024562118,0.00004903636,0.00032121787,0.000012195107,0.000060690054,0.00088515895],"study_design_scores_gemma":[0.000009827131,0.000061676845,0.99671304,0.0000038027383,0.000016991684,0.0024554632,0.000067747744,0.0003006665,0.00015597092,0.000022952045,0.00018951789,0.0000024650158],"about_ca_topic_score_codex":0.001874494,"about_ca_topic_score_gemma":0.0016430841,"teacher_disagreement_score":0.001874494,"about_ca_system_score_codex":0.00018346767,"about_ca_system_score_gemma":0.00014488987,"threshold_uncertainty_score":0.004375875},"labels":[],"label_agreement":null},{"id":"W4224221548","doi":"10.1038/s41408-022-00668-8","title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; AbbVie","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cytarabine; Placebo; Myeloid leukemia; Visual analogue scale; Oncology; Physical therapy","score_opus":0.008543927453387928,"score_gpt":0.2656750802293543,"score_spread":0.2571311527759664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224221548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422073,0.004751822,0.0001157087,0.00012465836,0.000037318667,0.0000932308,0.0001191783,0.000020980982,0.00051639945],"genre_scores_gemma":[0.99732924,0.0015390813,0.0003520054,0.00011742816,0.0000478089,0.000076199976,0.00018637197,0.0000033123663,0.00034858624],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997719,0.00014536026,0.000011929552,0.000021205726,0.000021075604,0.000028580333],"domain_scores_gemma":[0.99952424,0.00021218769,0.00014227604,0.000022044751,0.000015215034,0.00008404876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007902804,0.00025892412,0.0007311915,0.00014572925,0.00012775016,0.00042935353,0.00022408091,0.0002751222,0.0010717328],"category_scores_gemma":[0.00080336985,0.00012659366,0.00056715676,0.00021657463,0.00020232398,0.00021408484,0.00013418439,0.0010594386,0.00012344895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4600744,0.012454756,0.02615427,0.0011765356,0.0018532713,0.00018729767,0.00024377396,0.00416705,0.038782872,0.0004327003,0.0031518277,0.4513214],"study_design_scores_gemma":[0.24409716,0.5909847,0.14005792,0.00019468735,0.00148133,0.0008355646,0.00012223935,0.0049671633,0.008933947,0.00041747227,0.007844472,0.00006343351],"about_ca_topic_score_codex":0.0005627507,"about_ca_topic_score_gemma":0.0021280765,"teacher_disagreement_score":0.0010717328,"about_ca_system_score_codex":0.0002692195,"about_ca_system_score_gemma":0.00025596493,"threshold_uncertainty_score":0.0041794777},"labels":[],"label_agreement":null},{"id":"W4224221896","doi":"10.1038/s41408-022-00671-z","title":"Financial toxicity in hematological malignancies: a systematic review","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Malignancy; Internal medicine; Intensive care medicine","score_opus":0.0827086563937685,"score_gpt":0.3040631644147532,"score_spread":0.22135450802098466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224221896","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052278326,0.9986619,0.00007184137,0.00015571385,0.0000433682,0.00006884949,0.00024373115,0.0000036605165,0.00022813465],"genre_scores_gemma":[0.0067903376,0.992486,0.00016697029,0.00021657921,0.000042558608,0.00008869459,0.00013198766,0.0000021058647,0.00007471277],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977982,0.0006986027,0.0007148948,0.00016603971,0.0005339822,0.000088323315],"domain_scores_gemma":[0.98788816,0.009431804,0.0017369608,0.0001134022,0.0007148972,0.000114783375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030868778,0.0009728767,0.0039840504,0.005446758,0.0003597378,0.0017549243,0.001071769,0.0011634944,0.005444055],"category_scores_gemma":[0.01939843,0.00056003936,0.005184976,0.0069993366,0.00041242503,0.001296402,0.0009942288,0.0008149407,0.0002509529],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014513747,0.000016915641,0.0011431341,0.9245336,0.0074116113,0.00011126314,0.000080354584,0.00021683286,0.00006533659,0.0004194897,0.003728157,0.062128145],"study_design_scores_gemma":[0.00020896933,0.0001703539,0.0078105247,0.89347947,0.053294726,0.0006554878,0.00018663524,0.00016766418,0.00012222295,0.0008720081,0.042995807,0.000036140475],"about_ca_topic_score_codex":0.008195906,"about_ca_topic_score_gemma":0.022752773,"teacher_disagreement_score":0.008195906,"about_ca_system_score_codex":0.0026094178,"about_ca_system_score_gemma":0.0059602186,"threshold_uncertainty_score":0.01893276},"labels":[],"label_agreement":null},{"id":"W4224245023","doi":"10.1038/s41408-022-00659-9","title":"Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Monoclonal gammopathy of undetermined significance; Internal medicine; Medicine; Hazard ratio; Gastroenterology; Macroglobulinemia; Population; Waldenstrom macroglobulinemia; Body mass index; Proportional hazards model; Univariate analysis; AL amyloidosis; Multiple myeloma; Amyloidosis; Confidence interval; Oncology; Lymphoma; Immunology; Monoclonal; Multivariate analysis; Antibody; Immunoglobulin light chain; Monoclonal antibody","score_opus":0.016868981811633883,"score_gpt":0.3038341216571848,"score_spread":0.28696513984555094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224245023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992957,0.00013020946,0.0000374921,0.00005555444,0.000005695484,0.000004602167,0.00027676928,0.0000032688235,0.00019066443],"genre_scores_gemma":[0.9997141,0.000031837248,0.000021630805,0.000013137225,0.0000039824863,0.0000020754692,0.00013537303,6.842644e-7,0.00007718474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997664,0.00006860063,0.000019296955,0.00006407895,0.000033117336,0.000048498616],"domain_scores_gemma":[0.9989606,0.00011748649,0.00043033663,0.00006762412,0.00013135119,0.00029253168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036533462,0.00020962789,0.00018466692,0.0004899127,0.00043320926,0.00045142553,0.00033716793,0.00023260698,0.00094796676],"category_scores_gemma":[0.001206272,0.00021045461,0.00026578744,0.0005038461,0.00019229515,0.0001955708,0.00042144852,0.00037560845,0.00008957498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027771852,0.0000064428687,0.9995109,0.0000017388936,0.000009479196,0.000033425116,0.000026325552,0.000019410336,0.0000703987,0.000003913022,0.000060589977,0.0002295758],"study_design_scores_gemma":[0.00000255411,0.000024250869,0.9995414,0.0000027766885,0.000011348889,0.000052140997,0.00006432184,0.0002002472,0.000013266158,0.0000048084016,0.00008160671,0.0000012325853],"about_ca_topic_score_codex":0.10752505,"about_ca_topic_score_gemma":0.18075033,"teacher_disagreement_score":0.10752505,"about_ca_system_score_codex":0.0006373382,"about_ca_system_score_gemma":0.00053446536,"threshold_uncertainty_score":0.21379834},"labels":[],"label_agreement":null},{"id":"W4255030439","doi":"10.1038/s41408-020-00374-3","title":"Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients","year":2020,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research Society","keywords":"Imatinib mesylate; Chronic myelogenous leukemia; Leukemia; Medicine; Imatinib; STAT5; Cancer research; Immunology; Pharmacology; Oncology; Internal medicine; Receptor","score_opus":0.009923411100285665,"score_gpt":0.25646876323930656,"score_spread":0.2465453521390209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255030439","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016758434,0.0014727121,0.00040459455,0.048316125,0.94669557,0.000018468127,0.00082575745,0.00020073332,0.0018984234],"genre_scores_gemma":[0.020332193,0.020871358,0.0065938826,0.14681078,0.5391007,0.00024541325,0.003813525,0.0013253238,0.26090682],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973907,0.00037905373,0.000536632,0.00033167368,0.0011206046,0.00024143377],"domain_scores_gemma":[0.984313,0.004836544,0.00096002227,0.0006563165,0.008397395,0.0008366946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026092352,0.0017969505,0.0013180138,0.002819423,0.001841672,0.0026627989,0.0023680632,0.005871278,0.031948753],"category_scores_gemma":[0.0363658,0.00086832634,0.0015521898,0.0017251101,0.0016388451,0.0014435977,0.0011832792,0.009646199,0.019794395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043206594,0.000005895678,0.00005925816,0.00012710478,0.00001141566,0.000432837,0.000019320938,0.000038878836,0.00007335558,0.00041430476,0.99266595,0.0061084903],"study_design_scores_gemma":[0.000065515764,0.00002694722,0.00058073504,0.00032177236,0.000046006942,0.0014754211,0.00004808784,0.000188023,0.0004216871,0.0007482413,0.9960453,0.000032234133],"about_ca_topic_score_codex":0.011298872,"about_ca_topic_score_gemma":0.013040795,"teacher_disagreement_score":0.031948753,"about_ca_system_score_codex":0.0025690433,"about_ca_system_score_gemma":0.0037475526,"threshold_uncertainty_score":0.106879175},"labels":[],"label_agreement":null},{"id":"W4283698909","doi":"10.1038/s41408-022-00695-5","title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"National Cancer Institute; National Institutes of Health","keywords":"Multiple myeloma; Medicine; Clinical trial; Carfilzomib; Lenalidomide; Refractory (planetary science); Transplantation; Oncology; Salvage therapy; Intensive care medicine; Internal medicine; Chemotherapy; Biology","score_opus":0.15640130480209158,"score_gpt":0.3700564653846089,"score_spread":0.21365516058251732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283698909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015206626,0.8588272,0.0011187172,0.122477755,0.012592917,0.00020273421,0.00023798272,0.000052514264,0.004338265],"genre_scores_gemma":[0.0010859955,0.9516385,0.003748189,0.036196984,0.003679815,0.00024987495,0.00041550532,0.000027629752,0.0029574477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994712,0.0021468415,0.0010892568,0.00030835476,0.0013841343,0.00035935297],"domain_scores_gemma":[0.98452574,0.0047235982,0.0015411752,0.00029750064,0.0075154803,0.001396522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02138256,0.00105446,0.002651005,0.0034297914,0.00095249654,0.0037024391,0.0039171707,0.00644576,0.0045357803],"category_scores_gemma":[0.017866336,0.00062515656,0.002584678,0.0038299358,0.0012081382,0.005079403,0.0029841508,0.008246696,0.003540217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011785128,0.000093060786,0.00022781646,0.019799344,0.00012342267,0.00019321933,0.00026385923,0.00041247983,0.00040874837,0.008682512,0.42214942,0.5475282],"study_design_scores_gemma":[0.000032390744,0.000039640843,0.0001835808,0.018854074,0.00010653922,0.00015835937,0.00013597652,0.000053021995,0.00008325635,0.0026965567,0.97763854,0.000018116909],"about_ca_topic_score_codex":0.0067965467,"about_ca_topic_score_gemma":0.009058268,"teacher_disagreement_score":0.02138256,"about_ca_system_score_codex":0.0040278803,"about_ca_system_score_gemma":0.023781493,"threshold_uncertainty_score":0.113083124},"labels":[],"label_agreement":null},{"id":"W4288046493","doi":"10.1038/s41408-022-00706-5","title":"Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Pharmacyclics; Amgen; U.S. Department of Health and Human Services","keywords":"Haematopoiesis; Distribution (mathematics); Biology; Race (biology); Immunology; Plasma cell; Plasma cell neoplasm; Hematology; Internal medicine; Cancer research; Medicine; Stem cell; Genetics; Plasmacytoma; Antibody; Multiple myeloma","score_opus":0.009441518617760419,"score_gpt":0.23951033742045671,"score_spread":0.2300688188026963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288046493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9028823,0.0018880243,0.0007244035,0.071523644,0.0016146972,0.00002839506,0.0005390448,0.00007761878,0.02072184],"genre_scores_gemma":[0.9822609,0.00028833072,0.00026757357,0.013291,0.0022138257,0.00001278041,0.00008298312,0.00001613061,0.0015664786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994368,0.0001561709,0.00006433762,0.00008779832,0.00011042432,0.00014446618],"domain_scores_gemma":[0.99693596,0.0018145813,0.00030407216,0.00017663838,0.0003210102,0.00044771307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004645388,0.000197481,0.0005651014,0.00054723065,0.00069000304,0.00056825194,0.00040250193,0.0026778523,0.002202192],"category_scores_gemma":[0.0055480674,0.00019988877,0.00029666958,0.00063942815,0.0005161412,0.00057872874,0.00022286916,0.0015858186,0.00055540266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011435638,0.00012882675,0.8817437,0.00007271086,0.00007545966,0.0647971,0.00055481953,0.00026517813,0.0035140833,0.0008457988,0.025081363,0.021777427],"study_design_scores_gemma":[0.00012154102,0.00064711255,0.7644451,0.00014324255,0.00014272603,0.2013678,0.0012457735,0.0028205072,0.0013706868,0.0028834161,0.024743253,0.00006889449],"about_ca_topic_score_codex":0.0023073151,"about_ca_topic_score_gemma":0.0034630962,"teacher_disagreement_score":0.0026778523,"about_ca_system_score_codex":0.0005237215,"about_ca_system_score_gemma":0.00041057196,"threshold_uncertainty_score":0.007367015},"labels":[],"label_agreement":null},{"id":"W4289836925","doi":"10.1038/s41408-022-00710-9","title":"Venetoclax ex vivo functional profiling predicts improved progression-free survival","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Winship Cancer Institute; Emory University; Multiple Myeloma Research Foundation; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; American Cancer Society","keywords":"Ex vivo; Venetoclax; Profiling (computer programming); In vivo; Medicine; Oncology; Computational biology; Internal medicine; Biology; Bioinformatics; Cancer research; Leukemia; Computer science; Genetics","score_opus":0.038656709197645085,"score_gpt":0.31966684938514667,"score_spread":0.2810101401875016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289836925","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35830534,0.022270534,0.0071786265,0.5434284,0.017936442,0.0001702028,0.002987703,0.0007259959,0.046996716],"genre_scores_gemma":[0.85335946,0.0051517948,0.0029039157,0.10598314,0.008636186,0.00012822932,0.0013819821,0.000080283426,0.02237497],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99971837,0.000069936556,0.000019112444,0.00004516167,0.00009077051,0.000056579232],"domain_scores_gemma":[0.9990663,0.00057089125,0.00005880616,0.000075534175,0.00011783658,0.0001106968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005477567,0.0001889781,0.0004600021,0.0002043995,0.00030764155,0.0008079454,0.00023685624,0.0017505734,0.0023609945],"category_scores_gemma":[0.0021972521,0.00010826017,0.0002259709,0.00017692217,0.0002880819,0.00037259364,0.00013416033,0.0024621894,0.0011465471],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069835265,0.0006756624,0.0983251,0.00036604254,0.00018722333,0.01197815,0.00028754908,0.0014375419,0.07264291,0.006288852,0.42231348,0.37851393],"study_design_scores_gemma":[0.0013263542,0.003999104,0.20497414,0.0003111824,0.000565149,0.05701746,0.0007058615,0.014441147,0.06279586,0.024242101,0.6294886,0.00013303732],"about_ca_topic_score_codex":0.00053998636,"about_ca_topic_score_gemma":0.0010573464,"teacher_disagreement_score":0.0023609945,"about_ca_system_score_codex":0.0005885628,"about_ca_system_score_gemma":0.00020444665,"threshold_uncertainty_score":0.007898331},"labels":[],"label_agreement":null},{"id":"W4311358889","doi":"10.1038/s41408-022-00765-8","title":"Management of patients with lower-risk myelodysplastic syndromes","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Myelodysplastic syndromes; Medicine; Internal medicine; Disease; Myeloid leukemia; Oncology; Dysplasia; Hematologic disease; International Prognostic Scoring System; Intensive care medicine; Bone marrow","score_opus":0.03015095816860201,"score_gpt":0.3252116550783994,"score_spread":0.29506069690979736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311358889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024649536,0.9985183,0.00010108974,0.00039373338,0.00011412083,0.0000056751405,0.00001850218,0.0000042496245,0.0005978811],"genre_scores_gemma":[0.0021490473,0.9967663,0.00025561004,0.00037056787,0.00014961875,0.000009633749,0.000059519512,0.0000014101621,0.00023816274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979216,0.000060977145,0.000042387423,0.000025504407,0.00006302248,0.000015932223],"domain_scores_gemma":[0.9997322,0.0001312337,0.000051174266,0.0000060110756,0.000060282782,0.000019088882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353114,0.00045024304,0.0010328026,0.0009588813,0.00017921037,0.00060425623,0.0006987952,0.00065306074,0.0016896856],"category_scores_gemma":[0.0013565607,0.000108159256,0.0005598118,0.00063901296,0.00017695289,0.0005709684,0.0004426938,0.0012732708,0.0006950711],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008578047,0.000035593166,0.00040962794,0.014763437,0.0001522587,0.00023165942,0.00006646744,0.00023096014,0.0006506911,0.0012207052,0.020508995,0.96164376],"study_design_scores_gemma":[0.00011643661,0.00019367211,0.0045360704,0.022449365,0.00054519344,0.005617412,0.00015364445,0.00018085586,0.0006635323,0.002766823,0.96274513,0.000031838554],"about_ca_topic_score_codex":0.0007356405,"about_ca_topic_score_gemma":0.0016906222,"teacher_disagreement_score":0.0016896856,"about_ca_system_score_codex":0.00029815483,"about_ca_system_score_gemma":0.0006306048,"threshold_uncertainty_score":0.005652547},"labels":[],"label_agreement":null},{"id":"W4311587513","doi":"10.1038/s41408-022-00757-8","title":"Second- and third-line treatment strategies in multiple myeloma: a referral-center experience","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Referral; Medicine; Center (category theory); Internal medicine; Oncology; Family medicine; Intensive care medicine","score_opus":0.0614510644982715,"score_gpt":0.3488668860152637,"score_spread":0.28741582151699224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311587513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883759,0.008487652,0.00045181,0.00069451646,0.000042286476,0.000043495354,0.000113035916,0.000016849088,0.0017744226],"genre_scores_gemma":[0.99266785,0.0046470035,0.0009503281,0.0007870713,0.000091259164,0.00003644389,0.00029221794,0.000016006808,0.0005118651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854976,0.000615168,0.0001260329,0.00022725137,0.000277884,0.00020395426],"domain_scores_gemma":[0.9976319,0.00039569053,0.00065421604,0.00012713321,0.00026276975,0.00092821737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017788799,0.00025005772,0.0003999755,0.0004871197,0.0007383642,0.0010183506,0.00049180555,0.000561585,0.0015038399],"category_scores_gemma":[0.0032882157,0.00015453465,0.00040601476,0.0012999882,0.0003828397,0.0005036528,0.0011670297,0.0007924164,0.0002588059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001072414,0.0013944017,0.8068817,0.0003522479,0.00018216578,0.0041637663,0.0051031127,0.0003726349,0.0023773424,0.0005322814,0.003574625,0.17399316],"study_design_scores_gemma":[0.0002143378,0.004181707,0.93555593,0.0005709472,0.00027279256,0.027465846,0.008967231,0.0008605451,0.0014258361,0.00041010615,0.020002568,0.00007215611],"about_ca_topic_score_codex":0.0038293991,"about_ca_topic_score_gemma":0.009931734,"teacher_disagreement_score":0.0038293991,"about_ca_system_score_codex":0.0020055769,"about_ca_system_score_gemma":0.0015704624,"threshold_uncertainty_score":0.01455152},"labels":[],"label_agreement":null},{"id":"W4312114026","doi":"10.1038/s41408-022-00760-z","title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"Cilag; Pharmacyclics; Kite Pharma; Canadian Institutes of Health Research; Ipsen; MorphoSys; Associazione Italiana per la Ricerca sul Cancro; Aptitude Health; Cancer Research UK; Ascentage Pharma; BeiGene; Celltrion; Hairy Cell Leukemia Foundation; Adaptive Biotechnologies; Astex Pharmaceuticals; TG Therapeutics; Genentech; Blood Cancer UK; Amicus Therapeutics; Incyte; Pfizer; Biogen; University of Rochester; CancerCare Manitoba Foundation; MEI Pharma; Daiichi-Sankyo; MacroGenics; Sunesis; University of Pittsburgh; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Sanofi; Ipsen Biopharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; GlaxoSmithKline","keywords":"Minimal residual disease; Oncology; Medicine; Bone marrow; Internal medicine; Leukemia; Flow cytometry; Hematology; Hairy cell leukemia; Disease; Cancer research; Immunology","score_opus":0.10005170867196604,"score_gpt":0.40304154366956174,"score_spread":0.3029898349975957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114026","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026947266,0.77587783,0.001091905,0.10867029,0.10801156,0.00017058448,0.0003899664,0.00006275392,0.0054556536],"genre_scores_gemma":[0.0027895488,0.8167596,0.0021707022,0.11649061,0.052424196,0.0003046245,0.0008027968,0.000048045178,0.008209839],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692446,0.00066164415,0.0007330406,0.00037244437,0.0010417049,0.00026673963],"domain_scores_gemma":[0.99082094,0.00228425,0.00076002884,0.00014830241,0.005088745,0.00089768507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069878623,0.0011419615,0.0026588077,0.0031243998,0.00068145583,0.0027105696,0.0030885201,0.007116171,0.007562153],"category_scores_gemma":[0.011942403,0.0004735581,0.0019161663,0.0024294932,0.0011264349,0.0034754714,0.002434507,0.0061647277,0.005939118],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098027565,0.000027426397,0.00016816272,0.009406115,0.000081824364,0.00033991155,0.00009305826,0.00013383517,0.00054603396,0.0015717073,0.79470295,0.19283095],"study_design_scores_gemma":[0.000040847815,0.000036276197,0.00037249472,0.00693882,0.00010859258,0.00086954137,0.00008899743,0.000044220247,0.00014078547,0.0015222465,0.9898112,0.000025951851],"about_ca_topic_score_codex":0.0013770708,"about_ca_topic_score_gemma":0.0018492452,"teacher_disagreement_score":0.007562153,"about_ca_system_score_codex":0.0019609418,"about_ca_system_score_gemma":0.0047170324,"threshold_uncertainty_score":0.036955774},"labels":[],"label_agreement":null},{"id":"W4312114807","doi":"10.1038/s41408-022-00769-4","title":"Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Flatiron Health","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Chromosomal translocation; Internal medicine; Oncology; CD38; Daratumumab; Hematology; Bortezomib; Stem cell; Biology","score_opus":0.01845025648032841,"score_gpt":0.2758553600145342,"score_spread":0.2574051035342058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613823,0.0023282028,0.00021470031,0.026210327,0.000617229,0.00003127378,0.0005826294,0.00003880906,0.008594493],"genre_scores_gemma":[0.99272925,0.000574824,0.0002564261,0.0037851615,0.0012582921,0.000018421455,0.00030604872,0.000009380536,0.0010621169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996605,0.000093543276,0.000036881058,0.000049774357,0.00005858547,0.000100697434],"domain_scores_gemma":[0.99839145,0.00074804615,0.0002105569,0.00007898813,0.00015513385,0.00041585515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041118433,0.00025791,0.00064105034,0.0005607143,0.00056939916,0.00076485774,0.00037950248,0.0017715489,0.0015889903],"category_scores_gemma":[0.0034432868,0.00016846022,0.0002571557,0.0008570155,0.00042126657,0.00051474705,0.00026769354,0.0012543233,0.00046812696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036952517,0.00012991187,0.92477834,0.00006868921,0.00006389668,0.025405742,0.00029825314,0.00052771094,0.00397421,0.00036422687,0.013161917,0.027531883],"study_design_scores_gemma":[0.0003641958,0.0011439957,0.9036157,0.000109185145,0.00023473683,0.06951639,0.0011016051,0.0038883206,0.0013933106,0.0020637996,0.016515704,0.00005295875],"about_ca_topic_score_codex":0.0014254446,"about_ca_topic_score_gemma":0.0026277995,"teacher_disagreement_score":0.0017715489,"about_ca_system_score_codex":0.00078588416,"about_ca_system_score_gemma":0.00062784716,"threshold_uncertainty_score":0.0057020187},"labels":[],"label_agreement":null},{"id":"W4313545228","doi":"10.1038/s41408-022-00779-2","title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Ottawa Hospital; McMaster University","funders":"National Institute on Aging; National Cancer Institute; Hamilton Health Sciences Foundation; Cancer Research UK; Hamilton Health Sciences","keywords":"Medicine; Clinical trial; Population; Randomized controlled trial; Frailty syndrome; Multiple myeloma; Psychological intervention; Gerontology; MEDLINE; Internal medicine; Frailty Index","score_opus":0.19399017801219695,"score_gpt":0.4970273322898045,"score_spread":0.3030371542776076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313545228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015987561,0.9970386,0.0001569404,0.0001893187,0.0000875261,0.00039883133,0.00034464497,0.000010000557,0.00017532913],"genre_scores_gemma":[0.05816681,0.93649447,0.0013211996,0.0011175703,0.00018103498,0.002087681,0.00047998372,0.000017877619,0.00013339736],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97137827,0.01084383,0.012337991,0.0016708656,0.0033370082,0.0004320028],"domain_scores_gemma":[0.890948,0.08194069,0.019740848,0.00158494,0.005024608,0.00076085865],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.020612828,0.0016074888,0.013464368,0.008134136,0.0007573655,0.0035172426,0.0020551328,0.002235482,0.0033024694],"category_scores_gemma":[0.109668985,0.0012698439,0.012683148,0.009015605,0.001233842,0.0032401676,0.002175961,0.0015058067,0.00022567464],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041351467,0.000016263522,0.0015205842,0.95254713,0.025937436,0.000053949785,0.00015338628,0.000094222545,0.000078335164,0.00016498909,0.0007231245,0.018297011],"study_design_scores_gemma":[0.00077870657,0.00035065998,0.008594895,0.795897,0.18274294,0.00031557263,0.00023050471,0.00016230799,0.0001625836,0.00049212505,0.010216273,0.000056388144],"about_ca_topic_score_codex":0.0062698163,"about_ca_topic_score_gemma":0.016856993,"teacher_disagreement_score":0.9865356,"about_ca_system_score_codex":0.0045691165,"about_ca_system_score_gemma":0.00933575,"threshold_uncertainty_score":0.109012306},"labels":[],"label_agreement":null},{"id":"W4318191396","doi":"10.1038/s41408-022-00781-8","title":"DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease","year":2023,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Government of Canada; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Hyperactivation; Drug; Chronic lymphocytic leukemia; Biomarker; DNA; Disease; Leukemia; Cancer research; Hematology; Medicine; Immunology; Biology; Pharmacology; Internal medicine; Genetics","score_opus":0.03328712576353946,"score_gpt":0.3199920189238956,"score_spread":0.28670489316035613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318191396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42824584,0.028669208,0.004134696,0.38421512,0.008807629,0.0002510142,0.0006233991,0.00057516596,0.14447801],"genre_scores_gemma":[0.88750243,0.009693746,0.001557655,0.058218837,0.023210322,0.000083711086,0.00015977875,0.000052683004,0.019520838],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99946433,0.00016466045,0.0000425543,0.00009236069,0.00011509633,0.00012099423],"domain_scores_gemma":[0.99898475,0.00047194157,0.00021091705,0.00007478895,0.00010054322,0.00015710073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039098965,0.0004696406,0.00063935714,0.0007542479,0.0009255943,0.0008914622,0.00044747602,0.004971844,0.0039122826],"category_scores_gemma":[0.0023640785,0.0002829371,0.0002691243,0.0008239418,0.001254205,0.00096529967,0.00035492293,0.0027398772,0.002803724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036992464,0.00013175939,0.055469096,0.00027453445,0.000027710106,0.7993708,0.0003852136,0.00020679181,0.0076971715,0.0034382688,0.093834385,0.03879427],"study_design_scores_gemma":[0.00006075322,0.00018542395,0.017422546,0.00013744654,0.000032257056,0.917455,0.00040020593,0.0006729706,0.001328779,0.0032650945,0.0590213,0.000018174278],"about_ca_topic_score_codex":0.00077098864,"about_ca_topic_score_gemma":0.0011177331,"teacher_disagreement_score":0.004971844,"about_ca_system_score_codex":0.0011836878,"about_ca_system_score_gemma":0.00042102268,"threshold_uncertainty_score":0.013087869},"labels":[],"label_agreement":null},{"id":"W4319161971","doi":"10.1038/s41408-023-00791-0","title":"Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"European Regional Development Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Shota Rustaveli National Science Foundation; Ostravská Univerzita v Ostravě; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"RNA splicing; Biology; Alternative splicing; Transcriptome; Gene; RNA; Computational biology; Disease; Cancer research; Bioinformatics; Genetics; Gene expression; Messenger RNA; Medicine; Internal medicine","score_opus":0.029960230637768478,"score_gpt":0.33604121860853825,"score_spread":0.30608098797076977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319161971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79381037,0.056686793,0.1379831,0.0029432331,0.00037703518,0.00023546236,0.0012668663,0.001066248,0.0056308955],"genre_scores_gemma":[0.89144975,0.023845749,0.080289304,0.0008941141,0.00013214837,0.00009433956,0.0010179484,0.00007408081,0.002202517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997528,0.00004728563,0.000020782603,0.0000658466,0.00009068029,0.000022607846],"domain_scores_gemma":[0.99985194,0.000041097548,0.00006365689,0.000014755972,0.000016612943,0.000011992105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056849077,0.00031742887,0.00042617822,0.00040656087,0.00022041271,0.000576128,0.0002529238,0.00049877376,0.0008635659],"category_scores_gemma":[0.00036485083,0.00019555513,0.00047845911,0.0003662188,0.00037916435,0.00029625636,0.00024546892,0.0008904918,0.00028739718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017708271,0.00006945023,0.0046924935,0.00035688342,0.000059666127,0.00042836837,0.000057479097,0.0028913997,0.93308574,0.0019053523,0.0004884326,0.055787668],"study_design_scores_gemma":[0.000052521147,0.0011995634,0.019032823,0.0001372058,0.00022215206,0.0039123455,0.00018932972,0.026120136,0.9077023,0.0047530695,0.03663354,0.000045044653],"about_ca_topic_score_codex":0.00027143527,"about_ca_topic_score_gemma":0.0006569508,"teacher_disagreement_score":0.0008635659,"about_ca_system_score_codex":0.0003851907,"about_ca_system_score_gemma":0.0003526258,"threshold_uncertainty_score":0.003006518},"labels":[],"label_agreement":null},{"id":"W4323316666","doi":"10.1038/s41408-023-00794-x","title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Minimal residual disease; Oncology; Positron emission tomography; Internal medicine; Negativity effect; Multiple myeloma; Nuclear medicine; Bone marrow","score_opus":0.06746045659604068,"score_gpt":0.32278984922358334,"score_spread":0.2553293926275427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323316666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985858,0.00042128738,0.0003924155,0.000033901175,0.000003811079,0.000008431318,0.00027571464,0.000009457182,0.00026914207],"genre_scores_gemma":[0.9994332,0.000053192187,0.00021874302,0.000018767438,0.0000053754948,0.0000044596477,0.00019595063,0.0000016821074,0.00006853665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970275,0.00012297396,0.000033512162,0.000058456455,0.00004423412,0.000038138598],"domain_scores_gemma":[0.99942017,0.00017182382,0.00021737827,0.000045493925,0.000064982654,0.000080217935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071161444,0.00017857924,0.00036710346,0.0005220638,0.00018744571,0.000593179,0.00017203827,0.00025412295,0.00084829936],"category_scores_gemma":[0.0011490751,0.00011690619,0.00029507637,0.00060451805,0.00013129995,0.00023851512,0.00025067147,0.00023540747,0.00016659987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011986077,0.000047850528,0.9881813,0.000021136686,0.000047825706,0.00019825794,0.000032641838,0.00039630628,0.0030120453,0.000026113072,0.00010688067,0.006731],"study_design_scores_gemma":[0.000028964256,0.0007495807,0.990599,0.000011012227,0.00012284273,0.0010662029,0.00011068795,0.0033761975,0.0031535581,0.00010751864,0.0006660902,0.0000083188415],"about_ca_topic_score_codex":0.001065536,"about_ca_topic_score_gemma":0.0012382399,"teacher_disagreement_score":0.001065536,"about_ca_system_score_codex":0.0002985809,"about_ca_system_score_gemma":0.0002205216,"threshold_uncertainty_score":0.0037634373},"labels":[],"label_agreement":null},{"id":"W4323362510","doi":"10.1038/s41408-023-00805-x","title":"Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS","year":2023,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development; National Cancer Institute; Amgen","keywords":"Daratumumab; Carfilzomib; Pleiades; Dexamethasone; Medicine; Oncology; Multiple myeloma; Internal medicine; Refractory (planetary science); Lenalidomide; Biology; Computer science","score_opus":0.07917735754631587,"score_gpt":0.36156698615345484,"score_spread":0.28238962860713895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323362510","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12895781,0.091812305,0.0022146157,0.71187294,0.019623948,0.0005073218,0.00044354363,0.00018295496,0.044384632],"genre_scores_gemma":[0.4541343,0.0602611,0.0049425825,0.36976224,0.077369906,0.00043855526,0.0010556051,0.000099298224,0.031936448],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995148,0.000105373234,0.00006758953,0.00005754835,0.00016567139,0.00008910798],"domain_scores_gemma":[0.999238,0.00028556833,0.0000527474,0.000026140162,0.00017494007,0.00022259625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073852565,0.00054204446,0.0008244688,0.00050193013,0.00089897384,0.0008961717,0.00058699475,0.0042469297,0.0018881721],"category_scores_gemma":[0.0016328729,0.00023293876,0.0004887892,0.00063425966,0.0005411632,0.00058588857,0.00020588175,0.003203377,0.0008599853],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040421467,0.0012337314,0.018649282,0.00071229425,0.00013280421,0.14446303,0.00035157162,0.0011525216,0.0063746027,0.009214696,0.52055323,0.29312003],"study_design_scores_gemma":[0.003256579,0.003859695,0.032841004,0.0009069003,0.0004633311,0.1970815,0.00033532604,0.0072764657,0.0054590176,0.0114349825,0.73699737,0.00008780223],"about_ca_topic_score_codex":0.0017003532,"about_ca_topic_score_gemma":0.0036417784,"teacher_disagreement_score":0.0042469297,"about_ca_system_score_codex":0.0022798728,"about_ca_system_score_gemma":0.0017857425,"threshold_uncertainty_score":0.01654172},"labels":[],"label_agreement":null},{"id":"W4353014868","doi":"10.1038/s41408-023-00804-y","title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Seagen; bluebird bio; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Lenalidomide; Medicine; Daratumumab; Multiple myeloma; Intensive care medicine; Clinical trial; Bortezomib; Oncology; Internal medicine","score_opus":0.5237619651572638,"score_gpt":0.5617298454699142,"score_spread":0.037967880312650415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353014868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041003892,0.997209,0.00010783159,0.0018633698,0.00024121652,0.000006276581,0.000013123791,0.0000037809064,0.0005143428],"genre_scores_gemma":[0.0006845267,0.9976024,0.00034760864,0.00093558664,0.00028507315,0.000012702553,0.000021583797,0.0000019689255,0.0001084764],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979657,0.0007828808,0.00037758955,0.00016596055,0.00061182433,0.000096026684],"domain_scores_gemma":[0.98931074,0.008097625,0.00075864716,0.0001673047,0.0014364851,0.00022927675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006591336,0.0007321174,0.0030072567,0.001972347,0.00040271858,0.0029224423,0.0019241524,0.0024327405,0.005055156],"category_scores_gemma":[0.0120042395,0.0004026322,0.0016883895,0.0022179743,0.0010788969,0.0029714648,0.0012083051,0.005023349,0.0018331681],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014361103,0.000048135196,0.00017979546,0.040465433,0.00034917623,0.00011230108,0.00007406922,0.00040163883,0.00027989523,0.007275106,0.03294662,0.91772425],"study_design_scores_gemma":[0.00012322841,0.00016340408,0.0011382097,0.08957461,0.00073244504,0.0007618137,0.00018842795,0.00023010223,0.00020588303,0.011504494,0.89533716,0.000040279025],"about_ca_topic_score_codex":0.0015883566,"about_ca_topic_score_gemma":0.0030886051,"teacher_disagreement_score":0.006591336,"about_ca_system_score_codex":0.0016160482,"about_ca_system_score_gemma":0.0047479775,"threshold_uncertainty_score":0.034858704},"labels":[],"label_agreement":null},{"id":"W4362614405","doi":"10.1038/s41408-023-00820-y","title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; Minimal residual disease; Gastroenterology","score_opus":0.036904548148674894,"score_gpt":0.3457851510166651,"score_spread":0.30888060286799024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362614405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980286,0.0013216925,0.0000714814,0.00007640685,0.0000059096355,0.000006556422,0.000076678116,0.000005740781,0.0004069374],"genre_scores_gemma":[0.9996383,0.000118140524,0.000044799286,0.000022533455,0.000009373216,0.0000023962514,0.00008103488,9.460764e-7,0.000082292005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996001,0.00016408836,0.000038354756,0.000044864308,0.000074819174,0.000077718585],"domain_scores_gemma":[0.9985593,0.00042894282,0.00059833634,0.000047475656,0.0000866133,0.00027932893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007699578,0.00016498708,0.000371921,0.00032573508,0.00021752305,0.00050396903,0.00021370388,0.00044739517,0.00067383016],"category_scores_gemma":[0.0019102758,0.00011898966,0.00025811073,0.00028905584,0.00022258288,0.00029294437,0.00023397246,0.0005236741,0.000186831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028800569,0.00011257602,0.98173714,0.00002098892,0.00004585114,0.0001939018,0.000049190763,0.00021540586,0.0021341648,0.000017661061,0.00013223017,0.01246087],"study_design_scores_gemma":[0.000037199665,0.0012697516,0.99634594,0.000008473535,0.000057678863,0.0006729899,0.000028805855,0.00049474835,0.0006690026,0.000031169464,0.00037894258,0.0000053212552],"about_ca_topic_score_codex":0.0008440599,"about_ca_topic_score_gemma":0.0014790412,"teacher_disagreement_score":0.0008440599,"about_ca_system_score_codex":0.00031617156,"about_ca_system_score_gemma":0.00021749838,"threshold_uncertainty_score":0.004071951},"labels":[],"label_agreement":null},{"id":"W4366822278","doi":"10.1038/s41408-023-00823-9","title":"Management of chronic myeloid leukemia in 2023 – common ground and common sense","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Dasatinib; Nilotinib; Ponatinib; Medicine; Imatinib; Oncology; Imatinib mesylate; Internal medicine; Myeloid leukemia; Intensive care medicine","score_opus":0.04700418793668781,"score_gpt":0.35556062656842063,"score_spread":0.3085564386317328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366822278","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02976488,0.24148954,0.014991677,0.5996916,0.021654367,0.00028128215,0.0002654273,0.00026454445,0.09159664],"genre_scores_gemma":[0.40621603,0.208379,0.02415665,0.2634682,0.06007977,0.00043121257,0.00094883866,0.00023521222,0.036085006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962174,0.0016140813,0.0005333839,0.00024620217,0.0010178048,0.00037123088],"domain_scores_gemma":[0.99754,0.00033490092,0.00045730564,0.00015702876,0.00067957345,0.0008311155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004061399,0.00034112297,0.0005612032,0.00084636884,0.0018075522,0.003918479,0.001207245,0.002748878,0.0032180839],"category_scores_gemma":[0.008193984,0.0001746234,0.0005413128,0.0010438751,0.002512718,0.0035883307,0.0044235117,0.0034899188,0.0011818885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024828568,0.00016616115,0.007109984,0.0014557851,0.00007122675,0.007881095,0.0037141324,0.0004902028,0.0014676417,0.042794883,0.26181498,0.6727857],"study_design_scores_gemma":[0.00004153242,0.00021161334,0.0042645866,0.0022012168,0.00002573635,0.014604727,0.002649061,0.00033226048,0.00022557467,0.03148539,0.94390315,0.00005509487],"about_ca_topic_score_codex":0.0022654254,"about_ca_topic_score_gemma":0.0040577473,"teacher_disagreement_score":0.004061399,"about_ca_system_score_codex":0.0032293133,"about_ca_system_score_gemma":0.0044426625,"threshold_uncertainty_score":0.023430467},"labels":[],"label_agreement":null},{"id":"W4367300469","doi":"10.1038/s41408-023-00840-8","title":"An atlas of the bone marrow bone proteome in patients with dysproteinemias","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Bone marrow; Atlas (anatomy); Medicine; Bone marrow transplantation; MEDLINE; Pathology; Internal medicine; Bioinformatics; Biology; Anatomy","score_opus":0.013879807561555286,"score_gpt":0.2832907785892708,"score_spread":0.26941097102771555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367300469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96989846,0.006713652,0.0028165607,0.00032010107,0.000050923896,0.00006671724,0.017687561,0.00034138234,0.0021047336],"genre_scores_gemma":[0.9478524,0.0045307474,0.014166284,0.00035723872,0.00007044584,0.00014025645,0.030711174,0.000074695505,0.0020968183],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99981755,0.000025090032,0.00002471297,0.000050003146,0.000054330467,0.000028382374],"domain_scores_gemma":[0.99984074,0.00002069501,0.000047121866,0.000013517647,0.000048425733,0.000029555851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021937554,0.0004022238,0.0003567655,0.0017534764,0.00035408698,0.00040635667,0.0001716388,0.00024128525,0.00096254953],"category_scores_gemma":[0.00033742454,0.00012607686,0.00025373633,0.0016662437,0.000101911464,0.00019343622,0.0005036146,0.00028134522,0.00038011727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002081139,0.00009642296,0.22697331,0.0008685846,0.0004712688,0.0018592369,0.000450861,0.00058501924,0.67439586,0.0002700087,0.006301678,0.085646555],"study_design_scores_gemma":[0.000028620467,0.00021532642,0.9402495,0.000037515274,0.00018003708,0.0046586376,0.0002472214,0.0013889982,0.032907546,0.00034987612,0.019718163,0.000018511904],"about_ca_topic_score_codex":0.0010541566,"about_ca_topic_score_gemma":0.0013522028,"teacher_disagreement_score":0.0017534764,"about_ca_system_score_codex":0.00021770688,"about_ca_system_score_gemma":0.00024447535,"threshold_uncertainty_score":0.0032200813},"labels":[],"label_agreement":null},{"id":"W4376133376","doi":"10.1038/s41408-023-00843-5","title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Frailty in Older Adults","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Medicine; Cohort; Confidence interval; Cohort study; Population; Epidemiology; Multiple myeloma; Gerontology; Internal medicine; Demography","score_opus":0.009676987236834574,"score_gpt":0.2988752424923265,"score_spread":0.2891982552554919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376133376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829155,0.00023552848,0.00013133646,0.000051410963,0.00000883742,0.000040365325,0.0010382404,0.0000031009718,0.0001996816],"genre_scores_gemma":[0.9982734,0.00019622038,0.00016788932,0.00008192469,0.00002079018,0.00005419407,0.0010806374,0.0000027514957,0.00012212763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993666,0.00010508858,0.000085378255,0.00021717123,0.00011602807,0.00010972523],"domain_scores_gemma":[0.9990363,0.00007409041,0.00030264034,0.00019574081,0.00015058907,0.00024075266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012875508,0.00049510936,0.00078488694,0.0008040997,0.00086584815,0.0010752549,0.00052301266,0.00074394,0.0008309765],"category_scores_gemma":[0.002302556,0.0005683822,0.001126883,0.0017537803,0.00026095833,0.0009146389,0.000999745,0.001353238,0.0002794629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022141564,0.00007758845,0.9981281,0.000010783853,0.00019002275,0.00008325462,0.00012357814,0.000040172934,0.0001297851,0.000019470914,0.00017857575,0.0007971442],"study_design_scores_gemma":[0.00004778842,0.00018126602,0.99864334,0.0000124042235,0.00015402888,0.00021482211,0.00018683425,0.00025209147,0.000019155395,0.000032449156,0.00024707863,0.0000088499055],"about_ca_topic_score_codex":0.014336728,"about_ca_topic_score_gemma":0.017062422,"teacher_disagreement_score":0.014336728,"about_ca_system_score_codex":0.0005533409,"about_ca_system_score_gemma":0.00068903936,"threshold_uncertainty_score":0.028506577},"labels":[],"label_agreement":null},{"id":"W4377287471","doi":"10.1038/s41408-023-00851-5","title":"Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Phenotype; Biology; Multiple myeloma; Mass cytometry; Malignancy; Genetic heterogeneity; Meta-analysis; Cancer research; Oncology; Internal medicine; Immunology; Genetics; Medicine; Gene","score_opus":0.03962556086710801,"score_gpt":0.30440145318038375,"score_spread":0.26477589231327575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377287471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99922943,0.0001566223,0.00022568091,0.000016287797,0.0000010141791,0.0000035509602,0.00023106803,0.000010281532,0.00012603031],"genre_scores_gemma":[0.9990239,0.00010238791,0.00029810634,0.000017383192,0.000003952719,0.000006979829,0.00042915755,0.0000036460856,0.000114497125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998765,0.0000151326585,0.000009524463,0.00003881153,0.000033473527,0.000026481555],"domain_scores_gemma":[0.9998091,0.000035634872,0.000074525226,0.000017767576,0.000029615887,0.000033450204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018669835,0.0001466378,0.0002363802,0.0009478344,0.00019079643,0.00040646808,0.00011024473,0.00021154543,0.000573148],"category_scores_gemma":[0.00042853638,0.0000882908,0.00012669487,0.00064310123,0.00015581913,0.00014107168,0.00031157766,0.00019142582,0.00015796075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006816611,0.000051640305,0.6283287,0.000044931,0.00011117371,0.00017981934,0.00019981079,0.00035629908,0.35670182,0.000074195785,0.00031636906,0.012953465],"study_design_scores_gemma":[0.000004837609,0.00008736556,0.98775417,0.0000029090927,0.00002775173,0.0004086697,0.00008211431,0.00082699093,0.010403873,0.0000819694,0.00031543564,0.0000039649517],"about_ca_topic_score_codex":0.0007265197,"about_ca_topic_score_gemma":0.0010880112,"teacher_disagreement_score":0.0009478344,"about_ca_system_score_codex":0.00017027215,"about_ca_system_score_gemma":0.00009704949,"threshold_uncertainty_score":0.0019174218},"labels":[],"label_agreement":null},{"id":"W4378188863","doi":"10.1038/s41408-023-00856-0","title":"Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Minimal residual disease; Medicine; Multiple myeloma; Oncology; Internal medicine; Residual; Medical physics; Bone marrow; Computer science; Algorithm","score_opus":0.05230070476117005,"score_gpt":0.3153324173812251,"score_spread":0.26303171262005504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378188863","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035247393,0.00064811297,0.0017672235,0.071228676,0.91917825,0.00004964125,0.003798037,0.0008944057,0.0020830994],"genre_scores_gemma":[0.040717553,0.007701299,0.019036954,0.20525709,0.5465979,0.0005088299,0.009141112,0.0051286006,0.16591072],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957852,0.0008761901,0.0009945546,0.00059471355,0.001422618,0.00032680313],"domain_scores_gemma":[0.9606568,0.013081618,0.0025337716,0.0023845502,0.019809205,0.0015340822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047572404,0.002098825,0.0016084227,0.0033962752,0.0018044825,0.0031245144,0.002828547,0.0053457045,0.041340984],"category_scores_gemma":[0.09829733,0.0013799657,0.0017786735,0.002122547,0.0016246361,0.0014319897,0.0015301555,0.009995571,0.02103709],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003777455,0.000004837199,0.00014616085,0.000099532735,0.000016469023,0.00031742526,0.000026776692,0.000058998146,0.00003623574,0.0003748411,0.99441683,0.004464159],"study_design_scores_gemma":[0.0001488057,0.000033870827,0.0018974509,0.00074678566,0.0001236638,0.0026753994,0.000111884816,0.001009467,0.0006049341,0.0022464597,0.99033195,0.00006931746],"about_ca_topic_score_codex":0.02388571,"about_ca_topic_score_gemma":0.019833757,"teacher_disagreement_score":0.041340984,"about_ca_system_score_codex":0.0029857615,"about_ca_system_score_gemma":0.004652678,"threshold_uncertainty_score":0.13829935},"labels":[],"label_agreement":null},{"id":"W4383197462","doi":"10.1038/s41408-023-00866-y","title":"Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Clinical decision making; Immune system; Intensive care medicine; Oncology; Immunology; Internal medicine","score_opus":0.27779533924331146,"score_gpt":0.4866892149139586,"score_spread":0.20889387567064716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383197462","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005036901,0.00055025856,0.0003415011,0.10401334,0.89293355,0.000025386496,0.00079936074,0.00019715675,0.0010890512],"genre_scores_gemma":[0.0064069373,0.00527853,0.0035091722,0.29000336,0.62731797,0.00032892934,0.0014117821,0.00095138577,0.064791955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990131,0.0025448243,0.0019722763,0.0010913513,0.0033430352,0.00091736764],"domain_scores_gemma":[0.91954315,0.03393497,0.0037496858,0.0030059845,0.036455166,0.0033110667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011231797,0.0036200772,0.002789389,0.003446638,0.0037787722,0.005309996,0.004954364,0.0149768265,0.052914754],"category_scores_gemma":[0.1532932,0.0018732445,0.0034374474,0.0026788306,0.0036877354,0.0030942275,0.0023849448,0.027176348,0.031241732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032975735,0.0000034473853,0.000028409324,0.000101629674,0.000011454336,0.0000947421,0.00001570521,0.000023180315,0.000015055636,0.00031675564,0.99753857,0.0018180996],"study_design_scores_gemma":[0.0003022347,0.00004447473,0.0008599066,0.0012533615,0.00013219872,0.00071527594,0.000107485925,0.0004893849,0.00031156707,0.0036118121,0.99208415,0.000088113564],"about_ca_topic_score_codex":0.02470823,"about_ca_topic_score_gemma":0.02474017,"teacher_disagreement_score":0.052914754,"about_ca_system_score_codex":0.0057017645,"about_ca_system_score_gemma":0.011040159,"threshold_uncertainty_score":0.17701751},"labels":[],"label_agreement":null},{"id":"W4384923381","doi":"10.1038/s41408-023-00883-x","title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; McGill University; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Juravinski Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"Janssen Canada","keywords":"Attrition; Medicine; Multiple myeloma; Internal medicine; Cohort; Surgery; Oncology","score_opus":0.12362651348174936,"score_gpt":0.38956669331827093,"score_spread":0.2659401798365216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384923381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97253865,0.0036946363,0.0014777487,0.0015069264,0.000042308748,0.00027151513,0.018984219,0.00005746481,0.0014264721],"genre_scores_gemma":[0.98751664,0.00077427825,0.0016837612,0.0003499634,0.000034901073,0.00012022515,0.008918444,0.000027778258,0.00057418115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935109,0.0014974013,0.00045035992,0.000673483,0.0024989818,0.0013688336],"domain_scores_gemma":[0.99064577,0.0020338274,0.0024249393,0.00093518995,0.0029017883,0.0010585081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010671961,0.0007770197,0.0011036358,0.002899294,0.0015642963,0.001236899,0.002139697,0.00085103465,0.0014351316],"category_scores_gemma":[0.015754439,0.0003716091,0.0043760743,0.0071416087,0.00050745805,0.0005240743,0.001443567,0.0017182734,0.00015594355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005089425,0.000040880135,0.9888925,0.000061873325,0.0010570731,0.000049380593,0.000114535986,0.00047492186,0.00005234826,0.00013542024,0.002139622,0.0064724623],"study_design_scores_gemma":[0.000047454876,0.000090600624,0.9938584,0.000034178607,0.000630696,0.000061246064,0.00017928713,0.0034058301,0.00004590142,0.00007787072,0.0015492558,0.000019412413],"about_ca_topic_score_codex":0.90211725,"about_ca_topic_score_gemma":0.8795525,"teacher_disagreement_score":0.09788275,"about_ca_system_score_codex":0.011940169,"about_ca_system_score_gemma":0.022144305,"threshold_uncertainty_score":0.19691837},"labels":[],"label_agreement":null},{"id":"W4386202664","doi":"10.1038/s41408-023-00888-6","title":"Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; McGill University; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; Juravinski Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Medicine; Attrition; Internal medicine; Oncology; Family medicine","score_opus":0.09519958533312171,"score_gpt":0.37304994375816725,"score_spread":0.2778503584250455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386202664","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040585521,0.0019485638,0.0010155949,0.1626991,0.81180185,0.000088833905,0.014478453,0.0006265139,0.006935267],"genre_scores_gemma":[0.03526359,0.014932207,0.01343571,0.2822926,0.22923705,0.00076173164,0.023219943,0.005540939,0.39531618],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9888088,0.0016229425,0.0014686835,0.0010664326,0.00598536,0.0010476826],"domain_scores_gemma":[0.90026873,0.020743255,0.004460475,0.0047598346,0.06556117,0.0042064963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012015765,0.0018313254,0.0017522015,0.003933789,0.0041203042,0.004228603,0.004024672,0.0054128296,0.088605076],"category_scores_gemma":[0.1867209,0.0009880781,0.0019013063,0.004693429,0.0024572741,0.001956678,0.0020083648,0.009330283,0.02885059],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019688729,0.0000018546532,0.00012769051,0.00004106568,0.000008396327,0.00004436623,0.000012917454,0.000016465961,0.00000575164,0.00034961847,0.9969722,0.0023999566],"study_design_scores_gemma":[0.000115893454,0.00001603457,0.0022725337,0.00073850056,0.00007724705,0.00041806343,0.000117652286,0.00027455913,0.00016437462,0.0014540353,0.9942889,0.00006208087],"about_ca_topic_score_codex":0.24052209,"about_ca_topic_score_gemma":0.27873525,"teacher_disagreement_score":0.24052209,"about_ca_system_score_codex":0.011181448,"about_ca_system_score_gemma":0.031161226,"threshold_uncertainty_score":0.4782442},"labels":[],"label_agreement":null},{"id":"W4386441220","doi":"10.1038/s41408-023-00905-8","title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Saint John Regional Hospital; McGill University; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; University of British Columbia; Institute of Cancer Research; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre; McMaster University; Western University; Hôpital Maisonneuve-Rosemont; Université Laval","funders":"","keywords":"Multiple myeloma; Medicine; Transplantation; Stem cell; Autologous stem-cell transplantation; Oncology; Internal medicine; Biology; Genetics","score_opus":0.07226150521320708,"score_gpt":0.361496175435274,"score_spread":0.28923467022206695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386441220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6805095,0.006948859,0.00030690152,0.0013969606,0.000039809955,0.00011681051,0.30613056,0.00006858755,0.004481987],"genre_scores_gemma":[0.8849889,0.002571043,0.00057836005,0.00044209577,0.000036458885,0.0000868963,0.110872075,0.000018667144,0.00040552297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938233,0.00057112763,0.0006709973,0.0008072058,0.0034227143,0.00070464984],"domain_scores_gemma":[0.98431826,0.0019495551,0.0055605625,0.00076347415,0.0061564106,0.0012517745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027514673,0.0004265554,0.0007596116,0.0033135405,0.0009769249,0.0021847226,0.0015267739,0.00063817186,0.0011203773],"category_scores_gemma":[0.013066873,0.00028023662,0.0005753756,0.011851166,0.000594822,0.0006261038,0.0007926143,0.0006244135,0.0002669623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027937687,0.0000228127,0.9826066,0.00022581729,0.00025362047,0.000104090206,0.00019189391,0.0003063638,0.00008484624,0.00019219097,0.009390584,0.0063418187],"study_design_scores_gemma":[0.00002848792,0.000018545912,0.99269193,0.000080365564,0.00009805307,0.00017861534,0.00023541457,0.0005668923,0.00010399352,0.000036811405,0.005932955,0.000027917926],"about_ca_topic_score_codex":0.9154457,"about_ca_topic_score_gemma":0.9215705,"teacher_disagreement_score":0.084554315,"about_ca_system_score_codex":0.018157296,"about_ca_system_score_gemma":0.016276475,"threshold_uncertainty_score":0.1701045},"labels":[],"label_agreement":null},{"id":"W4386704631","doi":"10.1038/s41408-023-00918-3","title":"The expanding CML treatment landscape: an introspective commentary","year":2023,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Toronto","keywords":"Introspection; Medicine; MEDLINE; Intensive care medicine; Psychology; Political science; Law; Cognitive psychology","score_opus":0.015809717900934883,"score_gpt":0.3357773604501388,"score_spread":0.3199676425492039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386704631","genre_codex":"editorial","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005469542,0.006964419,0.00010951909,0.28639588,0.7051906,0.000017234364,0.000034050867,0.00004922727,0.0011844288],"genre_scores_gemma":[0.0006063984,0.0041896133,0.00014247428,0.22433396,0.7682871,0.000020027595,0.000013656226,0.0000382872,0.0023684276],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916972,0.002258608,0.0011141461,0.0010082467,0.003462074,0.0004597633],"domain_scores_gemma":[0.95745957,0.025279244,0.0019945987,0.00087214797,0.010296,0.004098353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012057414,0.0026464902,0.00285741,0.002288305,0.0044380124,0.007833951,0.0040022563,0.026920067,0.005874025],"category_scores_gemma":[0.051129173,0.0009829716,0.0020990297,0.0015377641,0.005173333,0.008342343,0.0022708501,0.04205299,0.0056865355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001832791,0.0000074704444,0.000020491236,0.00012683809,0.000009577861,0.00014879476,0.00005630806,0.000016095415,0.000035072375,0.00036426066,0.9963331,0.0028636295],"study_design_scores_gemma":[0.000058592825,0.000040489256,0.00016711069,0.0007772899,0.000043105236,0.0006356428,0.00019117375,0.00011592421,0.00011357963,0.002193818,0.99562705,0.000036162804],"about_ca_topic_score_codex":0.0021603864,"about_ca_topic_score_gemma":0.0046504373,"teacher_disagreement_score":0.026920067,"about_ca_system_score_codex":0.004485209,"about_ca_system_score_gemma":0.0049743545,"threshold_uncertainty_score":0.06376642},"labels":[],"label_agreement":null},{"id":"W4388495570","doi":"10.1038/s41408-023-00939-y","title":"MRD negativity: considerations for older adults with multiple myeloma","year":2023,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University","funders":"National Cancer Institute; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Multiple myeloma; Medicine; Negativity effect; Internal medicine; Oncology; Gerontology; Psychology; Developmental psychology","score_opus":0.02538720888301478,"score_gpt":0.3279142641090423,"score_spread":0.3025270552260275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495570","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008976629,0.026901674,0.00022760038,0.098824896,0.87201446,0.00002905474,0.0000326938,0.00008396378,0.0017959671],"genre_scores_gemma":[0.00050944946,0.01535981,0.0001590361,0.04953511,0.9317921,0.000024280876,0.000018650522,0.000024400566,0.0025771568],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744344,0.00051939796,0.00051367463,0.00031978264,0.0010360741,0.00016766274],"domain_scores_gemma":[0.9832477,0.008046483,0.0008544285,0.00034801653,0.005135959,0.0023673892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007057531,0.002313214,0.0028143427,0.002132917,0.0022195692,0.005198082,0.00277289,0.018240549,0.0055767405],"category_scores_gemma":[0.026057255,0.00095810276,0.0019341791,0.00091920147,0.0022203075,0.006025098,0.0013954465,0.026192361,0.0052355328],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054952874,0.00002011409,0.00007811042,0.00044202013,0.000019456815,0.00027663852,0.000037885005,0.000029197083,0.00007164466,0.000503394,0.9758414,0.022625161],"study_design_scores_gemma":[0.00009926212,0.00006362664,0.0005168539,0.001326861,0.00009313819,0.0009970381,0.00009196105,0.00014239742,0.000094045645,0.0016385148,0.9949063,0.000030074363],"about_ca_topic_score_codex":0.0012438376,"about_ca_topic_score_gemma":0.003079624,"teacher_disagreement_score":0.018240549,"about_ca_system_score_codex":0.002092935,"about_ca_system_score_gemma":0.0021939185,"threshold_uncertainty_score":0.03732425},"labels":[],"label_agreement":null},{"id":"W4389485135","doi":"10.1038/s41408-023-00946-z","title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institutes of Health Research; University of British Columbia; Memorial University of Newfoundland; McGill University; McGill University Health Centre; London Health Sciences Centre; Western University; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Juravinski Cancer Centre; Jewish General Hospital; Alberta Cancer Foundation; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Dalhousie University","funders":"Pfizer Canada; Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Cohort; Lenalidomide; Salvage therapy; Bortezomib; Daratumumab; Oncology; Surgery; Chemotherapy","score_opus":0.15252260014164173,"score_gpt":0.41818446379962954,"score_spread":0.26566186365798783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389485135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90110797,0.0027516014,0.0003649821,0.00031835897,0.000011286046,0.000058666294,0.09346701,0.000028176757,0.0018920146],"genre_scores_gemma":[0.9525697,0.0008769124,0.0003169447,0.00011169533,0.00001557669,0.000040803592,0.0459647,0.000007236735,0.00009645172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969253,0.00035796087,0.0004449458,0.0004866019,0.0014670455,0.00031815167],"domain_scores_gemma":[0.98731357,0.0015165206,0.0065606623,0.0008891127,0.0029155693,0.0008045236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001955787,0.00029605956,0.0005380905,0.0030584112,0.00067329546,0.0013669247,0.0009673149,0.0003793399,0.00080256135],"category_scores_gemma":[0.0070045353,0.00020048335,0.00047492108,0.0081630945,0.00042725838,0.0005532446,0.0007123309,0.0004258803,0.00015026277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014068293,0.0000115826015,0.9957808,0.000076724034,0.00018993346,0.00004746453,0.00008095547,0.0001578266,0.00008204578,0.0000583443,0.001122376,0.0022512553],"study_design_scores_gemma":[0.000013910845,0.000019420828,0.9977087,0.000020055359,0.000067742054,0.00017387075,0.00011951534,0.00020703523,0.00006892804,0.000018218585,0.0015694946,0.000013136616],"about_ca_topic_score_codex":0.49383497,"about_ca_topic_score_gemma":0.5885145,"teacher_disagreement_score":0.506165,"about_ca_system_score_codex":0.005467983,"about_ca_system_score_gemma":0.005471301,"threshold_uncertainty_score":0.9819211},"labels":[],"label_agreement":null},{"id":"W4390875111","doi":"10.1038/s41408-023-00974-9","title":"Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Occupational Safety and Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; National Cancer Institute; National Institutes of Health; Alexander and Margaret Stewart Trust; Vanderbilt University Medical Center; Vanderbilt University; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Zygosity; Loss of heterozygosity; Germline mutation; Biology; Internal medicine; Uniparental disomy; Mutation; Oncology; Genetics; Medicine; Allele; Chromosome; Gene; Karyotype","score_opus":0.017966603771226337,"score_gpt":0.3262525614460847,"score_spread":0.3082859576748584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390875111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603325,0.0012538446,0.00071537937,0.00022887043,0.000025822308,0.000014824518,0.000557517,0.000025355146,0.0011452611],"genre_scores_gemma":[0.99889696,0.00019066161,0.0003020875,0.000032288397,0.000017213566,0.0000058081464,0.0003454552,0.0000061612914,0.00020330209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893683,0.00036782504,0.00010429534,0.00026412262,0.00022095142,0.00010605572],"domain_scores_gemma":[0.99569005,0.0018074624,0.0012609027,0.00041491629,0.00019785688,0.00062883523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001691825,0.00032322164,0.0005133198,0.0009858927,0.000366607,0.0010743083,0.00052361924,0.00070690055,0.0029671395],"category_scores_gemma":[0.009140615,0.00028317972,0.00053992565,0.0009580307,0.00045645732,0.00046802528,0.000665466,0.00077826995,0.0006251917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020675402,0.000011705293,0.9942596,0.000009571457,0.00006070469,0.00031536625,0.000031249918,0.00012695337,0.0009449162,0.00005950133,0.00017961625,0.0037940508],"study_design_scores_gemma":[0.000008776404,0.00009718583,0.99581677,0.000015312671,0.00008383114,0.0018592242,0.00005681832,0.0009481862,0.00044246463,0.00015649624,0.0005059856,0.000008949998],"about_ca_topic_score_codex":0.0026278447,"about_ca_topic_score_gemma":0.0026497105,"teacher_disagreement_score":0.0029671395,"about_ca_system_score_codex":0.0002393297,"about_ca_system_score_gemma":0.00028750626,"threshold_uncertainty_score":0.009926081},"labels":[],"label_agreement":null},{"id":"W4390893554","doi":"10.1038/s41408-024-00978-z","title":"Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?","year":2024,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Chromosomal translocation; Multiple myeloma; Medicine; Internal medicine; Biology; Genetics; Gene","score_opus":0.0379314257076081,"score_gpt":0.3384788602232021,"score_spread":0.300547434515594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390893554","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014143693,0.012853797,0.00017085935,0.060678255,0.92529035,0.000014506736,0.000028315133,0.000063051724,0.0007593687],"genre_scores_gemma":[0.0005462419,0.0046288325,0.00006738696,0.017038247,0.975723,0.000006362063,0.00001068409,0.000013281889,0.0019659025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780375,0.00041289334,0.00037933965,0.00038705833,0.0008496558,0.00016731431],"domain_scores_gemma":[0.9854859,0.0071937586,0.00081527856,0.00038417807,0.004190248,0.0019305899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005538667,0.0029915045,0.0028136282,0.0026707037,0.0020741965,0.0044218865,0.0029043274,0.013623835,0.0040287566],"category_scores_gemma":[0.016395617,0.00093675347,0.0015972317,0.001137027,0.0023046308,0.004035302,0.0010045575,0.01991186,0.003645412],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013062716,0.000031906166,0.0001946753,0.00042963913,0.000037340316,0.00065617636,0.00003882897,0.00004642364,0.00015016909,0.0005396293,0.9821123,0.01563228],"study_design_scores_gemma":[0.00017090906,0.00017118981,0.0012627168,0.0009716166,0.00018798563,0.0028806285,0.00012227744,0.00043197128,0.00033506006,0.0022069826,0.99120456,0.000054120446],"about_ca_topic_score_codex":0.0012417537,"about_ca_topic_score_gemma":0.0023196142,"teacher_disagreement_score":0.013623835,"about_ca_system_score_codex":0.0023510924,"about_ca_system_score_gemma":0.0014949612,"threshold_uncertainty_score":0.02929163},"labels":[],"label_agreement":null},{"id":"W4391226400","doi":"10.1038/s41408-024-00985-0","title":"Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Multiple myeloma; Randomized controlled trial; Clinical trial; Medicine; Internal medicine; MEDLINE; Chromosome; Oncology; Bioinformatics; Genetics; Biology; Gene","score_opus":0.2498751381734825,"score_gpt":0.5259056938982104,"score_spread":0.2760305557247279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391226400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015696221,0.9959298,0.00030645326,0.00034602365,0.00016898959,0.0009151448,0.0004492786,0.000020166073,0.00029463315],"genre_scores_gemma":[0.042291466,0.95058805,0.0016745295,0.0014676031,0.00020493026,0.003069223,0.00046328726,0.000020078041,0.0002207937],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9793966,0.009585129,0.007178529,0.0012379191,0.0022350987,0.00036664266],"domain_scores_gemma":[0.92671394,0.05753544,0.011141042,0.00086969364,0.0032712459,0.00046863148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018263329,0.0016174136,0.0144967865,0.0051282593,0.0006419154,0.0029764515,0.0021826196,0.0025343723,0.0064996425],"category_scores_gemma":[0.0767297,0.0012930194,0.011322329,0.0069625885,0.0010913705,0.0024848708,0.0014945029,0.0017069791,0.00040939436],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007245681,0.000016089922,0.00050500385,0.9594471,0.023480417,0.000041334104,0.00006519253,0.00009757436,0.00009084805,0.00016040888,0.00074313494,0.014628313],"study_design_scores_gemma":[0.0032766995,0.0005988246,0.0038081273,0.72906643,0.24995732,0.000210675,0.0001631248,0.00021752015,0.00022482581,0.00062235666,0.011800466,0.00005356857],"about_ca_topic_score_codex":0.005382086,"about_ca_topic_score_gemma":0.01368512,"teacher_disagreement_score":0.018263329,"about_ca_system_score_codex":0.0041957577,"about_ca_system_score_gemma":0.009393194,"threshold_uncertainty_score":0.09658682},"labels":[],"label_agreement":null},{"id":"W4391482982","doi":"10.1038/s41408-023-00966-9","title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Medicine; Multiple myeloma; Chimeric antigen receptor; Clinical trial; Adverse effect; Pharmacodynamics; Malignancy; Cytokine release syndrome; Immunotherapy; Oncology; Antigen; Internal medicine; Pharmacokinetics; Immunology; Immune system","score_opus":0.1028294294267789,"score_gpt":0.44232088335920794,"score_spread":0.339491453932429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391482982","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015981354,0.9987239,0.000107618085,0.00034922702,0.00018485026,0.000012005727,0.0000323871,0.0000057806737,0.00042434485],"genre_scores_gemma":[0.0007964183,0.99820924,0.00017762785,0.0003451431,0.00019886224,0.000016831209,0.000045763358,0.0000011947578,0.00020893758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997695,0.0000442234,0.00005717795,0.000044126173,0.00006757768,0.000017318249],"domain_scores_gemma":[0.9994966,0.00027165865,0.000103971026,0.000009727365,0.00008906311,0.000029043375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006506453,0.00074022484,0.0013788457,0.001896236,0.00025677425,0.001125593,0.0008855871,0.0010554735,0.002770095],"category_scores_gemma":[0.0010632403,0.0002236248,0.00085409527,0.0019342361,0.00029301812,0.0012146721,0.00057892984,0.001285,0.0007575513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015928302,0.0000741895,0.0002927348,0.09936412,0.00040708148,0.0003992586,0.00012465681,0.0005336995,0.0015952619,0.003144842,0.04068884,0.85321605],"study_design_scores_gemma":[0.000053979606,0.00025404434,0.0010969917,0.024447067,0.001132316,0.0023081475,0.000115251954,0.00023782895,0.0005632877,0.0015835348,0.9681728,0.000034660403],"about_ca_topic_score_codex":0.0008092499,"about_ca_topic_score_gemma":0.0011761945,"teacher_disagreement_score":0.002770095,"about_ca_system_score_codex":0.00051577477,"about_ca_system_score_gemma":0.0013884446,"threshold_uncertainty_score":0.009266913},"labels":[],"label_agreement":null},{"id":"W4392298224","doi":"10.1038/s41408-024-01002-0","title":"Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"Academy of Medical Sciences; Medical Research Council; National Institute for Health and Care Research; Cancer Research UK; European Hematology Association","keywords":"Flow cytometry; T cell; Staining; CD8; Cell; Antibody; Molecular biology; Biology; Antigen; Immunology; Pathology; Medicine; Immune system; Genetics","score_opus":0.015369231450475902,"score_gpt":0.31349333209872715,"score_spread":0.29812410064825123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392298224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90090895,0.0028230173,0.08900663,0.00013501948,0.0000782153,0.00025588472,0.00044352553,0.0005091727,0.00583959],"genre_scores_gemma":[0.905713,0.001187228,0.08897794,0.000078214835,0.00007045698,0.0003827019,0.0008569272,0.000061144536,0.0026723156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965835,0.00007967918,0.000042645042,0.00008911534,0.000065557055,0.000064643005],"domain_scores_gemma":[0.9997447,0.00009953038,0.00002870173,0.000042697193,0.000041560488,0.000042726402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007485318,0.0004352232,0.00025839044,0.0012369868,0.00022870152,0.00037993543,0.0002785449,0.00043840945,0.007698473],"category_scores_gemma":[0.00045777607,0.00015438428,0.00015675486,0.0003980713,0.00031014593,0.00033327274,0.00037130702,0.00042936706,0.0013994877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013018119,0.000023748646,0.0027276948,0.000043229804,0.000006021572,0.00009827031,0.0000317125,0.000070194474,0.99044484,0.00024824188,0.000119074924,0.006056846],"study_design_scores_gemma":[0.00011362971,0.0011638467,0.05225781,0.000060186892,0.00008493162,0.006324386,0.00014647965,0.023908237,0.89953524,0.0009620366,0.015412673,0.000030517465],"about_ca_topic_score_codex":0.0003524818,"about_ca_topic_score_gemma":0.00043853986,"teacher_disagreement_score":0.007698473,"about_ca_system_score_codex":0.00020024473,"about_ca_system_score_gemma":0.00017118001,"threshold_uncertainty_score":0.025753975},"labels":[],"label_agreement":null},{"id":"W4392516550","doi":"10.1038/s41408-024-01018-6","title":"Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Narrative; Medicine; Narrative review; Internal medicine; Bioinformatics; Intensive care medicine; Biology; Literature; Art","score_opus":0.0883671284899405,"score_gpt":0.4293044025224052,"score_spread":0.3409372740324647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392516550","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005807108,0.26462945,0.0013841274,0.2050252,0.5182676,0.00023792038,0.0036223335,0.00026393708,0.005988744],"genre_scores_gemma":[0.01814535,0.465879,0.0027961014,0.21644983,0.25905016,0.00076175167,0.003558071,0.0004524857,0.032907307],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965495,0.0009821809,0.00078535295,0.00039052608,0.0010266013,0.00026576623],"domain_scores_gemma":[0.9805853,0.00962239,0.0024442738,0.00061852956,0.0061109383,0.0006185897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005233,0.0013848526,0.0021569766,0.0030719829,0.0011453764,0.003098595,0.0030469901,0.004900583,0.036619555],"category_scores_gemma":[0.05896768,0.00047149177,0.0021702987,0.0026808747,0.0019007816,0.0044165766,0.0024046048,0.0054846224,0.009677027],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102135935,0.000006190626,0.00013232708,0.013501593,0.00011443211,0.00044848406,0.00012550566,0.00007892567,0.00008651672,0.0014646555,0.95049685,0.033442322],"study_design_scores_gemma":[0.00016499833,0.00003876851,0.00055242126,0.02773959,0.00041840097,0.0026458902,0.00021055623,0.00008755678,0.00021818928,0.002170615,0.9657047,0.000048342885],"about_ca_topic_score_codex":0.004636233,"about_ca_topic_score_gemma":0.0055933376,"teacher_disagreement_score":0.036619555,"about_ca_system_score_codex":0.0024171981,"about_ca_system_score_gemma":0.007531991,"threshold_uncertainty_score":0.12250459},"labels":[],"label_agreement":null},{"id":"W4399609630","doi":"10.1038/s41408-024-01071-1","title":"Premature thymic functional senescence is a hallmark of childhood acute lymphoblastic leukemia survivorship","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Université Laval; Centre Hospitalier Universitaire Sainte-Justine; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"Garron Family Cancer Centre; Leukemia and Lymphoma Society; Fonds de Recherche du Québec - Santé; Leukemia and Lymphoma Society of Canada; Hospital for Sick Children; Université de Montréal; Pediatric Oncology Group of Ontario; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Institute of Cancer Research; Cancer Research Society; Ministère de la Santé et des Services sociaux; Ontario Institute for Cancer Research","keywords":"Immunosenescence; Medicine; Cancer; Senescence; Survivorship curve; Immunology; Leukemia; T cell; Internal medicine; Chronic lymphocytic leukemia; Immunophenotyping; Biomarker; Oncology; Biology; Immune system; Flow cytometry","score_opus":0.01808758214467647,"score_gpt":0.2858207302296639,"score_spread":0.26773314808498744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399609630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974841,0.0013016654,0.00026026543,0.000027951217,0.000007009864,0.000012011859,0.00032815465,0.000018042187,0.0005607921],"genre_scores_gemma":[0.9988514,0.00048523108,0.00012523802,0.000018591496,0.000013616652,0.000008491497,0.00031509134,0.0000034496252,0.0001788719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998642,0.000033235592,0.000013321174,0.000031115596,0.000029486215,0.000028637898],"domain_scores_gemma":[0.99936146,0.000065137865,0.00036693638,0.000056483354,0.000056626013,0.00009335847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022192321,0.0001585931,0.00022812615,0.00056366326,0.00017678525,0.00032229975,0.000118164244,0.00013960652,0.001101904],"category_scores_gemma":[0.0006448316,0.000072090814,0.00013259018,0.00042723314,0.00017024876,0.00014510985,0.00028978955,0.00019953916,0.0001944939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007571085,0.000043375552,0.93581736,0.00010399927,0.000047519618,0.00083863677,0.00034630953,0.0000857215,0.039764732,0.000096247095,0.00033117444,0.021767825],"study_design_scores_gemma":[0.000002247283,0.00015956745,0.99536276,0.000008071025,0.000018048137,0.0017133765,0.00014544226,0.000053329004,0.0016436881,0.00004970805,0.00084031746,0.0000033550646],"about_ca_topic_score_codex":0.000648145,"about_ca_topic_score_gemma":0.0008327779,"teacher_disagreement_score":0.001101904,"about_ca_system_score_codex":0.00015497216,"about_ca_system_score_gemma":0.00013528529,"threshold_uncertainty_score":0.0036862493},"labels":[],"label_agreement":null},{"id":"W4399859940","doi":"10.1038/s41408-024-01080-0","title":"Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Oncology; Disease; Medicine; Internal medicine; Bioinformatics; Computational biology; Biology","score_opus":0.010928446282557208,"score_gpt":0.28998048298401574,"score_spread":0.2790520367014585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399859940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682295,0.00019069135,0.002096316,0.000056413537,0.000002739568,0.000009867368,0.00047980095,0.000025562927,0.000315665],"genre_scores_gemma":[0.99816763,0.000059885446,0.0011145136,0.000024198216,0.0000036315482,0.0000062765002,0.0005009659,0.000006166053,0.00011658324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997627,0.000053844746,0.000019713883,0.00006831196,0.00004947229,0.00004599883],"domain_scores_gemma":[0.99952424,0.0001051235,0.00020484897,0.000044163167,0.000052146916,0.00006948729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004393633,0.00032662254,0.0003977538,0.001470063,0.00020083215,0.0006229215,0.0001825465,0.00024709172,0.0008000527],"category_scores_gemma":[0.0008913713,0.00011427593,0.00033134685,0.0008803986,0.0001964329,0.00027688715,0.00053635,0.00027510754,0.00016288033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006492001,0.000072117466,0.84424585,0.000048509253,0.0002396019,0.00030777793,0.000094451534,0.002624646,0.1262114,0.000153236,0.00025076728,0.02510244],"study_design_scores_gemma":[0.000010077832,0.00020115031,0.97468024,0.000010343657,0.0001246006,0.00075835694,0.00014066936,0.012038379,0.0109068565,0.0005853309,0.00053038425,0.00001357966],"about_ca_topic_score_codex":0.0007762331,"about_ca_topic_score_gemma":0.0015941064,"teacher_disagreement_score":0.001470063,"about_ca_system_score_codex":0.00033263536,"about_ca_system_score_gemma":0.00022079323,"threshold_uncertainty_score":0.0026764274},"labels":[],"label_agreement":null},{"id":"W4400428906","doi":"10.1038/s41408-024-01084-w","title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Medicine; Cumulative incidence; Internal medicine; Univariate analysis; Incidence (geometry); Progression-free survival; Hematopoietic cell; Surgery; Retrospective cohort study; Hematopoietic stem cell transplantation; Transplantation; Multivariate analysis; Chemotherapy; Haematopoiesis","score_opus":0.027509978119901374,"score_gpt":0.29665129241502913,"score_spread":0.2691413142951278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400428906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991702,0.0005683713,0.000037549074,0.000022433213,0.000007485318,0.000009427524,0.00005604595,0.0000015965791,0.00012687239],"genre_scores_gemma":[0.9995789,0.00017555806,0.0000304155,0.000039528695,0.000016480055,0.0000075947073,0.000114528186,5.281529e-7,0.00003652886],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997129,0.00011947469,0.000033417175,0.000058140417,0.000030959847,0.000045143166],"domain_scores_gemma":[0.9992747,0.00023864985,0.0002728692,0.000036929072,0.000021310749,0.00015555002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718106,0.000105557934,0.0005000486,0.0001833734,0.00012914608,0.0003295835,0.00014626523,0.00023907474,0.000546923],"category_scores_gemma":[0.0010553529,0.00008238395,0.0005893242,0.0002887215,0.00015734983,0.00021728198,0.00016790135,0.00037509424,0.00008564408],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17268652,0.0025541396,0.7464077,0.00031045434,0.001239957,0.0006901239,0.00019969874,0.0011362161,0.006424726,0.00015237463,0.00060895755,0.06758923],"study_design_scores_gemma":[0.007563706,0.07455738,0.9091652,0.000061699204,0.0010959478,0.0017079684,0.00020011619,0.0020737215,0.0016497438,0.00025727155,0.0016479683,0.000019329662],"about_ca_topic_score_codex":0.00053291384,"about_ca_topic_score_gemma":0.00092042505,"teacher_disagreement_score":0.0005718106,"about_ca_system_score_codex":0.00033486134,"about_ca_system_score_gemma":0.0002766193,"threshold_uncertainty_score":0.0030241013},"labels":[],"label_agreement":null},{"id":"W4401392108","doi":"10.1038/s41408-024-01111-w","title":"Identification of genetic subtypes in follicular lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Jewish General Hospital; Vector Institute; Princess Margaret Cancer Centre; Queen's University; University of Toronto; University Health Network","funders":"National Cancer Institute; Terry Fox Research Institute; Government of Canada; Deutsche Forschungsgemeinschaft; National Institutes of Health; Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada; F. Hoffmann-La Roche; Génome Québec; Canadian Institutes of Health Research; Else Kröner-Fresenius-Stiftung; Leukemia and Lymphoma Society","keywords":"Identification (biology); Follicular lymphoma; Lymphoma; Medicine; Computational biology; Hematology; Internal medicine; Biology; Bioinformatics; Immunology; Oncology; Genetics; Pathology","score_opus":0.010477757073206589,"score_gpt":0.2798505639844227,"score_spread":0.2693728069112161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401392108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743015,0.00018949929,0.0018796311,0.000037679805,0.0000011992706,0.000014478518,0.00022398171,0.000021831847,0.00020158554],"genre_scores_gemma":[0.9983436,0.000053727363,0.0010322469,0.000014131865,0.0000031819766,0.0000103995335,0.00045642437,0.0000067545075,0.00007949467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996117,0.00013116607,0.000025593432,0.00010916568,0.00006290609,0.00005943998],"domain_scores_gemma":[0.9995964,0.0001434808,0.00013104203,0.000057570836,0.000033861485,0.000037678754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075858866,0.00016566573,0.00030345473,0.0011492162,0.00027220522,0.0005307897,0.00022588127,0.00026325765,0.00063297333],"category_scores_gemma":[0.0016581521,0.00012656229,0.00036486355,0.0007595507,0.00019920192,0.00019526447,0.00042484736,0.0002457736,0.0001359715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049982005,0.000029375775,0.955433,0.000018068917,0.00011960555,0.00012916591,0.00012355886,0.0028777968,0.013199291,0.0002846515,0.00025380764,0.027031887],"study_design_scores_gemma":[0.000038946455,0.00015609781,0.9658685,0.000012578923,0.00011364278,0.0011330796,0.00030023375,0.026441935,0.0024686914,0.002212776,0.0012333073,0.000020213347],"about_ca_topic_score_codex":0.004344143,"about_ca_topic_score_gemma":0.005666957,"teacher_disagreement_score":0.004344143,"about_ca_system_score_codex":0.00039156742,"about_ca_system_score_gemma":0.0003650344,"threshold_uncertainty_score":0.008637726},"labels":[],"label_agreement":null},{"id":"W4402460449","doi":"10.1038/s41408-024-01135-2","title":"Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org; Juravinski Cancer Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Dexamethasone; Subgroup analysis; Multiple myeloma; Internal medicine; Oncology; Medicine; Refractory (planetary science); Lenalidomide; Meta-analysis; Biology","score_opus":0.03603070339032477,"score_gpt":0.32597029922849974,"score_spread":0.28993959583817497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402460449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903324,0.0072318953,0.00030683668,0.00021698406,0.000092458715,0.0003091498,0.0007051293,0.000017317707,0.0007878002],"genre_scores_gemma":[0.9974802,0.00081794563,0.00020128446,0.0001931382,0.00009047027,0.00018983331,0.0007044458,0.000010380794,0.00031221483],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9983134,0.00096025487,0.00018902752,0.00022085774,0.00014598877,0.00017049858],"domain_scores_gemma":[0.99892634,0.0004245851,0.00021938149,0.00020709564,0.00008027378,0.0001423262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029661565,0.00094186456,0.0030099011,0.0004949355,0.00020905463,0.0010493547,0.00044852291,0.0006038087,0.0013584638],"category_scores_gemma":[0.0021326554,0.0002602951,0.006239943,0.000564211,0.00027559084,0.00041488762,0.0003922341,0.0009861192,0.00017931548],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74299943,0.0013113254,0.08042813,0.002210299,0.093636766,0.0008610665,0.00036164492,0.0027611104,0.017648172,0.00038890413,0.002579566,0.05481361],"study_design_scores_gemma":[0.32516378,0.09215705,0.3948379,0.00055719115,0.15467268,0.0022991425,0.0012458129,0.008776434,0.005849432,0.0031635503,0.011015618,0.00026142658],"about_ca_topic_score_codex":0.00062835746,"about_ca_topic_score_gemma":0.002103328,"teacher_disagreement_score":0.0030099011,"about_ca_system_score_codex":0.0004883475,"about_ca_system_score_gemma":0.00063192815,"threshold_uncertainty_score":0.01568669},"labels":[],"label_agreement":null},{"id":"W4402493149","doi":"10.1038/s41408-024-01139-y","title":"Bispecific antibodies in the treatment of multiple myeloma","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Antibody; Medicine; Hematology; Immunology; Internal medicine; Oncology; Cancer research","score_opus":0.12383453040322111,"score_gpt":0.4311017220673892,"score_spread":0.3072671916641681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402493149","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068146095,0.9987955,0.00007174095,0.00014300288,0.00014281017,0.000003916659,0.000008052367,0.000006562161,0.0007602388],"genre_scores_gemma":[0.0005738721,0.9982157,0.00013590652,0.00022969916,0.00011720646,0.0000055259416,0.00002407953,0.0000014400412,0.00069675944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997739,0.000040442228,0.00002530033,0.000033172968,0.00010426225,0.000022867276],"domain_scores_gemma":[0.9998053,0.00008463036,0.00003009524,0.000006090306,0.000050435574,0.000023435581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059043436,0.0008190314,0.0011188047,0.0025785693,0.00023113063,0.0007070087,0.00086204446,0.0010871601,0.0036688435],"category_scores_gemma":[0.0005688738,0.00023212419,0.00055266666,0.0019215662,0.0004364902,0.0010039203,0.0006535178,0.0026618594,0.0025459114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010629465,0.00009694829,0.00009237946,0.013218531,0.00010545086,0.00014791366,0.000045823264,0.0003991923,0.001834479,0.003779131,0.033372793,0.94680107],"study_design_scores_gemma":[0.000024169689,0.00009694337,0.00037051074,0.0024051666,0.00007407318,0.00075640145,0.000021835724,0.000051539537,0.0004049762,0.0016926205,0.99409145,0.000010307366],"about_ca_topic_score_codex":0.0010399206,"about_ca_topic_score_gemma":0.0016636709,"teacher_disagreement_score":0.0036688435,"about_ca_system_score_codex":0.00061757164,"about_ca_system_score_gemma":0.00065185566,"threshold_uncertainty_score":0.01227349},"labels":[],"label_agreement":null},{"id":"W4403173763","doi":"10.1038/s41408-024-01153-0","title":"MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"Agencia Estatal de Investigación; European Regional Development Fund; Instituto de Salud Carlos III; Ministerio de Economía y Competitividad; Generalitat de Catalunya; European Commission; Michael Smith Health Research BC","keywords":"Lymphoma; Burkitt's lymphoma; Medicine; Cancer research; Hematology; B cell; Oncology; Internal medicine; Immunology; Antibody","score_opus":0.004214530295685977,"score_gpt":0.22791742188011657,"score_spread":0.2237028915844306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403173763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774194,0.0013361666,0.00024744042,0.000020511934,0.0000032086243,0.000011470249,0.00014915616,0.000015721616,0.00047444509],"genre_scores_gemma":[0.99820065,0.00078642316,0.0003923057,0.000037173675,0.0000072108037,0.000008571228,0.0003860871,0.0000030175918,0.00017854343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998801,0.000023760555,0.000012078332,0.000030089253,0.000028407954,0.000025629643],"domain_scores_gemma":[0.99978393,0.000036551584,0.00007881458,0.000019001704,0.000031762378,0.000050061197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022348475,0.00020429974,0.00023531659,0.0002953032,0.00024340359,0.00031317156,0.00007657799,0.00017088777,0.0008232378],"category_scores_gemma":[0.0004896718,0.0001215376,0.000111205125,0.00039609196,0.00023207975,0.00026018222,0.00023002875,0.00027053745,0.0002482999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087298955,0.000022307977,0.9726309,0.000033956938,0.000020519816,0.00078683597,0.00016303231,0.000047664522,0.00859054,0.00006662123,0.00022744633,0.01732287],"study_design_scores_gemma":[0.000009871722,0.00018761425,0.9842832,0.00002045322,0.000028996126,0.010424326,0.0003562823,0.00009124485,0.0017359194,0.000088329056,0.0027704486,0.0000033804556],"about_ca_topic_score_codex":0.0014211878,"about_ca_topic_score_gemma":0.0024649724,"teacher_disagreement_score":0.0014211878,"about_ca_system_score_codex":0.00017354083,"about_ca_system_score_gemma":0.0002288564,"threshold_uncertainty_score":0.0028258562},"labels":[],"label_agreement":null},{"id":"W4403400873","doi":"10.1038/s41408-024-01159-8","title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Universitätsklinikum Heidelberg; Deutsches Krebsforschungszentrum","keywords":"Multiple myeloma; Cohort; Medicine; Internal medicine; Oncology","score_opus":0.029946250782767674,"score_gpt":0.3128324942580536,"score_spread":0.2828862434752859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403400873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972473,0.00038955951,0.00008308815,0.00046147872,0.000018581688,0.000018453726,0.00082945253,0.000009002991,0.00094303937],"genre_scores_gemma":[0.9972772,0.00035308642,0.00012524604,0.0005063245,0.000094207484,0.000026351978,0.0011257646,0.000006776046,0.00048499406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995746,0.000058475387,0.000047677408,0.0001350143,0.0000938348,0.00009043795],"domain_scores_gemma":[0.99912244,0.00014753148,0.00026620933,0.00007500012,0.00014806993,0.00024084507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029042407,0.00020167147,0.00044945444,0.00092115975,0.0008908912,0.0009841762,0.00038687856,0.00080903515,0.0017928137],"category_scores_gemma":[0.0016476514,0.0002675175,0.00021774572,0.0015515699,0.00030456015,0.0007320522,0.0004728578,0.0009178695,0.0007054328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014603412,0.00005343089,0.99456984,0.000008158732,0.000017486955,0.001278663,0.00026226946,0.000042623484,0.00014868264,0.00003650383,0.00077245664,0.0026639262],"study_design_scores_gemma":[0.00003145218,0.00032550612,0.9870237,0.000017416982,0.00003432253,0.008516573,0.00088332593,0.00042820815,0.000066720604,0.0001836288,0.0024695788,0.00001955855],"about_ca_topic_score_codex":0.0072739325,"about_ca_topic_score_gemma":0.005186127,"teacher_disagreement_score":0.0072739325,"about_ca_system_score_codex":0.0007360402,"about_ca_system_score_gemma":0.0004276712,"threshold_uncertainty_score":0.014463186},"labels":[],"label_agreement":null},{"id":"W4403458741","doi":"10.1038/s41408-024-01164-x","title":"Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Huntsman Cancer Institute; McMaster University; University of Arkansas for Medical Sciences; Hamilton Health Sciences","keywords":"Multiple myeloma; Retrospective cohort study; Medicine; MEDLINE; Internal medicine; Pediatrics; Oncology; Political science","score_opus":0.05742110478828666,"score_gpt":0.38477372673609556,"score_spread":0.3273526219478089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403458741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98710865,0.00087203155,0.00011320363,0.0016177582,0.000039119885,0.00004650269,0.0083728405,0.000015565342,0.0018144131],"genre_scores_gemma":[0.9961569,0.00045449744,0.00012598438,0.0005614923,0.00005398173,0.00002865677,0.0022728827,0.00000456628,0.00034108787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874496,0.00019112098,0.00017570895,0.00024469843,0.0003568881,0.00028649537],"domain_scores_gemma":[0.9958697,0.00049314986,0.0015107015,0.00040637323,0.0010544155,0.0006655933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009098016,0.00023315764,0.00041308528,0.0010754043,0.0011763502,0.0008754068,0.00085732085,0.0008881303,0.0020196126],"category_scores_gemma":[0.0043578404,0.0003891534,0.00060091226,0.0035495784,0.00045666422,0.00057419564,0.00056029164,0.0009797586,0.00037736332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044665878,0.00001129884,0.9984282,0.0000075194325,0.00003084885,0.00007702447,0.000054341446,0.000013253937,0.000023276405,0.000014890379,0.0008028917,0.0004917032],"study_design_scores_gemma":[0.000011145494,0.000024021243,0.99868673,0.00001717078,0.000042339587,0.00023324914,0.00021749153,0.00018593937,0.000012344493,0.000023408958,0.00053877843,0.0000072652833],"about_ca_topic_score_codex":0.54106873,"about_ca_topic_score_gemma":0.60914433,"teacher_disagreement_score":0.54106873,"about_ca_system_score_codex":0.0052827243,"about_ca_system_score_gemma":0.00506847,"threshold_uncertainty_score":0.923268},"labels":[],"label_agreement":null},{"id":"W4403584947","doi":"10.1038/s41408-024-01160-1","title":"Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Coronavirus disease 2019 (COVID-19); Multiple myeloma; Refractory (planetary science); Medicine; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Internal medicine; Phase (matter); Oncology; Intensive care medicine; Virology; Biology; Disease; Chemistry","score_opus":0.03408087033670494,"score_gpt":0.3724803498232491,"score_spread":0.3383994794865442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403584947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7139971,0.041158244,0.00043221135,0.20930043,0.005400074,0.00027477922,0.0044303094,0.00008418607,0.024922624],"genre_scores_gemma":[0.90990144,0.0099262055,0.0006226936,0.06585683,0.007980321,0.00027785444,0.0024186443,0.000023071007,0.0029928298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898845,0.00046248376,0.00010961406,0.00009059549,0.00020235464,0.00014658977],"domain_scores_gemma":[0.9972167,0.0009328986,0.0005022092,0.000109948945,0.00045620903,0.00078189716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017458352,0.00015521856,0.0006436439,0.0002455127,0.00059972645,0.0009762164,0.00033692791,0.00147209,0.0014256096],"category_scores_gemma":[0.0067362613,0.00010604968,0.00049876334,0.0006055119,0.00024381682,0.00064386264,0.00040180152,0.002135336,0.00045264495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03418699,0.0014720926,0.59930557,0.00074002263,0.00097266445,0.0042517027,0.0004481317,0.00088931026,0.0013101144,0.0010832193,0.16625659,0.18908364],"study_design_scores_gemma":[0.0118628405,0.013204707,0.8199358,0.0018087301,0.0026496006,0.009202915,0.0010440032,0.0047854003,0.0010829454,0.0063252943,0.12789507,0.00020282708],"about_ca_topic_score_codex":0.0015554397,"about_ca_topic_score_gemma":0.003329701,"teacher_disagreement_score":0.0017458352,"about_ca_system_score_codex":0.0012728628,"about_ca_system_score_gemma":0.0011681063,"threshold_uncertainty_score":0.009235263},"labels":[],"label_agreement":null},{"id":"W4403946959","doi":"10.1038/s41408-024-01166-9","title":"Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Core binding factor; Internal medicine; Genetics; Bioinformatics; Biology; Computational biology; Gene; Transcription factor","score_opus":0.054128508804982337,"score_gpt":0.3452643679558103,"score_spread":0.29113585915082796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403946959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949739,0.0018124173,0.00025251711,0.00019375549,0.000016235994,0.000010973854,0.00130339,0.0000104415085,0.0014262715],"genre_scores_gemma":[0.99718386,0.00048511862,0.00008740537,0.000086150874,0.000037156424,0.000009046836,0.0018445085,0.000007547094,0.00025917668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997155,0.000049019396,0.00003473663,0.00007880452,0.000057392288,0.000064504435],"domain_scores_gemma":[0.9990657,0.0001704197,0.00041568183,0.00004349755,0.00007776931,0.0002269957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035525026,0.00013386909,0.0003053012,0.0007288887,0.00019167385,0.00053577824,0.0002787351,0.0003367423,0.0017831229],"category_scores_gemma":[0.002121297,0.000063730855,0.00018356426,0.0008389877,0.0002139728,0.0004932675,0.0005343018,0.0004136143,0.00036881812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007431547,0.000042675314,0.9847771,0.000032520547,0.000074702635,0.00048009027,0.00016101827,0.00013765295,0.0010368155,0.00018249032,0.0003469709,0.011984654],"study_design_scores_gemma":[0.000009130444,0.00027334288,0.9957974,0.000020481077,0.00006321407,0.001530252,0.00025690655,0.00021460146,0.00017383564,0.0004885292,0.0011628168,0.000009424929],"about_ca_topic_score_codex":0.0007536425,"about_ca_topic_score_gemma":0.0009153046,"teacher_disagreement_score":0.0017831229,"about_ca_system_score_codex":0.00029351606,"about_ca_system_score_gemma":0.00016919653,"threshold_uncertainty_score":0.0059651732},"labels":[],"label_agreement":null},{"id":"W4403947139","doi":"10.1038/s41408-024-01165-w","title":"Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society; U.S. Department of Health and Human Services","keywords":"CD34; Medicine; Plerixafor; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Autologous stem-cell transplantation; Melphalan; Haematopoiesis; Propensity score matching; Internal medicine; Urology; Stem cell; Surgery; Oncology; CXCR4; Biology","score_opus":0.019294930824064492,"score_gpt":0.27803633748950685,"score_spread":0.2587414066654424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403947139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999316,0.00041596484,0.00010816541,0.000018765293,0.000002946368,0.0000026429163,0.000046011133,0.000001877937,0.00008773355],"genre_scores_gemma":[0.9997782,0.00005857985,0.00006864503,0.000014671985,0.0000045514366,0.0000021537512,0.0000523776,4.9288127e-7,0.000020383774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997583,0.00008588177,0.00002763646,0.000045131095,0.00003883012,0.000044197022],"domain_scores_gemma":[0.9994517,0.00013432426,0.00028328365,0.000015935246,0.000027280417,0.00008744898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035568982,0.00013057866,0.00035636695,0.00033806096,0.00022436651,0.0004848098,0.0001803799,0.0002600079,0.0007296361],"category_scores_gemma":[0.0011215295,0.00011924715,0.00021984876,0.00050950993,0.00016186343,0.00027251552,0.00020209013,0.00040380977,0.00011572032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001068986,0.000052506228,0.9921302,0.000014548256,0.000030276007,0.00022094524,0.000029074086,0.0002506705,0.0012221729,0.000029331417,0.00007622727,0.0048749363],"study_design_scores_gemma":[0.00005637035,0.00131645,0.9935666,0.000020259042,0.00009510914,0.00141775,0.0001421677,0.0013114589,0.0015158012,0.00013969731,0.00041102356,0.00000739514],"about_ca_topic_score_codex":0.0006384045,"about_ca_topic_score_gemma":0.00054150424,"teacher_disagreement_score":0.0007296361,"about_ca_system_score_codex":0.00037798475,"about_ca_system_score_gemma":0.00023943813,"threshold_uncertainty_score":0.0027424693},"labels":[],"label_agreement":null},{"id":"W4404222964","doi":"10.1038/s41408-024-01177-6","title":"Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Lenalidomide; Multiple myeloma; Dexamethasone; Bortezomib; Medicine; Internal medicine; Hematology; Induction therapy; Oncology; Chemotherapy","score_opus":0.021626995701039278,"score_gpt":0.3043724535718073,"score_spread":0.28274545787076805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404222964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940814,0.001495976,0.00005201844,0.00030011008,0.000014932925,0.000102040045,0.005990336,0.000012019465,0.0026242668],"genre_scores_gemma":[0.98389107,0.0009817918,0.00017355489,0.0002680524,0.00004924451,0.00015463225,0.013911848,0.000010650167,0.00055921363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986981,0.0006696266,0.00008889841,0.00017186152,0.00028462493,0.00008680694],"domain_scores_gemma":[0.9968035,0.00087033113,0.0015495501,0.0001876416,0.000191929,0.00039707296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282318,0.00015242829,0.00043146036,0.0004185265,0.0002226712,0.0006586572,0.0003863316,0.00021031479,0.0013354117],"category_scores_gemma":[0.0030609185,0.00014356371,0.00056005886,0.0013006328,0.00019389582,0.000340597,0.00053095067,0.00046454484,0.00024628945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020872753,0.0007570554,0.94703364,0.00022671596,0.0007897009,0.00011343222,0.00010536587,0.00090241217,0.0007192324,0.00009227094,0.00401152,0.024375891],"study_design_scores_gemma":[0.0021051732,0.0025129046,0.99052495,0.00008091407,0.00052413676,0.00018667092,0.00010066051,0.0004148557,0.0004440452,0.00003573477,0.003057538,0.000012421564],"about_ca_topic_score_codex":0.0053996504,"about_ca_topic_score_gemma":0.017064853,"teacher_disagreement_score":0.0053996504,"about_ca_system_score_codex":0.0007083738,"about_ca_system_score_gemma":0.0011485147,"threshold_uncertainty_score":0.010736406},"labels":[],"label_agreement":null},{"id":"W4404719809","doi":"10.1038/s41408-024-01187-4","title":"RSK1 dependency in FLT3-ITD acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Edward P. Evans Foundation; National Heart, Lung, and Blood Institute; McGill University; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; MPN Research Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Cancer research; Fms-Like Tyrosine Kinase 3; Leukemia; Biology; Cycloheximide; Immunology; Cell culture; Mutation; Genetics; Gene","score_opus":0.017955739931584908,"score_gpt":0.3294307861238656,"score_spread":0.3114750461922807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404719809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971656,0.0010913211,0.00053658796,0.00007015574,0.000011413314,0.00000959147,0.00037371548,0.000065208995,0.00067633745],"genre_scores_gemma":[0.9980934,0.0004217317,0.0004486982,0.000021566473,0.0000035067371,0.000008548415,0.0003867559,0.0000076190136,0.0006081717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998932,0.000015398422,0.000011464633,0.00002788379,0.00003047283,0.00002156553],"domain_scores_gemma":[0.9999255,0.000009608941,0.00003258444,0.000010664902,0.000004909274,0.000016792957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104553146,0.00027740316,0.00018291605,0.0002169907,0.00015359139,0.0002451693,0.00010487548,0.00013850928,0.001143308],"category_scores_gemma":[0.00010982366,0.00008691604,0.0001817228,0.00015942185,0.00023029625,0.0001447642,0.00015574442,0.0003637624,0.0003083451],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002202439,0.000038242913,0.0012122598,0.000037805014,0.0000082439,0.00010650431,0.000008882222,0.00020828324,0.994752,0.00016198082,0.000076281256,0.0031692795],"study_design_scores_gemma":[0.000014028416,0.00036978378,0.025396643,0.0000036263184,0.00001686936,0.0009968084,0.000018587009,0.0010732507,0.97009295,0.000096546144,0.0019152369,0.00000567791],"about_ca_topic_score_codex":0.00027561816,"about_ca_topic_score_gemma":0.0007490063,"teacher_disagreement_score":0.001143308,"about_ca_system_score_codex":0.00036539874,"about_ca_system_score_gemma":0.0001588198,"threshold_uncertainty_score":0.0038247705},"labels":[],"label_agreement":null},{"id":"W4404828842","doi":"10.1038/s41408-024-01192-7","title":"Molecular monitoring in CML—a modern example of an old proverb","year":2024,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; University of Toronto","keywords":"Medicine; Computational biology; MEDLINE; Bioinformatics; Biology; Intensive care medicine; Biochemistry","score_opus":0.015990089796937803,"score_gpt":0.3082338323487274,"score_spread":0.29224374255178964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404828842","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059560738,0.023714669,0.000205556,0.06189451,0.9120224,0.000017267103,0.00003178024,0.00004740791,0.002006854],"genre_scores_gemma":[0.0005016529,0.017011622,0.00013907194,0.03923134,0.9378187,0.000011658051,0.000020336405,0.000024924693,0.0052406704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979023,0.000540986,0.00026326944,0.0002382355,0.00094945496,0.00010583157],"domain_scores_gemma":[0.99049836,0.0048501245,0.00038734553,0.00024223332,0.002899322,0.001122593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041858503,0.0021799472,0.0016534966,0.002111429,0.0016570243,0.0037796665,0.0021742233,0.008196953,0.0076628863],"category_scores_gemma":[0.0149255125,0.000575447,0.0014249091,0.000873736,0.0020953964,0.0042992695,0.0010674752,0.01834693,0.005663782],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000533034,0.000016819447,0.000029171417,0.00024684926,0.000011637743,0.00010565161,0.000017954479,0.000024042298,0.00007379013,0.0008617024,0.9836299,0.014929178],"study_design_scores_gemma":[0.00004906094,0.000045997585,0.00013312712,0.00038695234,0.0000286856,0.00034244027,0.000026054127,0.00007792812,0.00008130467,0.0013319558,0.9974853,0.000011099531],"about_ca_topic_score_codex":0.00084688194,"about_ca_topic_score_gemma":0.0020066814,"teacher_disagreement_score":0.008196953,"about_ca_system_score_codex":0.0018064341,"about_ca_system_score_gemma":0.0018086031,"threshold_uncertainty_score":0.025634944},"labels":[],"label_agreement":null},{"id":"W4407238709","doi":"10.1038/s41408-025-01212-0","title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Seagen","keywords":"Medicine; Pomalidomide; Context (archaeology); Clinical trial; Multiple myeloma; Oncology; Internal medicine; Dexamethasone; Daratumumab; Clinical endpoint; Lenalidomide","score_opus":0.1447630802165594,"score_gpt":0.4704130007054941,"score_spread":0.3256499204889347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407238709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005886199,0.9918452,0.00042893167,0.005709193,0.00045125003,0.000010995001,0.000023971332,0.000014604162,0.0009273251],"genre_scores_gemma":[0.006149393,0.98785233,0.0009985158,0.0036109018,0.00064833846,0.000030462348,0.000038129645,0.000009496481,0.0006622727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992895,0.00030115235,0.00012934084,0.00008192367,0.00015018988,0.000047854424],"domain_scores_gemma":[0.9973775,0.00174043,0.0001837683,0.000059095128,0.00052587094,0.00011322835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034675386,0.00038768523,0.0014313747,0.00075111305,0.00029051903,0.0019304401,0.00081418664,0.0012212377,0.0016962626],"category_scores_gemma":[0.004812609,0.00027294716,0.00064472907,0.00070775364,0.0009139838,0.0032291,0.00066977035,0.0035283894,0.00068438135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003355133,0.0000914798,0.0003689455,0.012975933,0.00014947054,0.00031521355,0.0004424421,0.00093041884,0.0014085523,0.014370048,0.03703339,0.9315786],"study_design_scores_gemma":[0.000112326496,0.00056503474,0.00059167156,0.008035824,0.00016089046,0.0008048766,0.00028313303,0.0003704078,0.00052930857,0.012202593,0.97630715,0.000036713187],"about_ca_topic_score_codex":0.0010378279,"about_ca_topic_score_gemma":0.002490675,"teacher_disagreement_score":0.0034675386,"about_ca_system_score_codex":0.00096370984,"about_ca_system_score_gemma":0.0018289045,"threshold_uncertainty_score":0.018338323},"labels":[],"label_agreement":null},{"id":"W4408310298","doi":"10.1038/s41408-025-01242-8","title":"Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; Hôpital Charles-Le Moyne; Université de Sherbrooke; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; McGill University; Université Laval; Centre Hospitalier de l’Université de Montréal; The Quebec Population Health Research Network; Université du Québec à Montréal; Université du Québec; Centre hospitalier universitaire de Québec; Université de Montréal; Institut universitaire en santé mentale de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Affect (linguistics); Medicine; Intensive care medicine; Prospective cohort study; Family medicine; Internal medicine; Psychology","score_opus":0.013173212410804247,"score_gpt":0.2912117035899546,"score_spread":0.2780384911791503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408310298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97450054,0.0011729853,0.00019655097,0.005156021,0.000076048054,0.00014072287,0.008600297,0.000019067302,0.010137821],"genre_scores_gemma":[0.99288356,0.0006557988,0.00014676945,0.0025466948,0.00012097277,0.000051934807,0.0019774055,0.000011035067,0.001605834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983511,0.00035934,0.00016775803,0.0002582435,0.00040840518,0.00045508408],"domain_scores_gemma":[0.9925276,0.001219877,0.0024819148,0.0005449135,0.0021696982,0.0010559037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014228298,0.00019398645,0.00033107025,0.0009947754,0.0021894898,0.0015833292,0.00074164406,0.0009081803,0.0033933036],"category_scores_gemma":[0.0064733755,0.00022854263,0.00025105895,0.0040130424,0.00066383113,0.0006239393,0.00044384736,0.00086369587,0.00055433856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012842102,0.000062194944,0.988214,0.000025836149,0.000025559413,0.0005709245,0.00034414674,0.000031294938,0.000074373944,0.000115238,0.0062383846,0.0041697966],"study_design_scores_gemma":[0.00006794479,0.00011348235,0.98959374,0.00008705873,0.000055349778,0.0015484815,0.0013174998,0.00050775293,0.0000634195,0.000108992725,0.006508197,0.000028022121],"about_ca_topic_score_codex":0.6855238,"about_ca_topic_score_gemma":0.77024776,"teacher_disagreement_score":0.3144762,"about_ca_system_score_codex":0.009636483,"about_ca_system_score_gemma":0.008802389,"threshold_uncertainty_score":0.6326564},"labels":[],"label_agreement":null},{"id":"W4408868147","doi":"10.1038/s41408-025-01243-7","title":"Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","year":2025,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Drug development; Internal medicine; Drug; Oncology; Intensive care medicine; Pharmacology; Biology","score_opus":0.07078477127089412,"score_gpt":0.39924263271318067,"score_spread":0.32845786144228656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408868147","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008429017,0.0012406908,0.0009121928,0.05183598,0.94251025,0.000025664034,0.0011307526,0.00036030644,0.0018997946],"genre_scores_gemma":[0.010050943,0.013637169,0.011297175,0.17422087,0.6615899,0.00027514462,0.0036270875,0.002880057,0.12242165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99187016,0.0015493085,0.001809936,0.0009521339,0.0032846034,0.00053387665],"domain_scores_gemma":[0.9329129,0.020294404,0.0031793865,0.003984077,0.03739954,0.002229667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009472636,0.0020346388,0.0017498261,0.0033821112,0.0023364362,0.005074032,0.0030585623,0.005989751,0.034404267],"category_scores_gemma":[0.11535396,0.0011767538,0.0026095405,0.0025769463,0.0023664583,0.0028038267,0.0017231611,0.017230008,0.029151518],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034007648,0.0000042582133,0.000033636232,0.00008516848,0.000009039465,0.000104316874,0.000014573097,0.000033610166,0.000027526476,0.0005631841,0.9932387,0.005852004],"study_design_scores_gemma":[0.00005974723,0.00002390647,0.0003040956,0.00046041046,0.000040753013,0.00045333253,0.000037396923,0.00017122547,0.00021707978,0.0013882285,0.9968141,0.000029704908],"about_ca_topic_score_codex":0.015402184,"about_ca_topic_score_gemma":0.017161366,"teacher_disagreement_score":0.034404267,"about_ca_system_score_codex":0.0039566904,"about_ca_system_score_gemma":0.0077296584,"threshold_uncertainty_score":0.11509377},"labels":[],"label_agreement":null},{"id":"W4408957812","doi":"10.1038/s41408-025-01263-3","title":"Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; AbbVie","keywords":"Azacitidine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Medicine; Myeloid leukemia; Venetoclax; Leukemia; Antecedent (behavioral psychology); Internal medicine; Myeloid; Oncology; Immunology; Chronic lymphocytic leukemia; Bone marrow; Psychology; Psychotherapist; Biology","score_opus":0.013960923690989883,"score_gpt":0.2738220891699498,"score_spread":0.25986116547895993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408957812","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37573117,0.06457253,0.0013277616,0.40044266,0.01247554,0.00020729692,0.00036945177,0.00022535595,0.14464822],"genre_scores_gemma":[0.8435084,0.016217705,0.00086882914,0.1074286,0.016141199,0.00006125596,0.00022960069,0.000024177472,0.0155201],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9997603,0.000075718024,0.000024492208,0.000032824966,0.000052173265,0.00005438723],"domain_scores_gemma":[0.9994342,0.00021677744,0.00007933235,0.000024053441,0.000047452853,0.00019825307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002830202,0.0001936523,0.00034825748,0.00037473667,0.0009571225,0.0005731933,0.00034631585,0.0031906748,0.0029031592],"category_scores_gemma":[0.002431925,0.00012386164,0.00025888733,0.00046687634,0.00046189065,0.0005662884,0.00021808107,0.0022093388,0.0011702831],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001149741,0.00045981506,0.11902732,0.00033942584,0.00009503835,0.59117013,0.00070010626,0.00043642905,0.0031011614,0.0041711386,0.16532753,0.11402222],"study_design_scores_gemma":[0.00031688856,0.00087950425,0.06021481,0.00067607727,0.00010575537,0.7691454,0.00072482537,0.001608496,0.000983197,0.0073175146,0.15798427,0.00004313296],"about_ca_topic_score_codex":0.0019454021,"about_ca_topic_score_gemma":0.005506485,"teacher_disagreement_score":0.0031906748,"about_ca_system_score_codex":0.0010880869,"about_ca_system_score_gemma":0.0007329723,"threshold_uncertainty_score":0.00971204},"labels":[],"label_agreement":null},{"id":"W4409083304","doi":"10.1038/s41408-025-01234-8","title":"Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada); Hôpital Charles-Le Moyne; Université de Sherbrooke; Bausch Health (Canada); Cegep de Saint Jerome; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier de l'Université Laval; Montreal Heart Institute; St. Jerome's University; Cégep de Lévis; Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; McGill University; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Université Laval; Université de Montréal; McGill-Queen's University Press; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Internal medicine; Medicine; Hematology; Oncology; Gerontology","score_opus":0.04317865656157713,"score_gpt":0.3873996564677468,"score_spread":0.3442209999061697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409083304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521375,0.0006417559,0.00006781642,0.00010413587,0.000007318169,0.00006554771,0.0033379188,0.00000406203,0.0005576185],"genre_scores_gemma":[0.995726,0.0003503414,0.00011311732,0.00010427665,0.00001810887,0.000044321463,0.0031101436,0.000004151687,0.00052946305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995448,0.000058440026,0.000032726282,0.00012067231,0.0001244091,0.0001189189],"domain_scores_gemma":[0.998901,0.00010409326,0.00027675522,0.00006650713,0.0003655943,0.00028609778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006648131,0.00047629475,0.000546977,0.0010528283,0.0015407321,0.00097347656,0.001175106,0.0006295794,0.0018960986],"category_scores_gemma":[0.0013642047,0.00026682238,0.0003991522,0.0023356858,0.00063599815,0.0005500899,0.0006860312,0.0007036149,0.00045505862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001018153,0.000051944273,0.9967231,0.000017789049,0.00004959441,0.00008251674,0.00027080148,0.00004369873,0.0001581864,0.000017142838,0.00054593675,0.0019374039],"study_design_scores_gemma":[0.000011914547,0.00005003045,0.9989116,0.000010856009,0.000016492455,0.00007958397,0.00026420108,0.00014362404,0.00001759441,0.0000059498443,0.00048256316,0.0000056446593],"about_ca_topic_score_codex":0.79121906,"about_ca_topic_score_gemma":0.8245481,"teacher_disagreement_score":0.20878094,"about_ca_system_score_codex":0.0071891234,"about_ca_system_score_gemma":0.002847951,"threshold_uncertainty_score":0.42002094},"labels":[],"label_agreement":null},{"id":"W4409147719","doi":"10.1038/s41408-025-01259-z","title":"Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Cilag; Pharmacyclics; Genentech; National Institutes of Health; National Cancer Institute; University College London; National Institute for Health and Care Research; Ascentage Pharma; SkylineDx; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Celgene; Swedish Orphan Biovitrum; Array BioPharma; Kite Pharma; Gilead Sciences; BeiGene; Sanofi; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Progression-free survival; Dosing; Oncology; Surgery; Gastroenterology; Chemotherapy","score_opus":0.08100113878727644,"score_gpt":0.40975673512727917,"score_spread":0.32875559634000273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409147719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966697,0.0011900904,0.00033811465,0.00013606991,0.00001600102,0.0002567638,0.00068713294,0.000020090514,0.0006860512],"genre_scores_gemma":[0.99692106,0.00049567566,0.0005611834,0.0002570633,0.000072041876,0.00025577386,0.0012770107,0.000007383528,0.00015281199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806947,0.0013706934,0.00011367099,0.00017937564,0.00016892004,0.00009796604],"domain_scores_gemma":[0.99623626,0.0007800353,0.0014883714,0.00058678514,0.00030068925,0.00060776935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058495807,0.0005457852,0.0007331892,0.0002889131,0.00032402258,0.00085586234,0.00045166007,0.0005896459,0.00094460155],"category_scores_gemma":[0.004028527,0.00019973768,0.0007356675,0.0005191576,0.0005847223,0.0004807658,0.00034415413,0.0007124015,0.00038315917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27154064,0.01898957,0.51337,0.0008837934,0.003867667,0.0011448306,0.0011084871,0.0048135845,0.015556091,0.00034450297,0.0035404335,0.16484043],"study_design_scores_gemma":[0.0491391,0.25792453,0.6617305,0.00014349347,0.0033646089,0.0021023352,0.0004766863,0.0035811397,0.007562137,0.00022450382,0.013620061,0.0001308825],"about_ca_topic_score_codex":0.0007400919,"about_ca_topic_score_gemma":0.0006071094,"teacher_disagreement_score":0.0058495807,"about_ca_system_score_codex":0.0007548281,"about_ca_system_score_gemma":0.00064870424,"threshold_uncertainty_score":0.030935943},"labels":[],"label_agreement":null},{"id":"W4409578902","doi":"10.1038/s41408-025-01288-8","title":"Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Affect (linguistics); Medicine; Prospective cohort study; Intensive care medicine; Internal medicine; Psychology","score_opus":0.013395953033813964,"score_gpt":0.2998396381446816,"score_spread":0.28644368511086765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409578902","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007197576,0.0019823378,0.0002256356,0.9076719,0.08773607,0.00004352723,0.00067724864,0.00016676131,0.00077673234],"genre_scores_gemma":[0.004314206,0.0013330012,0.00033022565,0.91542655,0.076276936,0.00007940448,0.0002003579,0.00007749823,0.0019617893],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910851,0.0024367021,0.0016820162,0.0012897359,0.002702518,0.00080388004],"domain_scores_gemma":[0.9532677,0.021565998,0.0038627554,0.0017940806,0.016616413,0.0028929722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012854136,0.0015683597,0.0026811145,0.0015878554,0.0026063763,0.0035283107,0.0067026475,0.030605271,0.0076867994],"category_scores_gemma":[0.06626751,0.0008712083,0.0024896208,0.0020223844,0.0037532288,0.0042705475,0.0018883961,0.024188098,0.0075565185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084293395,0.000013229121,0.0010274758,0.00017226348,0.000041006006,0.00026786543,0.000115496594,0.000031931675,0.00007188116,0.00033658982,0.9954722,0.0023657659],"study_design_scores_gemma":[0.00030305143,0.00016311534,0.008416719,0.001707694,0.00023916022,0.0021676281,0.0009928016,0.0008476444,0.00076201215,0.0031009165,0.9809756,0.00032352944],"about_ca_topic_score_codex":0.022846851,"about_ca_topic_score_gemma":0.018504806,"teacher_disagreement_score":0.9771531,"about_ca_system_score_codex":0.0045495853,"about_ca_system_score_gemma":0.0056381323,"threshold_uncertainty_score":0.06797993},"labels":[],"label_agreement":null},{"id":"W4411396441","doi":"10.1038/s41408-025-01286-w","title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Fluorescence in situ hybridization; Risk stratification; Medicine; Multiple myeloma; Internal medicine; Oncology; Family medicine; Biology; Genetics; Chromosome","score_opus":0.22496739292696086,"score_gpt":0.42518130795705555,"score_spread":0.2002139150300947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411396441","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007534474,0.8764333,0.011779276,0.08558829,0.0087323105,0.0014285673,0.0026571096,0.00034619085,0.012281523],"genre_scores_gemma":[0.004592941,0.89891654,0.05660724,0.026164414,0.001581512,0.002083454,0.0052925316,0.00013736675,0.0046240133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9764083,0.0079571325,0.0080148,0.0009070918,0.006046996,0.00066564075],"domain_scores_gemma":[0.9455947,0.017686615,0.00628688,0.0014507333,0.027830644,0.0011503808],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.030579073,0.0012473078,0.0026108415,0.0106544215,0.0011807149,0.00301713,0.006175198,0.0057396134,0.0028371396],"category_scores_gemma":[0.0515532,0.0011785199,0.004513153,0.007605855,0.0019154459,0.0031070937,0.0026197957,0.0061295778,0.0036789773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010394656,0.00012096113,0.001229321,0.034977455,0.0003222094,0.00049345667,0.0007972805,0.0006084822,0.001091307,0.008717968,0.38236892,0.5691687],"study_design_scores_gemma":[0.00005534424,0.00005070586,0.0019061824,0.046732116,0.0005391636,0.00088325253,0.00026305916,0.00019214625,0.00048365124,0.0026778046,0.9461529,0.000063725616],"about_ca_topic_score_codex":0.018875979,"about_ca_topic_score_gemma":0.018237421,"teacher_disagreement_score":0.9694209,"about_ca_system_score_codex":0.004764077,"about_ca_system_score_gemma":0.026849402,"threshold_uncertainty_score":0.16171956},"labels":[],"label_agreement":null},{"id":"W4412820579","doi":"10.1038/s41408-025-01329-2","title":"Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Sanofi; Kyowa Hakko Kirin; Cilag; Italfarmaco; Seagen; Celltrion; Pfizer; Incyte; BeiGene; Astex Pharmaceuticals; Kite Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; Leukemia and Lymphoma Society; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen","keywords":"Brentuximab vedotin; Oncology; Medicine; Internal medicine; Chemotherapy; Subgroup analysis; Anaplastic large-cell lymphoma; Lymphoma; Front line; Clinical trial; Hodgkin lymphoma; Meta-analysis","score_opus":0.013720827726550729,"score_gpt":0.28571803154387887,"score_spread":0.2719972038173281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412820579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768788,0.017203603,0.00060339697,0.0004298971,0.00036593757,0.0005308275,0.0019809923,0.00003830871,0.0019681582],"genre_scores_gemma":[0.9940035,0.001992711,0.00035340013,0.00036312867,0.00022271679,0.0003370854,0.0018507282,0.000013237649,0.0008634358],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9992392,0.00034205944,0.000070542585,0.0001360891,0.00007427371,0.00013783554],"domain_scores_gemma":[0.99934524,0.00018544991,0.00019453862,0.000119019154,0.000039381717,0.000116262854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018156515,0.0008799767,0.0023176586,0.00040020037,0.00026057992,0.0010786472,0.00061356457,0.00070079794,0.0020473232],"category_scores_gemma":[0.0018109685,0.00029881616,0.0049035926,0.00051995023,0.00032458775,0.0008444452,0.0005222166,0.0017202466,0.00026759633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8500725,0.0011602674,0.044153843,0.0029829734,0.04996727,0.00030145844,0.00013549133,0.0029334263,0.0029283701,0.000410091,0.003550738,0.041403644],"study_design_scores_gemma":[0.50761014,0.07321423,0.29122838,0.0013050113,0.10136631,0.0007322098,0.0005500387,0.008154972,0.0020625014,0.0037039958,0.009901511,0.00017077569],"about_ca_topic_score_codex":0.0015985736,"about_ca_topic_score_gemma":0.0048602647,"teacher_disagreement_score":0.0023176586,"about_ca_system_score_codex":0.00071031385,"about_ca_system_score_gemma":0.00053814333,"threshold_uncertainty_score":0.009602189},"labels":[],"label_agreement":null},{"id":"W4413629863","doi":"10.1038/s41408-025-01353-2","title":"Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Refractory (planetary science); Medicine; Single Center; Center (category theory); Internal medicine; Oncology; Chemistry; Biology","score_opus":0.023582005949821728,"score_gpt":0.290717206242874,"score_spread":0.26713520029305227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413629863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86433053,0.017690802,0.0006758051,0.08951194,0.0003890201,0.00027563353,0.0042042425,0.000044564444,0.022877399],"genre_scores_gemma":[0.9603488,0.0060421578,0.0007870161,0.028638925,0.0011738759,0.000051137373,0.0011258536,0.000021878473,0.0018102787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989354,0.00019789767,0.00008510174,0.00014588414,0.00032074147,0.00031499166],"domain_scores_gemma":[0.9980223,0.00065623544,0.00033824725,0.000058795602,0.0004767745,0.0004477054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012584956,0.00015811823,0.0006944799,0.0006555239,0.0012045893,0.0011163157,0.00049871224,0.0013177941,0.0017237508],"category_scores_gemma":[0.0031342055,0.0001353,0.00045139,0.0020148244,0.00050362066,0.0005132459,0.00021035892,0.0009142391,0.00035738913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024458684,0.00037655642,0.82182384,0.00017275939,0.00019917582,0.0062072505,0.00047480228,0.0006605961,0.0019217184,0.001224863,0.04571652,0.118776076],"study_design_scores_gemma":[0.0006293911,0.0011165565,0.91446066,0.0003600365,0.00073705555,0.014403101,0.002285044,0.0034297013,0.0008493082,0.0030571963,0.058562152,0.000109825916],"about_ca_topic_score_codex":0.13669764,"about_ca_topic_score_gemma":0.36307925,"teacher_disagreement_score":0.86330235,"about_ca_system_score_codex":0.006737812,"about_ca_system_score_gemma":0.005091075,"threshold_uncertainty_score":0.27180398},"labels":[],"label_agreement":null},{"id":"W4413807594","doi":"10.1038/s41408-025-01352-3","title":"Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Saskatchewan Cancer Agency; McMaster University; Ottawa Hospital; Institute of Cancer Research; Saskatoon Medical Imaging; University of Alberta; University of Calgary; University of Ottawa","funders":"Janssen Pharmaceuticals","keywords":"Multiple myeloma; Incidence (geometry); Medicine; Retrospective cohort study; Observational study; Population; Cohort; Cohort study; Internal medicine; Environmental health","score_opus":0.0452434986231261,"score_gpt":0.35435939692169266,"score_spread":0.30911589829856656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413807594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272925,0.00044869963,0.00012030882,0.00008563819,0.000010878104,0.000055452918,0.006032627,0.000011271918,0.00050573825],"genre_scores_gemma":[0.99599105,0.00032998243,0.00016178403,0.00007960248,0.000011032527,0.00003675062,0.0032567866,0.0000044249227,0.00012876143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984989,0.00012833037,0.00016373307,0.0005511518,0.00035949092,0.00029830483],"domain_scores_gemma":[0.9976665,0.00012900827,0.0008627156,0.00024441953,0.00059151306,0.00050577905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009597323,0.0004221186,0.0005887075,0.0015022139,0.0012664251,0.0011359683,0.0016118515,0.00071482634,0.0010307477],"category_scores_gemma":[0.0022292,0.00069577334,0.0008188749,0.0036051923,0.000762542,0.0007401317,0.00087368937,0.0010543083,0.00022806025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031774645,0.0000170818,0.9992071,0.000011447766,0.000070632945,0.000039792012,0.00009036307,0.000024208426,0.0000522564,0.000014469621,0.00020675556,0.00023412192],"study_design_scores_gemma":[0.0000047424055,0.000030927204,0.9992779,0.000010906342,0.00003197272,0.00010583969,0.00022568519,0.000104149214,0.000009809011,0.000008657059,0.0001830611,0.0000062320864],"about_ca_topic_score_codex":0.60826224,"about_ca_topic_score_gemma":0.6310356,"teacher_disagreement_score":0.60826224,"about_ca_system_score_codex":0.0046738186,"about_ca_system_score_gemma":0.0042352476,"threshold_uncertainty_score":0.7880896},"labels":[],"label_agreement":null},{"id":"W4414853478","doi":"10.1038/s41408-025-01356-z","title":"Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Pomalidomide; Dexamethasone; Cyclophosphamide; Multiple myeloma; Clinical endpoint; Adverse effect; Lenalidomide; Refractory (planetary science)","score_opus":0.04355623544536998,"score_gpt":0.38981062880104506,"score_spread":0.3462543933556751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414853478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435956,0.0032368961,0.0007623304,0.00077813887,0.00039605194,0.006816589,0.0015138747,0.00010359969,0.0020328346],"genre_scores_gemma":[0.97981775,0.0023254403,0.002398408,0.0019980473,0.00034411054,0.008884475,0.0015340664,0.00003149824,0.0026662373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992787,0.0004919921,0.00002824579,0.00007618643,0.000051325747,0.00007359383],"domain_scores_gemma":[0.9991652,0.00020277413,0.00018508296,0.000060788458,0.00004934663,0.00033685466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025305192,0.0010556565,0.0021411423,0.000353773,0.00041221277,0.0009153786,0.0007372554,0.0009665112,0.006144279],"category_scores_gemma":[0.0015438219,0.0004608088,0.0016853685,0.00043559136,0.00073142635,0.00060529436,0.00049398036,0.0022321024,0.0006187582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.973294,0.008249779,0.001223141,0.00026213378,0.000910409,0.000042668442,0.000047755548,0.00028487126,0.0020785693,0.00010117364,0.0010080069,0.012497412],"study_design_scores_gemma":[0.9384992,0.057424314,0.0023952916,0.000022019294,0.0002973047,0.000026602065,0.000017926948,0.0002613212,0.0001925348,0.00013015784,0.00072450907,0.000008885373],"about_ca_topic_score_codex":0.0013835442,"about_ca_topic_score_gemma":0.0035196233,"teacher_disagreement_score":0.006144279,"about_ca_system_score_codex":0.00090761756,"about_ca_system_score_gemma":0.0018387362,"threshold_uncertainty_score":0.020554662},"labels":[],"label_agreement":null},{"id":"W4415521520","doi":"10.1038/s41408-025-01387-6","title":"35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Multiple myeloma; French; Autologous stem-cell transplantation; Clinical trial; Transplantation; Stem cell; Standard of care","score_opus":0.09186293333158163,"score_gpt":0.3964676674332405,"score_spread":0.3046047341016589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415521520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024439013,0.9984212,0.000078939054,0.00033916556,0.00014926182,0.00001440778,0.00003923712,0.0000036828678,0.0007097178],"genre_scores_gemma":[0.002459105,0.995784,0.00027034697,0.0008275785,0.00018378168,0.00002745031,0.000108598215,0.0000038283374,0.0003353632],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99918014,0.0002713104,0.00014020683,0.00013509572,0.00021863384,0.000054534594],"domain_scores_gemma":[0.9962213,0.0023731003,0.0004229337,0.00010138528,0.00069766364,0.00018358119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043135243,0.00082562916,0.0021187167,0.0021456033,0.0003147088,0.0014778423,0.0009773187,0.0012909706,0.0036269685],"category_scores_gemma":[0.004877294,0.00026201364,0.0016815389,0.0028659538,0.0004243125,0.0012287111,0.000784691,0.0017309857,0.0008825963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080350676,0.0001326814,0.000501937,0.05323075,0.00089024863,0.00014093681,0.0000978474,0.00052626914,0.0014726738,0.003779098,0.021507181,0.91691685],"study_design_scores_gemma":[0.00032309882,0.00078572606,0.002942342,0.03298812,0.0031676933,0.0010391681,0.000098999335,0.0001246327,0.0011467823,0.001678463,0.955668,0.000037088124],"about_ca_topic_score_codex":0.0014686568,"about_ca_topic_score_gemma":0.0030631793,"teacher_disagreement_score":0.0043135243,"about_ca_system_score_codex":0.001396987,"about_ca_system_score_gemma":0.0035028541,"threshold_uncertainty_score":0.022812366},"labels":[],"label_agreement":null},{"id":"W4416690579","doi":"10.1038/s41408-025-01416-4","title":"Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Juravinski Cancer Centre; Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Government of Ontario; Leukemia and Lymphoma Society of Canada; Cancer Research Society; Johns Hopkins Children's Center","keywords":"Stem cell; Transplantation; Hematology; Hematopoietic stem cell transplantation; Myeloid; Haematopoiesis; MEDLINE","score_opus":0.022391468870450293,"score_gpt":0.35069953915330787,"score_spread":0.3283080702828576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416690579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598664,0.0019793336,0.00014269515,0.00020795708,0.000034827935,0.00002965032,0.00073804357,0.0000048673933,0.000876031],"genre_scores_gemma":[0.9980233,0.000668894,0.000097548145,0.00019739347,0.00010315132,0.000024651052,0.0007274083,0.0000037107336,0.00015394483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986166,0.000554555,0.00014031563,0.00029308928,0.0002362009,0.00015923062],"domain_scores_gemma":[0.9974464,0.0006074344,0.00078005344,0.00029404045,0.00031012646,0.0005620058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024593123,0.00038145442,0.00053284987,0.00059956126,0.00038467784,0.001193501,0.00056047755,0.00095015863,0.0016602451],"category_scores_gemma":[0.004318264,0.00024752534,0.0011844215,0.001375988,0.00039738507,0.0008787384,0.00075995404,0.0014094515,0.0004035402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022897809,0.00038605003,0.9882619,0.000075687356,0.0014903264,0.0001464763,0.00015965966,0.000102545615,0.00016651179,0.00008725314,0.00053375214,0.0063000573],"study_design_scores_gemma":[0.00013578135,0.0015706535,0.9953076,0.00003428516,0.0010327263,0.0002839526,0.0002855311,0.00023103441,0.000040623334,0.00012112781,0.0009415301,0.0000151140475],"about_ca_topic_score_codex":0.0015515375,"about_ca_topic_score_gemma":0.00213528,"teacher_disagreement_score":0.0024593123,"about_ca_system_score_codex":0.0003274151,"about_ca_system_score_gemma":0.00045977507,"threshold_uncertainty_score":0.01300627},"labels":[],"label_agreement":null},{"id":"W7117694170","doi":"10.1038/s41408-025-01444-0","title":"Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hematology; Clinical trial; MEDLINE; Chemotherapy; Text mining","score_opus":0.019761591039750934,"score_gpt":0.34972406755008556,"score_spread":0.3299624765103346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117694170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98255426,0.012471953,0.0001322789,0.00057245063,0.00019901246,0.000088289016,0.0004239138,0.00003218125,0.0035256278],"genre_scores_gemma":[0.9962341,0.0016937163,0.00015634204,0.00030033462,0.00016008594,0.000058191552,0.0005881739,0.0000042859765,0.0008046963],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99982184,0.000060367012,0.000026325404,0.000028719553,0.000029584282,0.000033251017],"domain_scores_gemma":[0.99914014,0.00022440935,0.00015172514,0.00004744283,0.000038656293,0.00039755608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048551784,0.00023824736,0.0009138319,0.00020434141,0.00018646882,0.00045386792,0.0002506662,0.00033184444,0.0025706347],"category_scores_gemma":[0.0017903841,0.00009527535,0.0005309539,0.00019594803,0.00017829731,0.00049827865,0.00023288614,0.0014007151,0.00035127465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36461425,0.013345203,0.110326566,0.00097433187,0.00211569,0.0008957375,0.00047533825,0.0024004853,0.016560806,0.0003678561,0.0059178527,0.48200583],"study_design_scores_gemma":[0.028922176,0.27193862,0.6583381,0.00047391318,0.0038002415,0.0020512517,0.0003271305,0.004023407,0.0052685784,0.00079841894,0.02394829,0.00010986315],"about_ca_topic_score_codex":0.00035919264,"about_ca_topic_score_gemma":0.0012940186,"teacher_disagreement_score":0.0025706347,"about_ca_system_score_codex":0.00026603416,"about_ca_system_score_gemma":0.00037360363,"threshold_uncertainty_score":0.008599639},"labels":[],"label_agreement":null}]}